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1.1 – Epigenetics 
An organism comprises a wide variety of cell types. Yet all cells in an organism 
contain the same DNA, i.e. the same genetic information. The molecular mechanisms 
that determine which parts of the DNA are “read” and translated into the associated 
phenotype are epigenetic mechanisms. The term epigenetics thus refers to the study of 
all molecular and structural changes to DNA that establish the phenotype but are not 
directly encoded in the DNA sequence. An epigenetic trait is formally defined as “a 
stably heritable phenotype resulting from changes in a chromosome without alterations 
in the DNA sequence” by Berger et al. [1]. The epigenome of a cell, the epigenetic 
landscape across the whole genome [2], is governed by an interplay of developmental, 
physiological and environmental factors. The epigenome thus provides a crucial 
interface between the environment and the genome [3]. Perturbations of epigenetic 
regulation underlie a wide variety of pathologies, including cancer [4-5].  
 
DNA is organized in chromatin in the eukaryotic cell nucleus. The fundamental 
repeating unit of chromatin is the nucleosome [6], consisting of 147 base pairs of DNA 
wrapped around an octamer of core histones H2A, H2B, H3 and H4. The core histones 
are predominantly globular except for their N-terminal tails that are unstructured. 
Histone H1 is not part of the nucleosome but binds to linker DNA, sealing off the 
nucleosome at the location where DNA enters and leaves. Chromatin is a dynamic 
structure that can adopt various states of compaction, thereby altering the accessibility 
of the DNA. Epigenetic regulation takes place at the level of DNA, in the form of 
methylation, and at the chromatin level in the form of remodeling and covalent histone 
modifications (Fig.1).  
The majority of histone modifications take place at the histone tails, that can be 
modified by amongst others acetylation, methylation, phosphorylation, ubiquitination 
and sumoylation [7]. Histone modifications provide docking sites for proteins that 
contain specific recognition domains. Many of these proteins function as enzymes that 
modify chromatin or remodel nucleosomes, or act as recruiters of other complexes and 
activities. A diversity of enzymes that modify histones via addition of covalent 
posttranslational modifications (“writers”) or removal of these modifications 
(“erasers”) has been described, including various histone acetyltransferases (HATs) 
and deacetylases (HDACs and sirtuins), methyltransferases (HMTs) and demethylases 
(HDMs) [8-9]. Lysine acetylation almost always correlates with chromatin accessibility 
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and transcriptional activity. On the other hand, lysine methylation can be associated 
either with transcriptional activity or repression depending on the modified residue. 
Trimethylation of lysines 4, 36 or 79 on histone H3 (H3K4me3, H3K36me3 and 
H3K79me3, respectively) are associated with gene activation, whereas di or 
trimethylation of H3K9 (H3K9me2 and H3K9me3) and trimethylation of H3K27 
(H3K27me3) correspond with gene repression [10-12]. Chromatin modifications can 
communicate with each other in so called cross-talk, which can be cooperative or 
antagonistic [13]. Notably, all epigenetic processes work together to establish and 
maintain global and local chromatin states essential for regulation of gene transcription 
programs and other chromatin-based processes. 
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Figure 1 (Previous page). Layers of epigenetic regulation of the mammalian genome. The 
multiple layers of epigenetic regulation, at the level of DNA, histones and chromatin compaction, 
are schematically depicted. Epigenetic modifications or processes associated with silenced 
chromatin (off) or active chromatin (on) are shown on the left and right hand, respectively. At the 
DNA level, methylation (Me) occurs at cytosine residues in a CpG dinucleotide context. DNA is 
packaged into nucleosomes, that consist of 147 base pairs of DNA wrapped around an octamer of 
core histones. Histones are modified by covalent modifications, mainly at the histone tails 
(indicated by colored dots). DNA in chromatin may be further compacted, or may remain accessible 
to DNA binding proteins, such as transcription factors and RNA polymerase II. Chromatin can also 
organize into higher-order structures, such as nuclear lamina-associated domains. All epigenetic 
processes work in concert to establish and maintain specific chromatin configurations essential in 
chromatin-based processes. Figure adapted from [14]. 
Methylation is the only known widely occurring epigenetic modification at the 
level of the DNA. In this chapter various aspects of DNA methylation will be 
discussed. In this chapter, our current understanding of DNA methylation deposition, 
occurrence in the genome, functions and interpretation by methyl-CpG binding proteins 
will be discussed. Recent technical advances in DNA methylation research are 
discussed. Finally, the recent discoveries in hydroxymethylation, nonCpG methylation 
and DNA demethylation will be reviewed. 
 
1.2 – Methylcytosine: the fifth base of DNA 
DNA methylation in eukaryotes takes place at the carbon 5 position of cytosine 
residues (5mC) (Fig.2A). In prokaryotes DNA methylation occurs both on adenine and 
cytosine nucleotides [15]. Not all eukaryotes contain methylated DNA; yeast and many 
invertebrate species, including the nematode Caenorhabditis elegans and the fly 
Drosophila melanogaster, have no or barely detectable levels of DNA methylation [16-
19]. In vertebrates cytosine methylation is almost exclusively present in the context of 
CpG dinucleotides [20], whereas plants and some fungi also contain considerable 
levels of methylated cytosines in non-CpG contexts [21-22]. Recently, it has been 
found that non-CpG methylation does occur in mammals in specific cell types [23-24], 
mainly embryonic stem cells, but furthermore this is rare in most tissues and cell types. 
The majority of CpG dinucleotides throughout mammalian genomes is methylated, 
referred to as global methylation [20], with the exception of CpGs within CpG-islands 
that are generally unmethylated in primary cells. 
Chapter 1 
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Figure 2. Mammalian DNA methylation. (A) DNA methylation in mammals (and eukaryotes in 
general) occurs at the carbon 5 position of cytosine residues, as indicated. (B) Processes in 
mammalian DNA methylation. Cytosine methylation occurs almost exclusively in CpG dinucleotides 
in mammals. De novo methyltransferases DNMT3A and DNMT3B establish DNA methylation on 
fully unmodified DNA. Maintenance methyltransferase DNMT1 acts on hemimethylated DNA to re-
establish full methylation after DNA replication. DNA replication without maintenance of DNA 
methylation results in the passive loss of DNA methylation. In processes of active DNA 
demethylation, DNA methylation is actively removed independent of DNA replication. Figure 
adapted from [25]. 
CpG dinucleotides are underrepresented in mammalian genomes. This is thought 
to be the result of the high mutation rate of methylated CpGs, having led to depletion of 
the dinucleotide during evolution [26-28]. Methylcytosine deaminates into thymine, 
generating CpG:TpG mismatches, which, if unrepaired, are further propagated through 
DNA replication. CpG-islands are short regions of high CpG density that are 
unmethylated in the germline and in most somatic tissues [29-30], ensuring their 
continued existence in the light of the elevated mutation rate of methylcytosine. A 
CpG-island was originally defined as a region larger than 200 bp with a G + C content 
of more than 50% and an observed versus expected ratio for the occurrence of CpGs of 
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more than 0.6 [31]. Later this was adjusted to higher stringency [32]. CpG-islands are 
often found in association with genes, mostly in the promoters and first exons [29-30]. 
Approximately 70% of gene promoters contain CpG-islands in mammals. A small 
subset of CpG-islands becomes methylated during normal development in X-
chromosome inactivation, genomic imprinting and in tissue-specific gene repression 
[30,33-34]. Aberrant hypermethylation of CpG-islands is a hallmark of cancer [5,35-
36].   
 
In mammals DNA methylation is deposited by three DNA methyltransferases 
(DNMTs) that mediate the transfer of a methyl group from S-adenosylmethionine 
(SAM) to cytosine [37-38]. DNMT1 is primarily a maintenance methyltransferase and 
is responsible for the post-replicative restoration of hemi-methylated sites to full 
methylation (Fig.2B). DNMT3A and DNMT3B are referred to as de novo 
methyltransferases and work on fully unmodified DNA. Two additional family 
members, DNMT2 and DNMT3L, have been identified. DNMT3L is a catalytically 
inactive DNMT, but indispensable for de novo methylation of most imprinted loci in 
germ cells [39]. DNMT3L interacts with both unmethylated H3K4 and with DNMT3A, 
enhancing enzymatic activity of the latter. DNMT2 methylates cytosine 38 in the 
anticodon loop of tRNA(Asp) [40]; its biological role is unknown so far.   
DNMTs establish and maintain 5mC DNA methylation patterns. Genomic 
methylation patterns in somatic cells are generally stable and heritable [41-42]. 
However, there are two periods during mammalian development in which methylation 
patterns are reprogrammed: in primordial germ cells (PGCs) and in the early embryo 
from immediately after fertilization to the implantation [41-42]. In PGCs 5mC DNA 
methylation is globally erased, and newly established during subsequent stages in 
prenatal sperm development or postnatal oocyte maturation. In the second round of 
reprogramming, the paternal genome is demethylated directly upon fertilization. The 
embryonic genome continues to be demethylated during subsequent divisions in a 
passive manner, i.e. DNA methylation is not maintained, leading to loss of the maternal 
DNA methylation as well. DNA is remethylated around the time of implantation. 
Notably, methylated imprinted regions do not become demethylated during this second 
round of reprogramming, neither do unmethylated imprinted regions become 
methylated [43]. Imprints are permanently established during the first round of 
reprogramming during gametogenesis. Although biological mechanisms underlying 
DNA demethylation start to be uncovered (see paragraph on DNA demethylation), the 
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exact mechanisms in developmental demethylation are not completely understood thus 
far [42].  
DNMT3 enzymes are responsible for de novo methylation during development. A 
variety of mechanisms is thought to be involved in genomic targeting of DNMTs and 
(de novo) DNA methylation (recently reviewed in [44]). These involve inherent 
properties of DNMT enzymes and the influence of interacting partners. In vitro studies 
have shown that catalytic activities of DNMT3 enzymes are influenced by sequences 
next to target CpG sites [45], and have indicated a preference of the DNMT3A-
DNMT3L complex for 8-10bp regularly spaced CpGs [39]. Chromatin-mediated 
mechanisms are likely of major importance in DNMT targeting, as appears from 
genome-wide correlation studies of histone modifications and DNA methylation, and 
from (in)direct interactions between the DNA methylation machinery and chromatin 
marks [44]. Roles for RNA-based DNMT targeting mechanisms are emerging. In germ 
cells, PIWI-associated RNAs (piRNAs) are thought to guide DNMT3 activity [46]. 
Finally, DNMTs are subject to a variety of post-translational modifications that 
influence their functioning [44]. In DNA methylation maintenance, UHRF1 is an 
important factor for DNMT1 targeting: it binds hemimethylated CpGs via its SRA 
domain and recruits DNMT1 to these sites [47]. 
 
1.3 – Biological functions of DNA methylation 
DNA methylation is involved in a variety of biological processes. It is essential in 
mammalian embryonic development, during which methylation levels change 
dynamically [41-43]. Deletion of Dnmt1 or Dnmt3b results in embryonic lethality, 
whereas Dnmt3a knockout mice die at four weeks of age [48-49]. During development 
and differentiation cell type-specific differential epigenomes originate that define the 
specific cell phenotypes, for which correct i.e. cell-type specific DNA methylation 
patterns are essential. Moreover, DNA methylation plays crucial roles in imprinting, X-
inactivation and disease.  
Imprinted genes are transcribed in a monoallelic manner: only from the 
maternally or the paternally inherited chromosome [50]. About 100 imprinted genes 
have been identified in mammals of which most reside in clusters [51]. Genes in these 
clusters are coordinately regulated through imprinting control regions (ICRs) that are 
methylated on one allele [52-54]. As discussed before two waves of DNA methylation 
reprogramming occur during mammalian development, in the primordial germ cells 
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and in the zygote [41-43]. During the first round imprints are permanently established; 
ICRs are methylated in a sex-specific manner in the germline and methylation is 
maintained after fertilization. Allele-specific DNA methylation then regulates the ICR 
activity that controls all genes in the locus. Loss of methylation of the ICRs results in 
bi-allelic expression of imprinted genes [55].  
DNA methylation is associated with long-term repression in X-inactivation. In 
mammalian females one X chromosome in each cell undergoes inactivation at an early 
stage of development. The X chromosome that becomes inactivated shows 
upregulation of Xist RNA expression [56]. Xist RNA molecules accumulate over the 
chromosome and initiate silencing. Initially silencing involves changes in chromatin 
structure that restrict accessibility of DNA [57-58]. Many sequences then undergo de 
novo DNA methylation at a later post-implantation stage, after X chromosomal genes 
are already silenced. DNA methylation is thus a secondary event, however, it is thought 
to provide stable long-term repression. Indeed, in marsupials or in extra-embryonic 
tissues of mammals where X-inactivation takes place without DNA  methylation, genes 
on the inactive X chromosome slowly become reactivated as a function of age [59-60].  
The importance of precise regulation of DNA methylation patterns in normal 
mammalian development and functioning also appears from the link of aberrant DNA 
methylation – or the interpretation thereof - with pathological situations, particularly 
mental retardation syndromes and cancer [61]. Mutations in the DNMT3B gene cause 
immunodeficiency centromeric instability facial anomalies (ICF) syndrome [49,62]. 
Mutations in the MeCP2 gene cause Rett syndrome [63]. Imprinting anomalies lead to 
disorders, such as Prader-Willi, Angelman and Beckwith-Wiedemann syndrome [64-
65]. Furthermore, aberrant methylation patterns have been reported in various 
neurodevelopmental disorders including X-linked α-thalassemia and mental retardation 
(ATRX) and Fragile X [61].  
Cancer associated aberrant DNA methylation patterns have been widely studied 
[4-5,35-36,66]. The methylome, i.e. the overall genome-wide methylation pattern, of 
cancer cells is profoundly distorted. Such cells display global hypomethylation, but 
also acquire aberrant patterns of hypermethylation at CpG-islands. Hypomethylation 
leads to genomic instability and the reactivation of repressed repetitive elements and 
endogenous transposons. Promoter hypermethylation frequently silences tumor-
suppressor genes. However, CpG-island hypermethylation is abundant in cancer cells 
and many cancer-associated de novo DNA methylation events occur at the promoters 
of genes that are not tumor suppressors. The majority of these genes is already 
repressed in the normal tissue [67]. As will be discussed below, a significant proportion 
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of de novo methylated CpG-islands are target sites of Polycomb [68-70]. Specific sites 
of aberrant hypermethylation are being investigated as biomarkers for early prediction 
and prognostication [71]. Furthermore, DNA methylation profiling is used to define 
novel tumor subgroups [72]. Although several lines of evidence support its causal 
involvement in cancer progression [4,35], the extent to which disturbed DNA 
methylation directly contributes to cancer progression or is a secondary effect is not 
clear-cut and may vary per cancer type. DNA methylation inhibitors, including 
nucleoside analogues as well as non-nucleoside analogues, have been and currently are 
under investigation for usage as anti-cancer drugs [66,73]. Two inhibitors, azacitidine 
and decitabine, have gained FDA approval for treatment of myelodisplastic syndrome. 
 
1.4 – DNA methylation and transcription 
It is well established that DNA hypermethylation at promoters and repetitive sequences 
is associated with stable transcription silencing. At  first it was thought that DNA 
methylation works by interfering with the binding of key transcription factors. For 
instance, DNA methylation can directly inhibit binding of the transcription factors E2F 
and CREB [74-75]. However, this turned out not to be a general phenomenon. Many 
factors do not have CpGs in their binding sites, and even when present, methylation 
does not necessarily inhibit binding. Currently, the model is that DNA methylation 
mediates gene repression through Methyl-DNA Binding Proteins (MBPs, see next 
section). DNA methylation is specifically recognized by MBPs. It must be noted, 
however, that in vivo genomic binding by MBPs has been investigated only to a limited 
extent, mainly in ChIP-QPCR analyses of preselected loci (see also chapter 7). MBPs 
interact with a variety of proteins with repressive functions such as histone 
deacetylases and chromatin remodeling complexes that establish a repressive chromatin 
state [76].  
 
Studies of transcriptional regulation by DNA methylation have mainly focused on 
its role at promoters, where hypermethylation results in gene repression. However, 
recent genome-wide studies indicate that the functions of DNA methylation are more 
complex. Methylation patterns across the gene (intragenic or gene-body methylation) 
may have a role in transcriptional regulation and efficiency as well [77]. In genome-
wide studies of the Arabidopsis thaliana methylome, abundant DNA methylation was 
found within the bodies of active genes, which was highly correlated with transcription 
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levels [78-80]. Similar findings were then reported for mammals. Hellman and Chess 
found higher levels of gene body methylation at the active X chromosome compared to 
the inactive X chromosome [81]. Various studies reported a genome-wide positive 
correlation between gene body methylation and gene expression in various human cell 
types [23-24,82-84]. It was suggested that expressed genes have higher levels of gene 
body methylation to repress unwanted expression of ncRNAs or alternative promoter 
activity [79,83,85]. Laurent et al. found that exons were more highly methylated than 
introns, and sharp transitions of methylation occurred at exon-intron boundaries, 
suggesting a role for differential methylation in transcript splicing [24]. Altogether, 
current data suggest that gene body methylation plays a role in regulating gene 
expression. How gene body-specific DNA methylation is targeted and how it functions 
in gene regulation are subjects of current research.    
Another recent observation is cell type-specific DNA methylation at CpG-island 
shores. Using CHARM to profile whole genome methylation patterns of normal mouse 
tissues and human colon cancer, Irizarry et al. found that differentially methylated 
regions are often localized in regions flanking CpG-islands: CpG-island shores [86]. 
CpG-island shores are regions of lower CpG density that lie in close proximity, but 
often not within, CpG-islands. Substantial differential methylation at CpG-island 
shores was also identified in induced pluripotent stem cells as compared to their 
parental fibroblasts [87], in peripheral nerve sheath tumor cells as compared to normal 
Schwann cells [88] and during lineage commitment of hematopoietic progenitors [89]. 
Differential CpG-island shore DNA methylation correlated with gene expression and 
thus potentially regulates tissue-specific gene expression profiles. 
  
1.5 – Cross-talk with other chromatin marks 
Interplay and interdependencies between different epigenetic marks are essential in 
regulation of chromatin-based processes. Bidirectional cross-talk between DNA 
methylation and other chromatin modifications occur in various manners, e.g. via 
methylated DNA binding of MBPs that recruit chromatin modifying complexes, via 
interactions of DNMTs with chromatin modifying enzymes, and via repellant and 
recruiting effects of modifications on other proteins and complexes. The co-occurrence 
and interplay between DNA methylation and other chromatin modifications have been 
subject of intensive research [90]. First of all, histone H3K9 methyltransferases G9A 
and SUV39H have been shown to be involved in the regulation of DNA methylation. 
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Interactions  between G9A and SUV39H, and DNMTs have been reported [91-92]. 
Mouse embryonic stem cells lacking G9a showed a significant reduction in DNA 
methylation at G9A target genes, retrotransposons, major satellite repeats and densely 
methylated CpG-rich promoters [91,93-94]. It appeared that H3K9 methylation itself 
was not required for DNA methylation. It was therefore suggested that G9A directs de 
novo DNA methylation, independent of its histone methyl-transferase activity, by 
directly recruiting DNMTs to genomic sites. Double knockout of Suv39h1 and Suv39h2 
resulted in loss of DNA methylation at pericentric major satellite repeats in mouse 
embryonic stem cells and similarly SUV39H was suggested to mediate DNA 
methylation via recruitment of DNMTs to pericentric heterochromatin [92,95]. On the 
other hand, the H3K9 methyltransferase SETDB1 was found to regulate a distinct set 
of genes and repetitive elements compared to those regulated by DNA methylation, as 
apparent from knockout studies in mouse embryonic stem cells [96]. The H3K9 
methylation and DNA methylation machinery are thus directly linked via G9A and 
SUV39H, but not SETDB1, enzymes. 
Concerning the relation of DNA methylation to repressive mark H3K27me3 
various phenomena have been described. Direct interactions between Polycomb 
complexes and DNMTs were reported and it was suggested that Polycomb is involved 
in DNA methylation targeting [97]. However, these findings were not reproduced in 
another study [98]. Various studies reported H3K37me3 marking at hypermethylated 
promoters in cancer cells, suggesting cooperation of both modifications in silencing 
[68,99]. On the other hand, antagonism or mutual exclusiveness between DNA 
methylation and H3K27me3 has been described. DNA enriched for H3K27me3 did not 
show DNA hypermethylation and vice versa at the mouse Rasgrf1 locus [100] and at 
loci in human cancer cells [101]. In recent nucleosome affinity purifications, 
enrichment of PRC2 components at H3K27me3 nucleosomes was obstructed by DNA 
methylation of the nucleosome positioning sequence, suggesting negative regulation of 
PRC2 by DNA methylation [102]. In mouse postnatal neural stem cells non-promoter 
DNA methylation by DNMT3A was found to counteract PRC2 binding, thereby 
facilitating transcription of neurogenic genes [103]. Various studies described a 
correlation between Polycomb marking and de novo (aberrant) DNA methylation: 
cancer-specific or neural differentiation-specific hypermethylated promoters were 
shown to be DNA methylation free but associated with Polycomb/H3K27me3 in 
embryonic stem cells [68-70,104]. Similar observations were made in prostate cancer 
cells when compared with matching primary cells [105]. Although the different 
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observations are not necessarily incompatible, a consensus interpretation has not been 
reached thus far.  
Finally, correlations between DNA methylation and H3K4me3 and H3K36me3 
have been described. Genome-wide analyses showed an inverse correlation between 
DNA methylation and H3K4me3, suggesting that H3K4me3 protects DNA from de 
novo methylation [104,106-108]. In support of this hypothesis, DNMT3L, DNMT3A 
and DNMT3B interact with H3K4 via the ADD domain, whereas H3K4 trimethylation 
interferes with this binding [109-111]. DNA methylation occurs abundantly at gene-
bodies of active genes (see above), and here it coincides with H3K36me3. The 
distribution of the latter modification is positively correlated with DNA methylation 
[82,112]. In support of this, Dhayalan et al. found that the PWWP domain of DNMT3A 
specifically recognizes H3K36me3 in vitro and suggested that the interaction of the 
PWWP domain with H3K36me3 may be involved in targeting of DNMT3A to the 
chromatin in vivo [113]. 
 
1.6 – Methyl-CpG Binding Proteins 
Methylated CpGs are specifically bound by methyl-CpG binding proteins (MBPs) in 
vitro. In mammals, three structurally different types of MBPs have been identified so 
far: the methyl-CpG binding domain (MBD) proteins, the KAISO family proteins and 
the SET and RING finger-associated domain (SRA) family proteins. MeCP2 was the 
first identified MBD protein two decades ago. Methyl-DNA binding activity was 
detected in nuclear extracts by EMSAs and Southwestern assays [114-115]. MeCP2 
was subsequently purified by traditional biochemical approaches [115]. The domain 
responsible for binding of methylated DNA was mapped and named MBD [116]. Via 
homology searches other MBD proteins were identified: MBD1, MBD2, MBD3, 
MBD4, MBD5 and MBD6 [117-120]. However, MBD3, MBD5 and MBD6 lack 
methyl-CpG binding activity [118,121]. In a similar way, KAISO was detected and 
purified as methyl-DNA binding activity [122]. It was found to bind methylated DNA 
via three C2H2 zinc finger motifs. The KAISO-related proteins ZBTB4 and ZBTB38 
were then identified via homologous domains [123]. Most recently, the SRA domain 
present in UHRF1 and UHRF2 was found to specifically recognize methylated DNA 
[47,124-125].  
The various types of MBPs are schematically depicted in Fig.3. In addition to 
their methyl-CpG binding motifs they contain various additional domains. MBD1 has 
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additional CXXC zinc fingers, MBD2 a glycine and arginine rich domain and MBD4 a 
thymine glycosylase domain. Moreover, various non-homologous transcription 
repression domains have been mapped in the MBD proteins. KAISO contains, in 
addition to the three tandem C2H2 zinc fingers at the C-terminus responsible for 
methylation-dependent DNA binding, a BTB/POZ domain at the N-terminus. ZBTB4 
and ZBTB38 contain homologous zinc fingers and BTB/POZ domains. Moreover, they 
contain additional zinc fingers making them longer and more complex than KAISO. 
UHRF1 and UHRF2 contain besides the SRA domain, an ubiquitin-like domain, a 
tandem tudor domain, a PHD finger and a RING finger motif.  
 
Figure 3. Mammalian Methyl-CpG Binding Proteins. In mammals three structurally different 
types of MBPs exist, as indicated. MBD family proteins bind methylated DNA via the MBD domain. 
Only family members with methyl-CpG binding capacity are shown. UHRF1 and UHRF2 bind 
methylated DNA via the SRA domain. The KAISO family proteins contain three tandem zinc-fingers 
that are responsible for methylated DNA binding. Additional domains within the various MBPs are 
indicated. TRD, Transcription Repression Domain; CTD, Carboxyl Terminal Domain; CXXC, CXXC 
zinc finger domain; glycosylase, DNA glycosylase domain; Ubl, Ubiquitin-like domain; TTD, 
Tandem Tudor Domain; PHD, Plant Homeo Domain; SRA, SET and RING finger Associated 
domain; RING, RING finger domain; BTB/POZ, BTB/POZ domain; pink rectangles indicate 
Krüppel-like C2H2 zinc fingers. Figure adapted from [126]. 
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The structure of the MBD domain has been resolved [127-128]. It binds 
symmetrically methylated CpG. Sequence preferences for some of the MBD proteins 
have been reported. For example, MeCP2 prefers methylated sites flanked by A/T 
tracts in vitro, which is partly explained by tightening of the minor groove by these 
tracts [127,129]. Clouaire et al. reported that MBD1 binds more efficiently to 
methylated CpG in the context of TCpGCA and TGCpGCA sites [130]. Methyl-DNA 
binding by KAISO family members is likely to occur via the canonical DNA binding 
mechanism of C2H2 zinc finger proteins [131], however, the methyl-DNA  binding 
domain structure of these proteins has not been resolved yet. Notably, KAISO binds 
methylated DNA [122], as well as unmethylated DNA, namely the KAISO binding 
sequence CTGCNA [132]. The same applies to ZBTB4 that can bind either methylated 
DNA or the KAISO binding sequence [123]. Recently, Sasai et al. showed that the 
KAISO family proteins bind methylated DNA in a sequence-specific manner in vitro: 
the nucleotides surrounding the methylated CpG directly contribute to the binding 
affinity [131]. They also found that methylated DNA binding by KAISO family 
proteins is not symmetrical and that they have high affinity for hemimethylated DNA. 
Finally, the SRA domain of UHRF1 has been structurally resolved; it binds 
hemimethylated CpG and flips methylcytosine out of the DNA helix by a previously 
unknown binding module [133].  
MBPs interact with a variety of coregulators; many reports have described 
interactions between MBPs and other factors and transcriptional repressive complexes. 
Via recruitment of these coregulators, MBPs mediate DNA methylation associated 
gene silencing. Besides, it appears that MBPs carry out specific functions. MBD1 
associates with the H3K9 methyltransferases SETDB1 and SUV39H1 and the 
heterochromatin-binding protein HP1 [134-135]. Sarraf et al. showed that during DNA 
replication MBD1 recruits the H3K9 methyltransferase SETDB1 to chromatin 
assembly factor CAF-1 to facilitate H3K9 methylation during replication-coupled 
chromatin assembly [135]. It was concluded that MBD1 is involved in establishment 
and maintenance of H3K9 methylation to form stable heterochromatin at methylated 
DNA. For MeCP2 interactions with a wide variety of factors and complexes have been 
described [136], for example SIN3/HDAC, c-SKI and ATRX [137-141]. While the 
functional importance of many of these different interactions has not been clarified and 
it has been suggested that interactions are relatively unstable [136], neuronal-specific 
functions of MeCP2 have been well established [142]. Most importantly, Skene et al. 
reported MeCP2 to be nearly as abundant as the histone octamer in neuronal nuclei and 
described a role for MeCP2 as a global regulator of neuronal chromatin structure [143]. 
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MBD2 has been shown to be a subunit of the Mi-2/NuRD chromatin remodeling 
complex [144]. Also the highly homologous MBD3 is a subunit of the NuRD complex 
in a mutual exclusive manner; MBD2/NuRD and MBD3/NuRD are two distinct 
complexes [145]. KAISO has been shown to interact with the NCoR/HDAC3 complex 
[146]. Also, it is reported to be involved in the Wnt pathway via association with p120-
catenin [147]. As mentioned before, MBD4 contains a thymine glycosylase domain, 
and is involved in the DNA repair of T:G mismatches that originate from deamination 
of methylcytosine into thymine [148-149]. UHRF1 has been shown to be required for 
maintenance of DNA methylation [47,125]. It directly interacts with maintenance DNA 
methyltransferase DNMT1 and recruits the enzyme to newly replicated 
hemimethylated DNA, ensuring proper propagation of the methyl mark.  
Whereas the DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b are essential 
for mouse viability and development [150], Mbd1 [151], Mbd2 [152], Mbd4 [153], 
Mecp2 [154-155] and Kaiso [156] knockout mice are viable and fertile. Also 
simultaneous deficiency of three MBPs, namely, Mbd2, Mecp2 and Kaiso, is 
compatible with normal mouse embryogenesis [157]. Mbd1 knockout mice display 
reduced genomic stability and a number of minor neural defects [151]. Mbd2 [152] and 
Kaiso [156] knockout mice show no apparent abnormalities, apart from defective 
maternal behavior of Mbd2 deficient mice. However, when crossed with Apc(Min/+) 
mice susceptible for intestinal tumorigenesis, both knockouts display suppression of 
tumor formation [156,158]. Consistent with a role in DNA repair, Mbd4 knockout mice 
display increased CpG mutability and accelerated tumor formation on a cancer-
susceptible Apc(Min/+) background [153]. Mutations in the MeCP2 gene cause Rett 
syndrome in human, an X-linked neurological disorder that represents one of the most 
common causes of mental retardation in females [63]. Mecp2 deficient mice exhibit a 
Rett syndrome-like phenotype [154-155]. The only MBP that has been shown to be 
essential for early development so far is Uhrf1 [47]. Notably, deletion of Mbd3, that 
shows high sequence similarity with Mbd2 but does not recognize DNA methylation, 
results in embryonic lethality. Possible explanations for the lack of major phenotypes 
upon deletion of MBPs have been suggested [121]: DNA methylation is essential in 
development but may not act primarily by recruiting MBPs, extensive redundancy 
between MBPs may compensate for deletions, or additional proteins that interpret 
DNA methylation patterns may exist. 
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1.7 – CpG-islands 
CpG-islands, regions with a high G+C content and high CpG dinucleotide occurrence, 
are predominantly unmethylated [30,159]. Approximately 70% of annotated gene 
promoters are associated with CpG-islands, including virtually all housekeeping genes 
as well as a proportion of tissue-specific genes and developmental regulator genes 
[160-162]. A large group of CpG-islands is remote from annotated transcription start 
sites, called “orphan” CpG-islands [85,163]. Illingworth et al. employed a biochemical 
approach to isolate CpG-islands: they captured nonmethylated CpG-rich DNA by 
affinity purification using the CXXC domain, which has high affinity for 
nonmethylated CpG-sites [164], and subjected captured DNA to deep sequencing. 
They isolated and defined the complete CpG-island complement in human and mouse 
[34,163]. Whereas bioinformatic algorithms for CpG-island prediction largely depend 
on thresholds and predicted far fewer CpG-islands in the mouse genome than in the 
human genome [165], the biochemical approach by Illingworth revealed similar 
numbers of CpG-islands for human and mouse [163]. Approximately half of 
mammalian CpG-islands were found to be orphan and to be located within gene bodies 
as well as in between genes [163]. Many orphan CpG-islands show evidence of 
transcription initiation, as derived from RNA Polymerase II occupancies and RNA 
sequence data, and presumably represent novel promoters, alternative promoters or 
transcription start sites for ncRNAs [85,163]. Notably, orphan CpG-islands are more 
frequently subject to DNA methylation during development compared to CpG-islands 
at promoters [85,163]. Illingworth et al. reported that 21-26% of intragenic CpG-
islands and 13-15% of intergenic CpG-islands are methylated in somatic cells, 
accompanied by loss of active promoter features [163]. In contrast, only 2-3% of 
annotated promoter CpG-islands gains somatic DNA methylation.    
Unmethylated CpG-islands are organized in a characteristic chromatin structure 
that enables promoter activity [30]. CpG-islands are associated with histone H3 and H4 
acetylation [166-167], H3K4me3 [168-169] and a relative depletion of nucleosomes 
[170-172]. Two CXXC domain-containing proteins have recently been found to 
regulate CpG-island chromatin. The CXXC domain binds specifically to 
nonmethylated CpGs [164]. Thomson et al. found high enrichment of the CXXC 
protein CFP1 at unmethylated CpG-islands and showed that it targets H3K4me3 via its 
association with the H3K4 methyltransferase SETD1 [173]. Blackledge et al. showed 
recruitment of the H3K36 demethylase KDM2A to unmethylated CpG-islands via its 
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CXXC domain, resulting in removal of H3K36 methylation and depletion of this 
modification in CpG-island chromatin [174]. How CpG-islands are kept DNA 
methylation free is largely unknown. In vitro studies have shown that DNMT3L, 
DNMT3A and DNMT3B interact with H3K4 via the ADD domain [109-111]. H3K4 
trimethylation interferes with this binding and DNMT3A is catalytically less active in 
vitro on chromatin containing this modification. As such the prevailing CpG-island 
chromatin mark H3K4me3 may inhibit de novo DNA methylation in vivo. Also it has 
been suggested that the transcriptional activity at CpG-islands is antagonistic to DNA 
methylation, although the exact mechanisms are unresolved so far [30]. Apart from 
protection against DNA methylation, CpG-islands may be actively demethylated. It is 
speculated that hydroxymethylation-based mechanisms may be involved in active DNA 
demethylation of CpG-islands [175-176]. In support of this proposal, the methyl-
hydroxylating enzyme TET1 contains a CXXC domain and has been shown to 
associate with CpG-island promoters in vivo [177-179]. 
 
1.8 – Technical aspects in DNA methylation research 
DNA methylation information is lost using standard molecular biology techniques, 
such as cloning and PCR amplification. The main approaches for DNA methylation 
detection therefore rely either on methylation-dependent pretreatments of DNA, 
including methylation-sensitive restriction and bisulfite conversion, or on affinity 
enrichment of methylated DNA [180]. The methylation-sensitive restriction enzymes 
HpaII and SmaI, and their CpG methylation independent schizomers MspI and XmaI, 
are the most widely used restriction endonucleases in DNA methylation detection. 
Methylation-sensitive digestion followed by PCR across the restricted fragment is a 
commonly used method, although other read-outs are applied as well [180].  
Bisulfite conversion of DNA is the treatment of denatured DNA with sodium 
bisulfite that deaminates unmethylated cytosines to uracils [181-182]. Methylcytosines 
remain unconverted. After PCR amplification of treated DNA, fragments are obtained 
in which all uracil and thymine residues have been amplified as thymine and only 
methylcytosine residues have been amplified as cytosine [183]. PCR products can be 
cloned and sequenced to provide methylation maps at base-resolution of the targeted 
regions. Although bisulfite-based DNA methylation analyses are not easily adapted to 
array-hybridization techniques because of reduced sequence complexity after bisulfite 
conversion, several dedicated array platforms have been developed for bisulfite 
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analyses [180]. For example the Illumina Infinium HumanMethylation27k and 450k 
bead arrays interrogate corresponding numbers of selected CpG sites out of the 
approximately 28 million CpG sites in the human genome [184]. Nowadays, bisulfite 
treated DNA can be analyzed using next generation sequencing technology, for which 
it is particularly well suited.  
Affinity enrichment of methylated DNA can be performed using antibodies 
specific for methylcytosine or using MBPs. Immunoprecipitation of methylated DNA 
using specific antibodies, known as MeDIP [107,185], mDIP[67] or mCIP[78], is done 
on denatured DNA. MBPs have high affinity for methylated native genomic DNA and 
are applied on fragmented double-stranded DNA. The first demonstration of affinity 
enrichment of methylated DNA using a MBP was by Cross et. al with MeCP2 [186]. 
MethylCap is based on capture with the MBD domain of MeCP2 [187], whereas other 
methods use multimerized MBD1 domains [188] or a protein complex containing 
MBD2b and MBD3L1 (MIRA) [189-190]. Affinity enriched DNA is analyzed in 
QPCR, array hybridizations or deep sequencing.  
 
Over the last years major advances in DNA methylation analysis technology have 
taken place. Next generation sequencing technology has been integrated into genomic 
DNA methylation studies and has largely replaced microarray methods. Several next 
generation sequencing platforms exist that are able to sequence a very large number of 
sequence reads in parallel, i.e. massively-parallel short-read DNA sequencing [191-
192]. The Roche 454 GS FLX can generate approximately one million longer sequence 
reads (400bp) per instrument run, whereas the Illumina and Life Technologies 
machines can produce several hundred million shorter sequence reads (<150bp) [193]. 
This technology enables sequencing of DNA at full-genome depth. Compared to 
microarray based methods, next generation sequencing offers several advantages, 
including the large and quantitative dynamic range of signal, no limitations to the 
genomic regions that can be analyzed originating from array composition, the single-
base resolution and absence of cross-hybridization issues and low demands for amounts 
of starting material [194].  
Whole genome shotgun bisulfite sequencing, yielding genome-wide base-
resolution DNA methylation information, was first applied on the small genome of the 
eukaryote Arabidopsis thaliana [80,195] in 2008. One year later the complete 
methylomes of human embryonic stem cells and fetal lung fibroblasts were uncovered 
[23]. Using next generation sequencing-based bisulfite shotgun sequencing, Lister et al. 
were able to cover 94% of all cytosines in the human genome [23].  The availability of 
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genome-wide base resolution DNA methylation maps [23-24,196] has led to new 
insights and discoveries, for example the relatively large extent of non-CpG 
methylation occurring in human embryonic stem cells. The usage of whole genome 
bisulfite sequencing is however limited by the cost of the required sequencing depth of 
entire genomes. Methods have been developed to obtain a restricted genomic 
representation for bisulfite sequencing. Reduced representation bisulfite sequencing 
(RRBS) applies a digestion step, using the methylation-insensitive restriction enzyme 
MspI, and size-selection to obtain a CpG-rich subfraction of the genome covering the 
majority of CpG-islands and other regions of interest [106,197]. In this thesis ChIP-BS-
seq is described, in which ChIP-capturing is integrated with bisulfite sequencing, 
yielding DNA methylation information for the sub-genomic regions occupied by a 
specific histone modification or transcription factor.  
Also affinity-based DNA methylation analyses have been widely integrated with 
next generation sequencing. Affinity-based sequencing methods include MeDIP-seq 
[198] and MethylCap-seq [187] and permit for efficient genome-wide assessment of 
DNA methylation. These methods do not yield information at base resolution and have 
a strong CpG-density bias. Consequently, instead of absolute DNA methylation levels 
per CpG, the relative enrichment of methylated DNA is measured. Overrepresented 
sequences (peaks) correspond with methylated regions of the genome. CpG-densities 
influence capturing efficiencies [199]: low read counts can indicate the relative absence 
of CpGs or the absence of DNA methylation in the presence of CpGs. High read counts 
indicate methylated CpG-dense regions, but may also occur at partially methylated 
CpG-dense regions. For this reason statistical corrections for CpG-densities are applied 
[199]. In MethylCap-seq, step-wise elution of captured DNA is implemented to stratify 
the genome into fractions with different CpG-densities [187].    
Sequencing technology is constantly developing further, giving rise to ever more 
powerful platforms. More reads are generated per sequencing run, whereas overall 
costs decline. Consequently, powerful bioinformatic tools are required to accurately 
analyze the vast and numerous DNA methylation datasets being generated, and 
integrate DNA methylation information with other epigenomic data types, e.g. 
generated in the international consortia that tackle the epigenome [200]. Next to this, 
new methods are being developed; the so-called third generation sequencing 
technology which is characterized by single molecule DNA sequencing [201-202]. 
Single molecule real-time (SMRT) sequencing and nanopore sequencing offer the 
potential for direct DNA methylation detection without the need for bisulfite 
conversion [203-205]. Affinity-based and bisulfite-based next generation sequencing 
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approaches for DNA methylation analysis dominate for the moment, but third 
generation technology may herald the next revolution in high-throughput DNA 
methylation analyses [180]. 
 
1.9 – Non-CpG methylation 
In vertebrates methylcytosine is almost exclusively present in a CpG context. However, 
non-CpG methylation does occur in specific cell types in mammals and was 
investigated in several recent studies. Ramsahoye et al. detected non-CpG methylation 
in mouse embryonic stem cells but not somatic tissues [206]. Using whole genome 
bisulfite sequencing, Lister et al. found that in human embryonic stem cells almost 25% 
of all cytosines at which DNA methylation was identified occur in non-CpG contexts, 
whereas in fetal lung fibroblasts non-CpG methylation is virtually absent [23]. The 
base following a non-CpG methylcytosine is most commonly an A [23]. Non-CpG 
methylation in embryonic stem cells is lost upon differentiation. Similar findings were 
described in another genome-wide bisulfite sequencing study [24]. Thus it appears that 
non-CpG methylation is confined to the pluripotent state.  
Methylation levels at identified methyl-CpG and methyl-non-CpG sites in human 
embryonic stem cells differ: 80-100% methylation was detected at the majority of 
methyl-CpG sites, versus 10-40% methylation at methylcytosines in non-CpG contexts 
[23]. Another striking observation is that, in contrast with CpG methylation, non-CpG 
methylation is highly asymmetrical, i.e. often occurring on only one strand of the DNA 
[23]. Ziller at al. analyzed non-CpG methylation within a large set of RRBS 
methylation maps of pluripotent and differentiated human cell types [207]. In line with 
previous observations, non-CpG methylation was found in pluripotent cell types but 
decreases upon differentiation and is absent in somatic cell types. Remarkably, patterns 
of non-CpG methylation are highly variable and show little conservation between 
different pluripotent cell lines [207].  
DNMT3 enzymes are thought to mediate deposition of non-CpG methylation. 
DNMT3A is able to methylate CpAs and CpTs in transgenic Drosophila expressing 
mouse DNMT3A [206]. Also in vitro studies showed that DNMT3A methylates CpA 
dinucleotides in addition to CpG sites that are most actively modified [208]. DNMT1 
displays almost no methylation activity at non-CpG sites in vitro [209]. Levels of non-
CpG methylation are largely unaffected by null mutations of Dnmt1 in mouse 
embryonic stem cell lines [206], but reduced by Dnmt3a and Dnmt3b knockout [210-
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211]. Recently, Ziller et al. showed that non-CpG methylation levels correlate with 
DNMT3  expression levels and knockdown of DNMT3A and DNMT3B in human 
embryonic stem cells results in global reduction of non-CpG methylation [207]. 
Whether non-CpG methylation is of functional importance, for example for 
pluripotency, or is a non-functional side-product of de novo DNMTs that is not actively 
maintained, remains subject for future investigations. 
 
1.10 – Hydroxymethylcytosine 
The recent discovery of 5-hydroxymethylcytosine (Fig.4) as a constituent of 
mammalian genomes is of major importance. It shows that additional chemistry occurs 
at methylcytosines, which likely plays important roles in biological processes [212-
213]. In a computational search for enzymes that could modify methylcytosine, 
Tahiliani et al. identified the ten-eleven translocation (TET) proteins [214]. TET1 was 
shown to catalyze conversion of methylcytosine to hydroxymethylcytosine in cultured 
cells and in vitro. Importantly, hydroxymethylcytosine was detected in the genome of 
mouse embryonic stem cells. Hydroxymethylcytosine was not present in other cell 
lines tested and its prevalence in embryonic stem cells decreased upon differentiation. 
At the same time, Kriaucionis et al. detected the presence of hydroxymethylcytosine in 
neuronal Purkinje and granule cells [215]. It was subsequently shown that all TET 
proteins (TET1, 2 and 3) are capable of hydroxylating methylcytosine to generate 
hydroxymethylcytosine [216]. Subsequently, it was found that TET proteins are able to 
further oxidize hydroxymethylcytosine to formylcytosine and carboxylcytosine (Fig.4) 
[217-218]. These variants were also detected in mouse embryonic stem cells [217-219]. 
Ito et al. detected levels of 0.13%, 0.002% and 0.0003% (% of all cytosine) for 
hydroxymethylcytosine, formylcytosine and carboxylcytosine, respectively [218]. 
While hydroxymethylcytosine and formylcytosine were also detected in various mouse 
tissues, carboxylcytosine could only be reliable detected in mouse embryonic stem 
cells [212,218]. 
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Figure 4. Conversion of methylcytosine by TET enzymes. TET enzymes catalyze conversion of 
methylcytosine (5mC) to hydroxymethylcytosine (5hmC). Hydroxymethylcytosine can be further 
oxidized by TET enzymes to formylcytosine (5fC) and carboxylcytosine (5caC). Figure adapted 
from [212].  
 
Bisulfite-based technologies for DNA methylation detection are incapable to 
distinguish methyl- and hydroxymethylcytosines. New techniques that can specifically 
detect hydroxymethylcytosine have been developed. TLC-based and MS-based 
methods were initially used in discovery and quantification of total levels of 
hydroxymethylcytosine in genomes [214-215,218-220]. Hydroxymethylcytosine-
specific antibodies and selective chemical labeling approaches are used in genome-
wide mapping techniques [221-226]. Single-molecule real-time sequencing allows 
discrimination between methylcytosine and hydroxymethylcytosine and yields base-
resolution information [203], but is not widely applied yet as it is still at a testing 
phase. Levels of genomic hydroxymethylcytosine are tissue specific. Globisch et al. 
found highest levels of hydroxymethylcytosine (0.3%-0.7%) in neuronal tissues, 
whereas kidney, nasal epithelium, bladder, heart, sekeletal muscle and lung contain 
medium levels (0.15%-0.17%) and liver, spleen and endocrine glands lowest amounts 
(0.03%-0.06%) [220]. As a comparison, methylcytosine levels of 4.3% were measured 
in all tissues using the same LC-MS method [220]. Roles of hydroxymethylation in 
demethylation processes are subject of intense current investigations. 
Hydroxymethylcytosine may aid passive demethylation because it is not recognized or 
replicated by DNMT1 [227], but it could also represent an intermediate step in active 
removal of methylcytosine, as discussed below. Hydroxymethylcytosine likely 
represents a functional epigenetic mark in mammalian genomes, but it is thus far 
unknown whether it recruits specific “readers” or DNA  binding proteins. Methyl-DNA 
binding MBD proteins do not recognize hydroxymethylcytosine [228-229]. However, 
the MBP UHRF1 has been shown to bind hydroxymethylcytosine in vitro [230]. Most 
recently, a role for MBD3 in hydroxymethylcytosine biology has been postulated 
[231]. 
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1.11 – DNA demethylation 
As discussed before, global erasure of DNA methylation takes place in specific 
embryonic stages in mammals. In addition, locus-specific active demethylation upon 
specific stimuli in somatic cells has been described. For example Bruniquel et al. 
reported replication independent demethylation at the interleukin-2 promoter-enhancer 
region in T lymphocytes following activation [232]; Martinowich et al. described 
locus-specific demethylation at the promoter of brain-derived neurotrophic factor in 
post-mitotic neurons upon stimulation [233]. Finally, recent base-resolution DNA 
methylation maps of pluripotent and differentiated cells indicated that DNA 
methylation undergoes extensive changes during cellular differentiation [23,106]. 
These observations suggest the existence of enzymatic activities that erase DNA 
methylation patterns. Elucidation of DNA demethylation mechanisms has been and still 
is subject of intense research and a variety of mechanisms by which active DNA 
demethylation can occur has been proposed (reviewed in [25,234-235]). These include 
mechanisms in which the methyl-group is removed, the methylcytosine-base is 
removed, or the methylcytosine-nucleotide is removed and replaced by normal 
cytosine. None of the mechanisms has been conclusively proven and many aspects are 
still contentious.  
 
In plants demethylation is well established; methylcytosine-specific bifunctional 
glycosylases remove the methylcytosine-base and then cleave the DNA backbone at the 
abasic site, resulting in a gap that is then filled with an unmethylated cytosine 
nucleotide by DNA polymerase and ligase enzymes [236]. DNA demethylation through 
base excision-repair (BER) pathways has been proposed for mammals as well [25,234]. 
No mammalian homologs of the plant methylcytosine-specific glycosylases have been 
found. Thymine DNA glycosylase (TDG) and MBD4 were reported to possess 
glycosylase activity towards methylcytosine, but this activity is 30-40 times lower than 
T-G mismatch glycosylase activity [237-239]. However, an alternative mechanism, 
BER upon deamination of methylcytosine to thymine, has gained certain support. In 
this scenario deamination of methylcytosine, resulting in T-G mismatches, is followed 
by BER initiated by T-G mismatch glycosylases, such as MBD4 and TDG. Activation-
induced cytosine deaminase (AID) and apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 1 (APOBEC1) can deaminate methylcytosine to thymine and are 
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expressed in mouse PGCs, oocytes and embryonic stem cells, suggesting a possible 
role in demethylation here [240]. In zebrafish embryos demethylation of injected DNA 
was observed when AID and MBD4 were coexpressed [241]. Male and female PGCs 
from Aid-null mouse embryos displayed 4% and 13% increase in DNA methylation 
levels, respectively, compared to wild type PGCs [242]. On the other hand, neither Aid 
knockout nor Apobec1 knockout mice shows developmental defects [243-246]. Both 
enzymes strongly prefer single-stranded DNA for methylcytosine deamination [240]. 
Also, it is unknown whether thymine glycosylases would use double TG-GT 
mismatches, resulting from deamination of methylcytosine on both strands in 
symmetrically methylated DNA, as a substrate [234]. Finally it has been mentioned 
that the involvement of repair-based mechanisms in global DNA demethylation would 
put tremendous pressure on the repair machinery [234].  
In addition to BER, nucleotide excision repair (NER) may play a role in active 
DNA demethylation [25,234]. In this case dual incisions in the DNA release a 24-32 
nucleotide oligomer and the resulting gap is filled in by repair polymerases and sealed 
by ligases. Barreto et al. showed that GADD45A overexpression activates methylation-
silenced reporter plasmids and promotes global DNA demethylation, whereas 
knockdown leads to DNA hypermethylation [247]. It was reported that demethylation 
occurs by NER and that GADD45A interacts with and requires the DNA repair 
endonuclease XPG. A role for GADD45A and NER in DNA demethylation in rRNA 
gene activation was also described by Schmitz et al. [248]. However, two independent 
studies, exploiting similar experiments as by Barreto et al. and analyzing Gadd45a-null 
mice, could not find evidence for a role of GADD45A in DNA demethylation [249-
250]. Similarly, a role for GADD45B in DNA demethylation is controversial [251-
252]. Therefore, functioning of NER in DNA demethylation has not been firmly 
established so far.    
 
The discovery of hydroxymethylcytosine in mammalian cells has suggested new 
possibilities for DNA demethylation. Methylcytosine is converted to 
hydroxymethylcytosine by TET proteins that are capable of acting on both fully 
methylated and hemi-methylated DNA [214]. TET proteins may facilitate passive DNA 
demethylation in dividing cells, as hydroxymethylcytosine is not recognized by 
DNMT1 [227]. Also hydroxymethylcytosine may be an intermediate in active 
demethylation pathways. Hydroxymethylcytosine may be deaminated to form 
hydroxymethyluracil, followed by repair through glycosylases and the BER pathway. 
The glycosylases TDG and SMUG1 display activity at hydroxymethylU-G sites, 
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whereas they have no or very low activity at hydroxymethylC-G sites [253]. Guo et al. 
found support for this model in analysis of (hydroxy)methylated reporter DNA upon 
cotransfection with glycosylases and deaminases [254]. However, whether deaminases 
have sufficient activity for hydroxymethylcytosine needs further biochemical evidence. 
Also, hydroxymethyluracil does not accumulate to detectable levels in mammalian 
cells [219-220], although this may be because it is short-lived. Recently, it was found 
that hydroxymethylcytosine can be further oxidized to formylcytosine and 
carboxylcytosine by TET proteins [217-218]. This raises the possibility that DNA 
demethylation may occur through TET-catalyzed oxidation followed by 
decarboxylation [218]. A putative decarboxylase capable of removing the carboxyl 
group from carboxylcytosine to regenerate unmodified cytosine remains to be revealed. 
Recent studies showed that formylcytosine and carboxylcytosine, but not 
hydroxymethylcytosine, are recognized and excised by TDG [217,255]. Notably, TDG 
shows higher activity at formylcytosine than at G-T mispairs [255]. These findings 
suggest that iterative oxidation of methylcytosine by TET proteins and TDG-mediated 
BER of formed products constitutes a pathway for active DNA demethylation 
[217,255]. In support of a role for TDG in DNA demethylation, knockout of Tdg leads 
to embryonic lethality and aberrantly elevated DNA methylation levels at a cohort of 
gene promoters [253,256].  
Finally, Okada et al. uncovered a role for the elongator complex protein 3 (ELP3) 
in DNA demethylation [252]. They identified this protein in a screen for factors 
responsible for zygotic paternal genome demethylation, using knockdown of candidate 
genes coupled with live-cell imaging of the demethylation process by CXXC-EGFP 
binding. A mechanism for ELP3-catalyzed DNA demethylation has been proposed 
[234], however, future studies are required to elucidate the role of the elongator 
complex in DNA demethylation. It is possible that multiple DNA demethylation 
mechanisms exist that act in specific biological contexts, e.g. global demethylation may 
involve mechanisms different from those involved in locus-specific demethylation. Yet 
clearer data are required concerning DNA demethylation. The recent discovery of 
hydroxymethylcytosine and the development of new technologies have opened new 
avenues of research and studies in the coming years will undoubtedly shed more light 
on DNA demethylation in mammals. 
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1.12 – Outline of this thesis 
DNA methylation forms one of the multiple layers of epigenetic regulation and is 
essential in many biological processes. Abnormalities in DNA methylation have been 
linked with disease. The last decades DNA methylation has been subject of intensive 
research having led to major insights in the functioning of this epigenetic mark. A good 
understanding of the DNA methylation code is vital to the biology and cancer research 
fields.   
 
DNA methylation patterns are ‘read’ by MBPs that include the MBD family 
proteins MeCP2, MBD1, MBD2 and MBD4, the three BTB/POZ-Zn-finger containing 
proteins KAISO, ZBTB4 and ZBTB38, and UHRF1 and UHRF2. They specifically 
bind methylated DNA and, as part of various transcriptional complexes, are thought to 
establish and/or maintain a specific chromatin state. Most of the known MBPs have 
been identified via homology with the MBD or BTB/POZ-Zn- finger domains as 
present in MeCP2 and KAISO, respectively. It is conceivable that other proteins exist 
that specifically recognize methylated DNA by protein domains that are thus far 
unknown to bind methylated DNA or uncharacterized. To search for putative novel 
MBPs, we developed a screen in which proteins that preferably bind to a methylated 
probe are identified. In methyl-CpG pull-downs, proteins interacting with a 
(methylated) DNA probe are isolated from SILAC-labeled nuclear extracts and 
analysed by mass spectrometry. Proteins that directly or indirectly specifically bind to 
methylated DNA in vitro are identified by significant heavy/light ratios. Chapter 2 
describes this method and shows results of this screen using a human CpG-island DNA 
sequence and U937 nuclear extracts. Apart from the known MBPs, the RBPJ 
transcription factor was found to specifically bind the methylated probe. Follow-up 
experiments showed that methylation-dependent binding of RBPJ is sequence-specific 
and occurs in the context of an atypical RBPJ binding motif.       
The MBD proteins MBD2 and MBD3 are found in mutually exclusive NuRD 
complexes [145]. The NuRD complex forms a large heterogeneous multiprotein 
complex that participates in various aspects of chromosomal biology [257]. NuRD core 
subunits are CHD3 and CHD4, that have ATP-dependent chromatin remodeling 
activity, histone deacetylases HDAC1 and HDAC2, and structural and/or targeting 
components RBAP48, RBAP46, MTA1-3, p66α, p66β and MBD2 or MBD3. Chapter 
3 shows that in addition to these proteins, DOC-1 is a bona fide subunit of the 
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MBD2/NuRD and MBD3/NuRD complexes. Virtually all NuRD complex subunits co-
purify with DOC-1 as apparent from SILAC-based mass spectrometry analysis of 
DOC-1-GFP complex. Using the previously described methyl-CpG pull-down 
approach in combination with SILAC and mass spectrometry analysis, it was shown 
that the MBD2/ NuRD complex and DOC-1 are specifically enriched on methylated 
DNA.     
In chapter 4 follow-up research is described for another transcription factor that 
we and others identified in methyl-CpG pull-downs as a methylation-dependent DNA 
binding protein: ZHX1. Bartke et al. found that this protein was specifically enriched 
by methylated DNA on its own or in a nucleosomal context using methyl-CpG pull-
downs combined with mass spectrometry analysis. ZHX1 is a multidomain protein that 
contains two tandem C2H2 zinc-fingers and five tandem homeodomains. We detected 
DNA methylation dependent binding in vitro and showed this binding is sequence-
specific and occurs via the homeoboxes. However, in vivo the generation of genome-
wide ZHX1 binding and DNA methylation maps showed that ZHX1 is recruited to 
unmethylated CpG-dense regions with active histone marks.  
Cross-talk between different epigenetic marks is of major importance in the 
regulation of chromatin-based processes. It is therefore of great interest to analyze the 
co-occurrence of DNA methylation with specific chromatin modifications or 
transcription factors. Chapter 5 describes a new approach for direct mapping of DNA 
methylation within subregions of the genome occupied by a specific modification or 
factor. In this method, called ChIP-BS-seq, ChIP captured DNA is subjected to 
bisulfite conversion and deep sequencing to directly determine DNA methylation at 
base-resolution within the regions of interest. Using this method we showed that DNA 
methylation and H3K27me3 generally co-occur, but are mutually exclusive at CpG-
dense regions.  
Chapter 6 continues on the RBPJ transcription factor, initially identified in our 
methyl-CpG pull-down assays as a methylation-dependent and sequence-specific DNA 
binding protein. Following the development of several tools to study this factor, 
including ChIP-seq, we were able to study genome-wide RBPJ binding in relation to 
Notch signaling status. According to the current model of Notch signaling RBPJ is 
constitutively associated with its targets, either in a transcriptional repressive complex 
in the absence of Notch signaling or in an activating complex following Notch 
activation, as described in a short additional introduction to chapter 6. In contrast with 
the current paradigm we showed that RBPJ binding at Notch targets depends on Notch 
signaling status. RBPJ displayed low/no binding at Notch targets when cells were 
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Notch inhibited and strong binding when cells were Notch activated. Finally, chapter 7 
provides a general discussion of all our findings. 
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Abstract 
DNA methylation is an epigenetic modification that plays a crucial role in a variety of biological 
processes. Methylated DNA is specifically bound by Methyl-CpG Binding Proteins (MBPs). 
Three different types of MBPs have been identified so far: the Methyl-CpG Binding Domain 
(MBD) family proteins, three BTB/POZ-Zn-finger proteins, and UHRF1. Most of the known 
MBPs have been identified via homology with the MBD and Zn-finger domains as present in 
MeCP2 and Kaiso, respectively. It is conceivable that other proteins are capable of recognizing 
methylated DNA. For the purpose of identifying novel ‘readers’ we set up a methyl-CpG pull-
down assay combined with stable-isotope labeling by amino acids in cell culture (SILAC). In a 
methyl-CpG pull-down with U937 nuclear extracts, we recovered several known MBPs and 
almost all subunits of the MBD2/NuRD complex as methylation specific binders, providing 
proof-of-principle. Interestingly, RBPJ, the transcription factor downstream of Notch receptors, 
also bound the DNA in a methylation dependent manner. Follow-up pull-downs and 
electrophoretic mobility shift assays (EMSAs) showed that RBPJ binds methylated DNA in the 
context of a mutated RBPJ consensus motif. The here described SILAC/methyl-CpG pull-down 
constitutes a new approach to identify potential novel DNAme readers and will advance 
unraveling of the complete methyl-DNA interactome.  
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2.1 – Introduction 
DNA methylation is an epigenetic modification that is essential for a variety of 
biological processes. In mammals, DNA methylation primarily occurs at cytosines in a 
CpG dinucleotide context. De novo DNA methyltransferases Dnmt3a and Dnmt3b and 
maintenance methyltransferase Dnmt1 are responsible for the establishment and 
maintenance of the DNA methylation mark, respectively. With the exception of CpG-
islands, short regions of high CpG-density that are often associated with gene 
promoters, the mammalian genome is globally methylated [1]. Most CpG-islands 
remain unmethylated during normal development, whereas aberrant CpG-island 
hypermethylation is a hallmark of cancer. CpG-island methylation is generally 
associated with transcriptional repression, and more recently gene-body DNA 
methylation has been associated with transcriptional activity [2]. 
Methylated CpGs are specifically bound by methyl-CpG binding proteins, and 
three families of MBPs are known in mammals (reviewed in [3-4]). The MBD family 
proteins MBD1, MBD2, MBD4 and MeCP2, bind methylated DNA via the Methyl-
CpG Binding Domain (MBD) [5]. Family members MBD3, MBD5 and MBD6 are, 
however, incapable of binding methyl-CpG [5-6]. The BTB/POZ-Zn-finger proteins 
Kaiso, ZBTB4 and ZBTB38 bind methylated DNA via three C2H2 zinc finger motifs 
[7-8]. Most recently, the SET and RING finger-assocoiated domain (SRA), present in 
UHRF1 and UHRF2, was also identified to specifically recognize methylated DNA [9-
11]. Many reports have shown interactions between MBPs and other proteins or 
complexes that function in heterochromatinization and transcriptional repression (e.g. 
[12-14]), which is thought to account for DNA methylation associated gene silencing.  
 NMR and crystal structures of MBD and SRA proteins in complex with 
methylated DNA have shed light on the modes of methyl-CpG binding, which are 
completely different for the two types of domains [15-17]. Methylated DNA binding by 
Kaiso family members may occur via the canonical DNA binding mechanism of C2H2 
zinc-finger proteins, as has been suggested in [18], however, the DNA binding domain 
structure of these proteins has not been resolved yet. Whereas UHRF1 and the Kaiso-
related proteins have high affinity for hemimethylated DNA [15,18], the MBD fold 
binds symmetrically methylated DNA [17]. For several MBPs sequence context 
dependent binding to methylated DNA has been described. MeCP2 prefers methylated 
sites flanked by A/T tracts, which in part is explained by tightening of the minor 
groove by these tracts [16,19]. The Kaiso-family members and MBD1 bind methylated 
Chapter 2 
 54 
DNA in a sequence-specific manner only, and the nucleotides surrounding the methyl-
cytosine directly contribute to binding affinity ([18,20]). With the recent discovery of 
hydroxymethyl-cytosine in genomic DNA of certain tissues, the question raised 
whether this modification is also recognized by MBPs. It was shown before that 
hydroxylation of methyl-cytosine interferes with binding of the MBD of MeCP2 [21], 
and in accordance recently it was reported that full-length MBD1, MBD2 and MBD4  
do not bind sequences containing hydroxymethyl-cytosine [22]. In contrast, the SRA 
domain of UHRF1 binds methylated and hydroxymethylated DNA with similar affinity 
[23].     
The earliest studies on identification of MBPs were performed two decades ago 
and describe the detection of methyl-DNA binding activities in nuclear extracts by 
EMSAs and Southwestern assays [24-25]. MeCP2 was the first MBP that was 
subsequently purified by traditional biochemical approaches [25]. The definition of the 
MBD domain of MeCP2 [26], led to the identification of the other MBD family 
members via homology searches for this domain [5,27]. Similarly, ZBTB4 and 
ZBTB38 were identified via homology searches for Kaiso-like Zn-fingers [8], after 
characterization of Kaiso [7]. The latter was, like MeCP2, initially discovered as a 
methyl-DNA binding activity in nuclear extracts and biochemically purified. The last 
decade major developments in mass-spectrometry-based proteomics have taken place, 
enabling the identification and quantification of thousands of proteins in complex 
mixtures. High-throughput interactomics approaches are now also starting to be applied 
in methyl-DNA interactome research. In a recent study, SILAC-based screening was 
performed to identify proteins whose binding to nucleosomes is regulated by 
methylation of DNA and/or histones [28]. Nucleosome interacting proteins were 
purified from SILAC-labeled nuclear extracts and enrichment on modified versus 
unmodified DNA/nucleosomes was quantitatively determined in mass spectrometry. 
The results revealed many proteins and complexes that can read the chromatin 
modification status.   
We here follow a similar SILAC-based approach for the identification of potential 
novel methyl-DNA binding proteins. As outlined above, most of the known DNAme 
readers have been identified via homology searches. Other DNAme readers may exist 
that were thus far unidentified due to the lack of unbiased screening methodology. It is 
conceivable that ‘novel’ protein folds, as well as known DNA binding motifs, may 
allow for recognition of methylated DNA. Indeed, an example of the latter 
phenomenon is the Kaiso-family, that binds methylated DNA via canonical C2H2 zinc-
fingers. Thus, possibly other known DNA binding motifs bind methylated DNA in 
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sequence context dependent or independent ways. We here describe a screening 
method to explore the methyl-DNA interactome, by combining SILAC labeling and 
quantitative mass spectrometry with methyl-CpG pull-downs. We show the results of a 
methyl-CpG pull-down/SILAC experiment with U937 nuclear extracts and DNA oligos 
based on a human CpG-island. Among various known DNAme readers we uncovered 
RBPJ as a methylation dependent binder to the DNA used in the pull-down. Follow-up 
experiments showed that RBPJ binds to methylated DNA in a sequence specific 
manner, namely in the context of a mutated consensus sequence. 
 
 
 
 
 
 
 
 
Figure 1 (Next page). A SILAC-based approach to identify novel methyl-CpG binding 
proteins. (A) Schematic depiction of the methyl-CpG pull-down assay combined with SILAC. 
Synthetic DNA is coupled to beads to capture binding proteins from a nuclear extract. Shown is a 
forward experiment, in which fully methylated DNA is used in a heavy-labeled extract and 
unmethylated DNA in an unlabeled extract. In a reverse experiment unmethylated DNA is used in a 
heavy-labeled extract, whereas methylated DNA is used in an unlabeled extract. After several 
washing steps and elution, both pull-down fractions are combined and analysed by mass 
spectrometry. Proteins that directly or indirectly specifically bind to the methylated DNA are 
identified by the quantitative ratios between heavy and light form. (B) DNA used in the methyl-CpG 
pull-down. The DNA fragment contains part of the sequence of the GSTP1 CpG-island, sites for 
primer annealing and a methylation-sensitive restriction site. After ligation a mixture of fragments 
with different lengths is obtained, which is subsequently biotinylated and methylated. Methylation is 
checked by a methylation-sensitive digestion followed by quantitative PCR. 
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2.2 – Results  
2.2.1 A SILAC-based assay to identify novel Methyl-CpG Binding 
Proteins 
To identify novel DNAme readers, we set up a methyl-CpG pull-down assay combined 
with SILAC, schematically depicted in Fig.1A. In this assay, proteins are captured 
from a protein extract by DNA coupled to beads, and quantitatively analyzed by mass 
spectrometry. In a forward experiment, fully methylated synthetic DNA is used as a 
bait for MBPs in a heavy-labeled nuclear extract, whereas unmethylated DNA is used 
in a light (normal) extract. In a reverse experiment, methylated DNA is used in a light 
extract and unmethylated DNA in a heavy extract. Both pull-down fractions (heavy and 
light) are mixed, and proteins that directly or indirectly specifically bind to methylated 
DNA in vitro will be identified by high heavy/light ratios in the forward experiment 
and low heavy/light ratios in the reverse experiment in subsequent mass spectrometry 
analyses.   
We performed a methyl-CpG pull-down with U937 nuclear extracts in forward 
and reverse using oligos containing part of the sequence of the human GSTP1 CpG-
island (Fig.1B); its hypermethylation is characteristic in prostate cancer [29]. Proteins 
that showed at least 1.5 fold enrichment or exclusion on methylated DNA in both 
forward and reverse experiments are presented in TableS1. A list of all identified 
proteins with accompanying forward and reverse heavy/light ratios is given in TableS4. 
To visualize the results, we generated a scatter-plot of forward and reverse heavy/light 
ratios of all identified proteins (Fig.2A). Proteins that specifically bind to methylated 
DNA cluster in the lower right quadrant, whereas proteins that are repelled by 
methylation of the DNA reside in the higher left quadrant of the scatter-plot. MBD2 
was most strongly enriched on methylated oligonucleotides and showed forward and 
reverse ratios of 12.89 and 0.08, respectively. Moreover, we identified the known 
DNAme readers Kaiso, MeCP2, UHRF1 and MBD4, as well as almost all subunits of 
the MBD2/NuRD complex in the lower right quadrant of the scatter plot with ratios of 
enrichment higher than 1.5 (Fig.2A, TableS1), indicating that they are methyl-specific 
binders to our DNA. These results provide proof of principle of our approach and also 
show the usefulness of the method in the elucidation of protein complexes. MBD3, 
which does not bind specifically to methylated DNA [5,13], was identified with 
forward and reverse ratios close to one (TableS4), which indicated background binding. 
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MBD1, that has both MBD and CXXC domains, of which the first shows sequence 
specificity [20], was not identified in our experiment. This may be related to low 
MBD1 protein levels in U937 cells [30]. CGGBP1 was the only protein that showed an 
exclusion ratio above 1.5 in forward and reverse (Fig.2A, TableS1), and was therefore 
identified as repelled by DNA methylation. Indeed, it has been described to bind 
specifically nonmethylated, but not methylated, 5’-(CGG)(n)-3’ repeats in the promoter 
of the fragile X mental retardation gene [31-32]. Altogether, the results demonstrate 
that our approach successfully identifies proteins and protein complexes recruited or 
repelled by DNA methylation.    
Interestingly, RBPJ/CBF1, the primary mediator of Notch signaling, was found to 
specifically bind the methylated DNA, as it displayed a high ratio in the forward pull-
down and a low ratio in the reverse pull-down (Fig.2B). The RBPJ interacting protein 
SPEN was identified in the experiment as well (TableS1 and Fig.S1). To confirm our 
findings using a different read-out instead of mass spectrometry, we repeated the pull-
downs with methylated and unmethylated DNA followed by western blotting with 
MBD2 (positive control) and RBPJ specific antibodies. Again, recruitment of MBD2 
and RBPJ to the methylated DNA but not to the unmethylated DNA was observed 
(Fig.2C, upper and middle panel). To address whether RBPJ binds directly to the 
methylated DNA, cleared lysates of E. coli  expressing GST-tagged full-length human 
RBPJ [33] were used as input for the pull-downs. In the absence of potential human 
interacting proteins, GST-RBPJ was specifically recruited to the methylated DNA 
(Fig.2C, lower panel). Thus, RBPJ binds directly and specifically to the methylated 
DNA.  
 
Figure 2 (Next page). RBPJ preferentially binds a methylated CpG-island sequence in vitro. 
(A) Results of a methyl-CpG pull-down/SILAC experiment with U937 nuclear extracts. Forward and 
reverse pull-downs were performed, and forward heavy/light ratios of identified proteins were 
plotted against their reverse heavy/light ratios in a scatter-plot. Proteins that bind specifically to the 
methylated DNA show high ratios in the forward experiment and low ratios in the reverse 
experiment and therefore cluster in the lower right quadrant. Background binders appear around 
the centre of the axes with ratios close to one in both experiments. (B) RBPJ specifically binds to 
the methylated GSTP1 CpG-island DNA. Shown are MS signals of peptides from MBD2 (upper 
panel) and RBPJ (lower panel) from both forward (left) and reverse (right) experiments. L, light; H, 
heavy. (C) RBPJ directly binds to the methylated GSTP1 CpG-island DNA. Methyl-CpG pull-down 
experiments were performed, using western blotting as a read-out. Upper and middle panel: pull-
down with U937 nuclear extract and probing for MBD2 (positive control) and RBPJ. Lower panel: 
pull-down with cleared lysate of E. coli  expressing GST-tagged human RBPJ and probing for 
RBPJ.  
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Figure 3 (Previous page). Preferential binding of RBPJ to methylated DNA is sequence 
specific. (A) RBPJ binds methylated GSTP1 CpG-island DNA but not methylated GAM12. EMSAs 
were performed with recombinant GST-tagged human RBPJ, and DNA fragments as indicated. 
Recombinant MBD2 was used as a positive control. Anti-RBPJ and anti-MBD2 antibodies were 
added to supershift the DNA. Anti-RBPJ(1): ab25949 (Abcam); anti-RBPJ(2): ab33065 (Abcam); 
anti-MBD2: 07-198 (Millipore). (B) RBPJ binds to the first part of the methylated GSTP1 CpG-island 
DNA and not to methylated GAM4. Methyl-CpG pull-downs were performed with U937 nuclear 
extract and different DNA fragments as indicated. In GSTP1-del the double CpG is replaced by a 
single CpG. Western blotting was used as a read-out, and MBD2 was probed as a positive control. 
2.2.2 RBPJ is identified as a sequence context-specific methyl-
CpG binding protein 
To further explore DNA methylation dependent binding of RBPJ we performed 
electrophoretic mobility shift assays. Two different DNA oligonucleotides were used: 
the GSTP1 oligonucleotide used in the methyl-CpG pull-downs and an oligonucleotide 
termed GAM12 that contains 12 consecutive 5’-(CAG)-3’ repeats [25]. GST-tagged 
full-length human MBD2b was used as a positive control for DNAme dependent 
binding [34]. MBD2b contains the MBD domain, but lacks a 149-amino acid N-
terminal domain containing the glycine-arginine rich region in comparison with 
MBD2a. GST-tagged full-length human RBPJ [33] was used for investigation of RBPJ 
binding to methylated DNA. RBPJ comprises three structurally integrated domains; the 
amino (NTD) and carboxy (CTD) terminal domains and a beta-trefoil domain (BTD) 
inserted in between them [35]. The NTD and BTD cooperate in DNA binding by 
specific interactions with base pairs in the major and minor grooves and formation of a 
positively charged surface that interacts non-specifically with the DNA backbone [35].  
Purified recombinant MBD2b and RBPJ were tested for DNA binding. As 
expected, both MBD2b and RBPJ were able to shift the methylated GSTP1 DNA 
(Fig.3A, lane 1-2 and 5-6). For RBPJ, also binding to the unmethylated GSTP1 DNA 
was observed, however, this binding was much weaker as compared to binding to the 
methylated DNA. Multiple molecules of either MBD2b or RBPJ bound to the 
methylated GSTP1 DNA sequence, as multiple shifts were visible per lane. Antibodies 
against MBD2 and RBPJ were used to supershift the complexes (lane 3-4, 7-8 and 9-
10). Only one of two different antibodies against RBPJ was able to supershift (lane 7-
8), presumably related to recognition of the native protein. Thus, our EMSA results 
demonstrated direct and specific binding of RBPJ to methylated DNA.  
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Surprisingly, MBD2b but not RBPJ bound to methylated GAM12 DNA (lane 13-
14 and 15-16). MBD2 is known to bind methyl-CpG via the MBD domain largely 
independent of the surrounding DNA sequence composition. RBPJ evidently does not 
bind methylated DNA irrespective of DNA sequence. Therefore, we set out to 
determine the binding sequence of RBPJ in the GSTP1 DNA. Methyl-CpG pull-downs 
were performed with DNA corresponding to the first half and second half of GSTP1 
(Fig.3B). Also, DNA corresponding to the first half and containing a single instead of 
double CpG was tested, as well as oligonucleotide GAM4, containing 4 consecutive 5’-
(CAG)-3’ repeats. RBPJ only bound to the first part of GSTP1 DNA, and binding did 
not depend on the presence of a double CpG (Fig.3B). Thus, the methylation dependent 
RBPJ binding site is present in the first half of the GSTP1 DNA. Our results show that 
RBPJ is a sequence context dependent DNAme binding protein. 
 
2.2.3 RBPJ binding to a mutated consensus is methylation-
dependent 
RBPJ is the main mediator of Notch signaling (reviewed in [36]), and is an extensively 
studied transcription factor. The DNA binding consensus has been well described. One 
of the first reports on RBPJ determined the consensus motif by a combination of 
approaches, including enrichment of RBPJ bound oligonucleotides from a pool of 
random oligonucleotides [37]. The consensus sequence was established as 5’-
ag/ccGTGGGAActa/t-3’, of which the middle hepta-nucleotide sequence is the core 
recognition motif. We then asked whether and how the observed methylation 
dependent binding of RBPJ relates to the known consensus motif. For that purpose we 
designed a CpG-scan throughout the consensus motif; at every guanine or cytosine in 
the motif, a CpG was created by replacing the upstream or the downstream base by a 
cytosine and a guanine, respectively. The resulting 6 mutated motifs and the consensus 
were tested for RBPJ binding in EMSAs in unmethylated and methylated states 
(indicated in Fig.4, lane 7-8 contain the consensus).  
DNA containing the consensus was bound by RBPJ and methylation did not 
affect binding (Fig.4, lane 7-8). The CpG creating mutations weakened binding to 
various degrees; two motifs almost completely lost RBPJ binding (lane 9 and lane 11). 
Importantly, RBPJ binding to motif 5’-GCGGGAA-3’ was greatly increased by CpG 
methylation (Fig.4 lane 9 and lane 10, Fig.S2), whereas binding to other mutated motifs 
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Figure 4. RBPJ binding to a mutated RBPJ consensus site is restored by methylation in 
vitro. RBPJ binding to the perfect RBPJ consensus motif and various altered sites in unmethylated 
and fully methylated states. EMSAs were performed with recombinant GST-tagged human RBPJ, 
and DNA fragments as indicated. Altered motifs were designed by substituting residues in the 
normal consensus (5’-AGCGTGGGAACTT-3’) upstream of a guanine with a cytosine, and residues 
downstream of a cytosine with a guanine. When required, the single CpG site in the normal 
consensus was replaced by a TpG to maintain only one CpG per sequence. The resulting 6 altered 
sites with one CpG per sequence and the normal consensus (lane 7-8) sequence are indicated 
above lanes. 
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was not affected by methylation. Thus, replacing the thymine preceding the triple 
guanine by methyl-cytosine in the RBPJ consensus creates a strong RBPJ binding 
motif. The thymine residue is essential for RBPJ binding, however, a methylated 
cytosine can functionally substitute for the thymine. Indeed, the same motif that was 
identified as a methylation dependent binding site for RBPJ in our CpG-scan 
experiment, is present twice in the first half of the GSTP1 sequence (5’-GCGGGA-3’ 
at position 3 and 13). Our observations are summarized in Fig.5. The RBPJ binding 
motif is well described and the core sequence is 5’-GTGGGAA-3’. Substitution of the 
thymine by cytosine in the consensus abolishes RBPJ binding, however, methylation of 
this cytosine restores binding. Presumably, the structural resemblance of thymine and 
methyl-cytosine allows for interchangeability of these residues, and the mode of 
binding by RBPJ is similar. 
 
Figure 5. Schematic overview of RBPJ binding motifs in vitro. RBPJ is known to bind to the 
RBPJ consensus motif. Binding is maintained when replacing thymine by a methyl-cytosine, 
whereas replacement by cytosine results in very weak binding only. 
 
2.3 – Discussion 
Here we report the application of a methyl-CpG pull-down assay combined with 
SILAC as a new approach to identify potential novel DNAme readers. Using a DNA 
sequence that is based on the GSTP1 CpG-island and U937 nuclear extracts, we 
recovered several known MBPs and almost all subunits of the MBD2/NuRD complex 
as methylation specific binders. Moreover, we found RBPJ to bind to this DNA in a 
methylation dependent way. Follow-up pull-downs and EMSA experiments showed 
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that RBPJ binding to methylated DNA is sequence context dependent. RBPJ binds the 
consensus motif - 5’-GTGGGAA-3’; replacement of thymine by cytosine abrogates 
binding, however methylation of this cytosine restores binding.    
SILAC-based proteomic screening has been used before in the identification of 
proteins that interact with specific DNA sequences [38], modified peptides and 
nucleosomes [28,39]. The implementation of SILAC-based quantitative mass 
spectrometry allows for sensitive and rapid screening, and generally requires only a 
single-step capturing or purification prior to measurement (reviewed in [40]). In a 
recent study, the effects of DNA and histone methylation on the nucleosome 
interactome were investigated [28]. Unmethylated versus DNA methylated versions of 
nucleosome positioning elements, assembled into nucleosomes as well as in naked 
form, were used in pull-downs. Various proteins displayed methylation dependent 
binding to only one of the nucleosome positioning elements, thus recognizing CpG 
methylation in a sequence-specific manner. The most prevalent domains present in 
these proteins were zinc finger domains and homeoboxes. RBPJ was not identified as a 
methylation dependent binding protein in this study, which presumably can be 
attributed to the used DNA sequences. Therefore, the usage of various DNA sequences 
and extracts from diverse cell types is likely to identify a new group of sequence 
context-specific methylation dependent binding proteins with diverse DNA binding 
domains.          
We hypothesize that methyl-cytosine functionally substitutes the crucial thymine 
in the RBPJ consensus motif, creating a structurally similar platform for binding. This 
phenomenon has been described before. Methylated DNA binding protein (MDBP), a 
protein originally purified from human placenta, was shown to bind DNA in a 
sequence-specific and DNA methylation dependent manner [41-42]. Subsequently, 
methylation independent binding by MDBP in vitro was detected to sites that contain 
thymine residues replacing methyl-cytosine residues [43]. Methylation-dependent 
binding sites were located in mammalian genes [44-45] and methylation independent 
sites were identified in polyoma virus, cytomegalovirus and hepatitis B virus 
enhancers, and in a c-Myc intron [44,46-50]. MDBP was identified to be regulatory 
factor for X box (RFX)1 [51], and to be part of a family of closely related proteins with 
similar DNA binding properties [52-53]. Another example of thymine and methyl-
cytosine substitution in DNA binding sites concerns ZBTB4. Recently, site-selection 
assays (SELEX) and methyl-SELEX were used to identify the preferred binding sites 
of ZBTB4 on unmethylated DNA and methylated DNA, respectively. It appeared that 
ZBTB4 binds to the sequence: 5’-CMGCCAT-3’ (M being methyl-cytosine) [18]. The 
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second best binding site has been defined as 5’-CTGCCAT-3’, in which a thymine 
replaces the methyl-cytosine. Whether interchangeability of thymine and methyl-
cytosine in in vitro DNA binding assays applies to specific factors and to what extent 
this phenomenon occurs in vivo remains to be investigated. 
The mutated RBPJ consensus site, containing a methyl-cytosine instead of a 
thymine, is a bona-fide RBPJ binding site in vitro, and presumably RBPJ binding to 
this site is structurally identical to binding to the normal consensus. From our EMSA 
results, for example as shown in Fig.4, one might speculate that in vitro a thymine 
containing consensus maybe the preferred binding site of RBPJ over a methyl-cytosine 
containing consensus. As we have not performed EMSAs with cold competitor DNA, 
we cannot conclude whether thymine or methyl-cytosine containing sites are the better 
target. An interesting issue is whether the mutated consensus is used by RBPJ in vivo. 
If so, the DNA methylation status of this site determines RBPJ binding and 
consequently its Notch responsiveness. Such a DNA methylation dependent on/off 
switch would add a new layer of regulation to Notch signaling. So far, we did not find 
evidence for methylation dependent binding in genome-wide binding maps of mouse 
RBPJ in C2C12 cells (unpublished results S.J.J. Bartels and H.G. Stunnenberg). With 
the generation of more genome-wide binding profiles for RBPJ in various cell types, 
the contribution of the mutated consensus to RBPJ binding and gene regulation can be 
assessed. The here described SILAC-based screen enables unraveling of the complete 
methyl-DNA interactome, and subsequent in vitro assays and the generation of in vivo 
genome-wide binding maps will clarify the roles of potential novel DNAme readers. 
By using such a systematic approach, our understanding of the DNA methylation code 
and its interpretation by DNAme readers will be greatly increased. 
 
2.4 – Materials and Methods  
2.4.1 Cell culture and SILAC labeling 
U937 cells (ATCC) were cultured in RPMI medium containing 10% fetal bovine serum 
and 1% penicillin/streptomycin (Gibco/Invitrogen) at 37 °C in 5% CO2 atmosphere. 
For SILAC labeling, RPMI (-Arg, -Lys) medium (Gibco/Invitrogen) containing 10% 
dialyzed fetal bovine serum (Gibco/Invitrogen) and 1% penicillin/streptomycin was 
supplemented with either 
13
C6
15
N4 L-arginine and 
13
C6
15
N2 L-lysine (Isotec) or non-
labeled L-arginine and L-lysine (Sigma). Cells were cultured in SILAC medium for at 
least 8 doublings to ensure full incorporation of the labeled amino acids. 
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2.4.2 Nuclear extracts 
The procedure for nuclear extract preparation was derived from [54]. In short, PBS 
washed cells were resuspended in 2.5 volumes hypotonic buffer (10mM HEPES pH7.9, 
10mM KCl, 0.1mM MgCl2, 0.1mM EDTA pH8, 10% glycerol, 1mM DTT, 1mM 
PMSF, and complete protease inhibitors (Roche)), incubated for 30 min on ice, and 
lysed in a Dounce homogenizer (B type pestle). After centrifugation for 20 min at 
2000g, supernatant was removed and pelleted nuclei were washed twice with PBS. 
Nuclei were then resuspended in 1 volume hypertonic buffer (20mM HEPES pH7.9, 
420 mM NaCl, 1.5mM MgCl2, 0.1mM EDTA pH8, 10% glycerol, 1mM DTT, 1mM 
PMSF, and complete protease inhibitors), rotated for 1h at 4 °C, and centrifuged for 30 
min at 100,000g. The resulting supernatant/nuclear extract was frozen in liquid 
nitrogen and stored at -80 °C. 
 
2.4.3 Methyl-CpG pull-down assay 
Oligos used in pull-down experiments are listed in TableS2. PAGE purified oligos 
were annealed and phosphorylated. After ligation DNA fragments containing up to ten 
multimerized oligos were retrieved with lengths up to 600bp. The fragments were 
subsequently biotinylated by incorporation of biotin-14-dATP (Invitrogen) at the 3’end 
of the forward strand using Klenow Fragment (3’-5’exo-) (New England Biolabs), and 
purified on Illustra NAP10 columns (GE Healthcare). For MeCpG pull-downs, DNA 
was methylated by M.SssI (New England Biolabs). Methylation of GSTP1 DNA was 
checked by methylation-sensitive digestion followed by quantitative PCR. For pull-
downs followed by mass spectrometry, 75 µl of Dynabeads MyOne Streptavidin C1 
(Invitrogen) were incubated with 10 µg of DNA for 1h at RT in DNA binding buffer 
(150 mM NaCl, 50 mM Tris pH 8.0, 0.1% NP40). After washing twice in 1ml DNA 
binding buffer, the beads with coupled DNA were incubated with 400 µg nuclear 
extract and 10 µg poly(dI-dC) competitor DNA (Sigma) for 2h at 4°C in protein 
binding buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.25% NP40, 0.5 mM DTT, and 
complete protease inhibitors –EDTA (Roche)). Beads were washed five times in 1ml 
protein binding buffer, and bound proteins were eluted in SDS PAGE loading buffer 
and processed for mass spec analyses. For western blot analysis, the same procedure 
was followed using one quarter of materials (beads, DNA, extract) as described above.   
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2.4.4 Mass spectrometry 
In preparation for mass spectrometry, captured proteins from DNA pull-downs were 
separated by SDS PAGE and in-gel trypsin digested. Peptides were then extracted, 
desalted using StageTips [55], and analyzed on an Orbitrap Velos mass spectrometer, 
essentially as described [56]. Raw data were processed and analyzed using MaxQuant 
software (version 1.1.1.25) containing the integrated Andromeda search engine [57-58] 
and searched against a human decoy IPI database v3.68 using a false discovery rate of 
1% at the protein and peptide level. 
 
2.4.5 Western blotting 
Western blotting was performed according to standard procedures. The following 
antibodies were used: anti-MBD2 (Everest, EB07538), anti-RBPJ (Abcam, Ab25949). 
 
2.4.6 Recombinant proteins 
pETM30-RBPJ (VK91) plasmid and pGEX-5X-1-MBD2b plasmid, for bacterial 
expression of human His/GST-RBPJ and GST-MBD2b, respectively, have been 
described before [33-34]. Expression and GST purification of recombinant proteins 
were performed as described in [34]. For methyl-CpG pull-down experiments, crude E. 
coli  lysates were used, in which case the purification procedure was followed up to the 
addition of Glutathione Sepharose beads. For EMSAs, purified proteins were used.       
 
2.4.7 EMSA 
DNA oligos used in EMSAs are listed in TableS3. GAM12 DNA has been described 
before [25]. PAGE purified oligos were annealed and methylated by M.SssI (New 
England Biolabs). DNA was subsequently labeled using gamma-32P-ATP and T4 
Polynucleotide Kinase (New England Biolabs), and purified on Illustra ProbeQuant 
G50 columns (GE Healthcare). 0.1 ng DNA was incubated with 100 ng protein in 20 µl 
binding buffer (20mM HEPES pH7.9, 1mM EDTA, 3mM MgCl2, 10mM β-
mercaptoethanol, 10% glycerol, 0.1% Triton-X100) containing 2 µg BSA and 10 ng 
poly(dI-dC) for 30min on ice. For supershifting, 500 ng of the following antibodies 
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were added: anti-MBD2 (Millipore, 07-198), anti-RBPJ (Abcam, Ab25949) and anti-
RBPJ (Abcam, Ab33065). DNA-protein mixtures were run on non-denaturing 6% 
polyacrylamide and gels were analyzed according to standard procedures.  
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2.7 – Supplemental Figures and Tables 
 
 
 
 
 
 
 
Figure S1. The RBPJ interacting protein SPEN is preferentially recruited to methylated 
GSTP1 CpG-island DNA. Shown are MS signals of a peptide from SPEN from both forward (left) 
and reverse (right) experiments. L, light; H, heavy. 
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Figure S2. RBPJ binding to a mutated RBPJ consensus site is restored by methylation in 
vitro. EMSAs were performed with recombinant GST-tagged human RBPJ and the DNA probe 
containing a mutated RBPJ consensus site as indicated. Increasing amounts of RBPJ were added 
to binding reactions. 
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TableS4. Results methyl-CpG pull-down/SILAC of all identified proteins. This table can be 
found at http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0025884#s5. 
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CDK2AP1/DOC-1 is a bona fide subunit of 
the Mi-2/NuRD complex 
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Abstract 
The Mi-2/NuRD (NUcleosome Remodeling and histone Deacetylase) chromatin remodeling 
complex is a large heterogeneous multiprotein complex associated with transcriptional 
repression. Here we apply a SILAC based quantitative proteomics approach to show that 
virtually all known Mi-2/NuRD complex subunits co-purify with Cyclin Dependent Kinase 2 
Associated Protein1 (CDK2AP1), also known as Deleted in Oral Cancer 1 (DOC-1). DOC-1 
displays in vitro binding affinity for methylated DNA as part of the meCpG binding 
MBD2/NuRD complex. In luciferase reporter assays, DOC-1 is a potent repressor of 
transcription. Finally, immunofluorescence experiments reveal co-localization between MBD2 
and DOC-1 in mouse NIH-3T3 nuclei. Altogether, these results indicate that DOC-1 is a bona 
fide subunit of the Mi-2/NuRD chromatin remodeling complex. 
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3.1 – Introduction 
In eukaryotic cells, DNA is packed in a structural polymer called chromatin. 
Nucleosomes form the fundamental building blocks of chromatin and in general these 
nucleosomes are inhibitory to processes that require access to the DNA template, such 
as transcription and DNA repair. During the last two decades many protein complexes 
have been identified and characterized that use ATP hydrolysis to alter the position of 
nucleosomes on DNA. In doing so, these protein complexes can regulate the 
accessibility of transcription factors or repair proteins to DNA [1-2]. One of these ATP 
dependent chromatin remodeling complexes is the Mi-2/NuRD complex (NUcleosome 
Remodeling and histone Deacetylase complex). This complex was first biochemically 
purified by a number of labs more than a decade ago [3-5]. The two highly homologous 
proteins CHD3 and CHD4 (or Mi-2α and Mi-2β) represent the catalytic ATP 
hydrolyzing subunits in the complex. In addition, the complex contains two histone 
deacetylases, HDAC1 and HDAC2, RbAp48 and RbAp46, MTA1-3, p66 α and β and 
MBD2 or MBD3. MBD2 and MBD3 were first described as common subunits within 
the NuRD complex [6] but a subsequent study revealed that MBD2 and MBD3 each 
assemble into a Mi-2/NuRD like complex in a mutually exclusive manner [7]. MBD2, 
unlike MBD3, binds to methyl CpG residues and it has been proposed that this protein 
forms the link between the MBD2/NuRD complex and transcriptionally silent, CpG 
methylated promoters. In addition to the reported (core) subunits, a number of 
transcription factors have been shown to interact with the Mi-2/NuRD complex [8-14]. 
These transcription factors could serve to recruit the Mi-2/NuRD complex to specific 
loci in the genome.  
In 2006 we identified DOC-1 (Deleted in Oral Cancer-1) peptides in 
MBD2/NuRD and MBD3/NuRD complex purifications [7], indicating that this protein 
may be an interactor or a novel subunit of the Mi-2/NuRD complex. DOC-1 was first 
described as a protein that is commonly mutated or deleted in various malignancies 
[15-16]. In addition, DOC-1 has been characterized as a Cyclin Dependent Kinase 2 
Associated Protein (CDK2AP1) [17]. In this study it was shown that, consistent with 
loss of the protein in tumors, over-expression of DOC-1 in 293T cells results in a G1 
arrest and significant growth retardation compared to wild-type cells.  Recently, 
interactions between MBD3 and DOC-1 were shown by co-immunoprecipitation and 
western blot analyses [18]. However, convincing evidence indicating that DOC-1 is a 
general Mi-2/NuRD interactor or even a core subunit of the complex is still lacking 
Chapter 3 
 80 
[19]. Here we show, using a variety of biochemical and functional experiments, that 
DOC-1 is indeed a bona fide subunit of the MBD2/NuRD and MBD3/NuRD 
complexes. 
 
 
Figure 1. DOC-1 is a subunit of the Mi-2/NuRD complex. (A) Nuclear extracts from DOC-1-GFP 
and wild-type HeLa cells were analyzed by western blotting using a DOC-1 antibody. Endogenous 
DOC-1 and DOC-1-GFP are indicated by  ⊳ and , respectively. Note that the signal intensities for 
endogenous DOC-1 and DOC-1-GFP are about equal, indicating that DOC-1-GFP is expressed at 
roughly endogenous levels.  The asterisk indicates antibody cross-reactivity. (B-C) Three 
dimensional representations (m/z= x-axis, chromatographic retention time= y-axis and MS 
intensity= z-axis) of MS signals from DOC-1 (B) and MBD2 (C) peptides that were obtained in the 
forward (upper spectra) and reverse (lower spectra)  DOC-1-GFP pull-downs. 
CDK2AP1/DOC-1 is a bona fide subunit of the Mi-2/NuRD complex 
 81 
Continuation from previous page. The indicated MBD2 peptide shows a high ratio in the forward 
pull-down and a low ratio in the reverse pull-down, indicating that MBD2 specifically interacts with 
DOC-1-GFP. (D) Ratio versus ratio plot of all the proteins that were identified and quantified with at 
least two peptides in the DOC-1-GFP pull-downs. In this plot background proteins appear around 
the centre of the axes with ratios close to 1 in both the forward and the reverse pull-down. In 
contrast, DOC-1-GFP and associated proteins show a high ratio in the forward pull-down and a low 
ratio in the reverse pull-down and therefore cluster together in the bottom right quadrant of the 
graph. Note that all the identified DOC-1-GFP interacting proteins are known subunits of the Mi-
2/NuRD complex. (E) Nuclear extracts from DOC-1-GFP and wild-type HeLa cells were subjected 
to GFP pull-downs using GFP nanotrap beads and tested for the presence of the indicated proteins 
by western blotting. The eluates from the beads as well as 12.5% of the non-bound fraction and 
10% of input extract was loaded on gel. Asterisks indicate MBD2a and b. (F) Endogenous DOC-1 
was immunoprecipitated from HeLa nuclear extracts using a DOC-1 antibody. Immunoprecipitates 
were tested for the presence of DOC-1, MBD2 and MBD3. PI= immunoprecipitation using pre-
immune serum.  
3.2 – Results 
3.2.1 DOC-1 exclusively associates with Mi-2/NuRD complex 
subunits in the nucleus 
To investigate a putative interaction between DOC-1 and the Mi-2/NuRD complex, we 
tagged and purified DOC-1 from human cells. We made use of the recently developed 
BAC-transgeneOmics approach [20] to obtain a HeLa cell line expressing DOC-1-GFP 
from its own promoter at endogenous levels (Fig.1A). This cell line and  wild-type 
HeLa cells were SILAC labeled ‘heavy’ and ‘light’, subjected to single step affinity 
purification on GFP-nanotrap beads [21] after which bound proteins were digested with 
LysC and measured in a single LC-MS run on an LTQ-Orbitrap mass spectrometer. 
Computational analysis of the data was done using the MaxQuant software [22]. In this 
approach, GFP-tagged proteins and proteins interacting with the bait are more abundant 
in the heavy compared to the light form and can therefore easily be distinguished from 
background binders that have a one to one ratio. As a control, a label swap experiment 
is performed in which the GFP-tagged cell line is labeled light and the wild-type cells 
labeled heavy. In this case, the bait and associated proteins have a low heavy/light 
ratio. Plotting ratios of the ‘forward’ experiment against ratios of the ‘reverse’ 
experiment results in four quadrants in which the GFP-tagged protein and its 
interactors cluster together in a single quadrant.  As expected, DOC-1-GFP derived 
peptides had a high ratio in the forward and a low ratio in the reverse pull-down, 
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indicating that the bait protein was specifically enriched in both pull-downs consistent 
with the SILAC labeling scheme (Fig.1B). MBD2 derived peptides showed a similar 
pattern, indicating that MBD2 is a DOC-1-GFP interacting protein in this experiment 
(Fig.1C). A ratio vs ratio plot of all the proteins that were identified and quantified in 
the pull-downs then revealed that DOC-1-GFP interacts specifically with essentially all 
Mi-2/NuRD complex subunits that have been described in the literature to date, 
including both MBD2 and MBD3 (Fig.1D and TableS1). To further validate these 
findings we used nuclear extracts derived from DOC-1-GFP cells for pull-downs with 
GFP-nanotrap beads, which were then tested for the presence of Mi-2/NuRD complex 
subunits using western blotting (Fig.1E). Consistent with our mass spectrometry data, 
all the Mi-2/NuRD complex subunits we tested for were specifically enriched on DOC-
1-GFP containing beads, whereas no enrichment could be observed on beads that were 
incubated with wild-type HeLa nuclear extract. Finally, to study the interaction 
between endogenous DOC-1 and MBD2/MBD3 we used an antibody against DOC-1 to 
precipitate the protein from HeLa nuclear extract (Fig.1F, upper panel). MBD2 and 
MBD3 were specifically co-immunoprecipitated with endogenous DOC-1 (Fig.1F, 
middle and lower panel). Taken together, these experiments show that DOC-1 interacts 
with the MBD2/NuRD and MBD3/NuRD complexes. Furthermore, no additional 
protein-protein interactions could be detected for DOC-1 in HeLa nuclear extracts by 
mass spectrometry, indicating that, at least in mammalian nuclei, the protein is 
primarily and exclusively associated with the Mi-2/NuRD complex. 
 
3.2.2 DOC-1 and MBD2 specifically interact with methylated CpGs 
in vitro 
DOC-1 is a small (115 aa) protein that does not carry an obvious methyl CpG binding 
motif. However, our biochemical data now clearly indicate that DOC-1 is part of the 
MBD2/NuRD complex. We therefore hypothesized that DOC-1 would indirectly bind 
to methylated DNA via an interaction with the MBD2/NuRD complex. To address this 
question we applied a DNA pull-down approach in combination with SILAC-based 
quantitative proteomics (Fig.2A) [23-24]. Methylated and non-methylated DNA bound 
to beads was incubated with heavy or light SILAC labeled U937 nuclear extracts, 
respectively. Following the pull-down and washes, beads from both pull-downs were 
combined and bound proteins were separated by one dimensional SDS PAGE. Proteins 
were subsequently digested with trypsin and peptide mixtures were 
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Figure 2 (Previous page). DOC-1 and MBD2 are specifically recovered on methylated DNA in 
vitro. (A) Schematic representation of the experimental approach. (B-D) SILAC labeled nuclear 
extracts from U937 cells were incubated with non-methylated and methylated DNA immobilized on 
streptavidin conjugated dynabeads. Shown in the figures is the three dimensional representation of 
the MS signal for the indicated peptides and their relative binding to methylated versus non-
methylated DNA. Note that for a background protein equal binding to methylated versus non-
methylated DNA is observed(B), whereas for MBD2(C) and DOC-1(D), preferential methyl DNA 
binding is observed. 
 
measured by high-resolution LC-MS on an LTQ-Orbitrap hybrid mass spectrometer. 
Proteins that interact with DNA irrespective of DNA methylation or bind non-
specifically to the beads are equally abundant in the light and heavy state and these 
proteins therefore show a one to one ratio in the mass spectrometer (Fig.2B). In 
contrast, proteins specifically interacting with the meCpGs are more abundant in the 
heavy form and have a heavy/light ratio higher than one. As a validation of the 
approach and consistent with previous observations, MBD2, one of the five “classic” 
proteins containing a meCpG binding domain (MBD) [25], was identified as a specific 
meCpG binding protein in our quantitative DNA pull-down experiment (Fig.2C and 
TableS2). In agreement with our hypothesis we also identified DOC-1 as a meCpG 
interactor in our pull-down (Fig.2D and TableS2). MBD3, which does not bind 
specifically to methylated DNA [7,25] was not identified in this experiment. These 
results indicate that DOC-1 binds to methylated DNA in vitro as part of the 
MBD2/NuRD complex. 
 
3.2.3 DOC-1 is a repressor of transcription and co-localizes with 
MBD2 in vivo 
To further functionally characterize the DOC-1 protein, we performed luciferase 
reporter gene assays using a DOC-1-Gal4 containing construct (Fig.3A). An expression 
construct containing the Gal4 DNA binding domain was used as a control and reveals 
the basal activity of the luciferase gene. Gal4-MBD2 and Gal4-Ash2L constructs were 
used as additional controls for repressive and activating activities, respectively. 
Consistent with previous observations and in line with its role in activation of 
transcription [26], Gal4-Ash2L potentiated reporter gene activity [27]. In contrast to 
this and in agreement with its known biological function, Gal4-MBD2 was a repressor 
of transcription in this experimental set-up (Fig.3B). DOC-1-Gal4 also conferred 
repression to the reporter gene in a dose dependent manner comparable to Gal4-MBD2, 
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indicating that in this luciferase reporter assay, DOC-1 is a potent repressor of 
transcription.  
To further study the DOC-1/Mi-2-NuRD interaction in vivo we performed 
immunofluorescence experiments. Mouse NIH-3T3 cells were transfected with an HA 
tagged MBD2 construct, and a combination of a mouse monoclonal HA antibody with 
a rabbit polyclonal antibody against endogenous DOC-1 was used to visualize the 
proteins in the cells. Both proteins were predominantly found in the nucleus and 
showed substantial overlap, indicating that MBD2 and DOC-1 co-localize in 
mammalian nuclei in vivo. It should be noted that DOC-1 interacts with both 
MBD2/NuRD and MBD3/NuRD, which are two distinct complexes. This may explain 
why MBD2 and DOC-1 do not co-localize completely.   
Collectively, the biochemical and cell biological assays presented in this paper 
reveal that CDK2AP1/DOC-1 is a subunit of the Mi-2/NuRD complex and a repressor 
of transcription. 
 
3.3 – Discussion 
In this paper we have provided compelling evidence that CDK2AP1/DOC-1 is a bona 
fide subunit of the Mi-2/NuRD complex. DOC-1 was first reported as a protein that is 
deleted in oral cancer and was subsequently described as a cyclin dependent kinase 2 
associated protein. Our quantitative mass spectrometry data did not reveal an 
association between CDK2 and DOC-1 in nuclear extracts. Although we cannot 
exclude that DOC-1 interacts with CDK2 in specific physiological conditions in the 
cytoplasm, western blotting as well as confocal microscopy revealed that DOC-1 is 
predominantly nuclear and there it exclusively associates with the Mi-2/NuRD 
complex. Interestingly, deletion of the Mi-2/NuRD subunit MBD2 in mice protects 
these mice from intestinal tumors [28]. This is in contrast to the pathology of DOC-1; 
reduced DOC-1 expression appears to be an inducer of malignant transformation 
[16,29]. In agreement with this, over-expression of DOC-1 in 293T cells results in a 
partial G1/S arrest [17], whereas over-expression of MBD2 in 293T cells enhances cell 
proliferation (Xavier Le Guezennec and M.V, unpublished data). Whether these 
observations are indicative of antagonistic functions for DOC-1 and MBD2 in the Mi-
2/NuRD complex or hinting towards a cytoplasmic DOC-1 function related to CDK2 
remains unclear at this point.  To further study the potential interplay between DOC-1 
and  MBD2  in tumorigenesis it  would  be informative  to cross  MBD2  deficient mice 
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Figure 3  (Previous page). DOC-1 is a repressor of transcription and co-localizes with MBD2 
in vivo. (A) Schematic representation of the Gal4-luciferase assay. Gal4-DBD (DNA binding 
domain) binds to the Upstream Activating Sequence (UAS) in front of the reporter gene. Gal4-
fusion proteins and their associated proteins can therefore be recruited to the TK promoter to exert 
their function. (B) Luciferase reporter gene assays with the indicated constructs. Transfection 
amounts are given in nanograms. (C) Anti Gal4 western blot to confirm expression of the Gal4 
fusion proteins that were used in figure 3B. 500 ng of the indicated constructs were transfected into 
293T cells. (D) Confocal microscopy of NIH-3T3 cells that were transiently transfected with HA-
MBD2 reveals co-localization of endogenous DOC-1 and HA-MBD2 in the nucleus. 
 
with a DOC-1 knock-out strain and look at survival rates in polyposis challenge 
experiments. Alternatively, immortalized MBD2 deficient MEFs could be subjected to 
DOC-1 siRNA in colony formation assays to look at their proliferation. 
Given its apparent general presence in both the MBD2/NuRD and MBD3/NuRD 
complexes, it is surprising that DOC-1 has not been identified by mass spectrometry 
previously in Mi-2/NuRD complex purifications. However, given the small size of 
DOC-1, the protein was not visualized by silver or coomassie stainings prior to LC-
MS/MS analyses in a number of studies [3-6] and therefore may have escaped 
identification. Although our study has clearly established DOC-1 as a Mi-2/NuRD 
subunit, future research is required to elucidate the molecular function of the protein 
within the complex, its putative association with methylated promoters as a component 
of the MBD2/NuRD complex and its link to carcinogenesis. 
 
3.4 – Materials and methods 
3.4.1 Cell culture 
HeLa Kyoto, NIH-3T3 and HEK 293 cells were cultured in DMEM containing 10% 
Fetal Calf Serum, 2mM Glutamine and 100 U/mL of Penicillin/Streptomycin 
(BioWhittaker), whereas U937 cells were cultured similarly in RPMI. The DOC-1-GFP 
BAC line was cultured in the presence of 400 µg/mL geneticin (G418) (Life 
Technologies/Gibco). For SILAC labeling experiments, DOC-1-GFP, wild-type HeLa 
and wild-type U937 cells were cultured in the presence of light and heavy lysine 
(
13
C6
15
N2, Isotec) (GFP pull-down) or light and heavy lysine and arginine (
13
C6
15
N2 and 
13
C6
15
N4, Isotec) (DNA pull-down) for > 8 doublings to ensure full incorporation of the 
heavy isotope prior to preparation of nuclear extracts.   
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3.4.2 GFP pull-downs 
Nuclear extracts (prepared essentially as described in [30]) derived from DOC-1-GFP 
and wild-type HeLa cells (200-300 µg for western blot analyses and 1 mg for mass 
spectrometric analysis) were incubated with 10 µl of GFP nanotrap beads (Chromotek) 
for 90 minutes at 4
o
C in binding buffer (PBS, 0.25% NP40, 0.5 mM DTT, 50 µg/ml 
ethidium bromide and complete protease inhibitors –EDTA (Roche)). Beads were 
washed extensively with binding buffer after which proteins were eluted using SDS 
PAGE loading buffer for western blot analyses or acidic glycine (0.1 M, pH 2.0) for 
subsequent mass spec analyses. The following antibodies were used for western 
blotting: MBD2 (Everest Biotech, EB07538); MBD3 (IBL, 3A3); RbAp46 (Abcam, 
72457-100); RbAp48 (Abcam, 74188-100); HDAC1 (Santa Cruz Biotechnology, H51 
sc-7872); HDAC2 (Santa Cruz Biotechnology, ACII sc-7899 -54); Gal4-DBD (Santa 
Cruz Biotechnology, RK5C1); GFP (Roche, 11814460001). A rabbit polyclonal 
antibody against recombinant full length DOC-1 was generated in-house.  
 
3.4.3 Generation of anti-DOC-1 antibodies 
A GST-DOC-1 fusion construct was created by ligating a DOC-1 cDNA-clone 
(IRATp970A0640D, RZPD-clone) into pGEX-2T. The DOC-1 cDNA was PCR-
amplified using the following oligos:  
5’CGCggatccATGTCTTACAAACCGAACTTGGC3’ (forward) and 
5’CCGgaattcCTAGGATCTGGCATTCCGTTC3’ (reverse).  
The amplified product was ligated into pGEX-2T using BamHI/EcoRI restriction sites. 
GST-DOC-1 protein was produced in E.coli BL21 (DE3) and purified using 
Glutathione Sepharose 4B-beads (GE Healthcare) according to standard procedures. 
The GST-tag was removed by thrombin cleavage and DOC-1 was subsequently 
isolated from preparative SDS PAGE gel and used for immunization of rabbits.  
 
3.4.4 Co-immunoprecipitation 
2 µl of DOC-1 antiserum or 2 µl pre-immune serum was immobilized on 30 µl protein 
A Dynabeads slurry (Invitrogen). Beads were then incubated with 50 µl HeLa nuclear 
extract (~ 5 mg/ml) in 150 µl binding buffer for 2.5 hours at 4
o
C. Beads were washed 
extensively with binding buffer after which bound proteins were eluted in SDS PAGE 
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loading buffer and analyzed by western blotting for the presence of DOC-1, MBD2 and 
MBD3.  
 
3.4.5 DNA pull-down 
The following oligos were used for preparation of pull-down DNA: 
5’aagcagacactggcaggtttCGGCGGGAGTCCGCGGGACCCTCCAGAAGAGCGGCC
GGCGCCGTGACctaaggctaaggctcata3’ (forward) and 
5’tttatgagccttagccttagGTCACGGCGCCGGCCGCTCTTCTGGAGGGTCCCGCGGA
CTCCCGCCGaaacctgccagtgtctgc3’ (reverse), containing a sequence derived from the 
GSTP1 CpG-island (in capitals), sites for primer annealing, and a methylation-sensitive 
restriction site (underlined). PAGE purified oligos were annealed, phosphorylated and 
ligated, resulting in fragments with lengths ranging from 85 to 600 bp. Subsequently, 
biotinylation was performed by incorporation of biotin-14-dATP (Invitrogen) at the 
3’end of the forward strand using Klenow Fragment (3’-5’exo-) (New England 
Biolabs). For the meCpG pull-down, DNA was methylated by M.SssI (New England 
Biolabs) and methylation was checked by methylation-sensitive digestion followed by 
quantitative PCR. 75 µl of Dynabeads MyOne Streptavidin C1 (Invitrogen) were 
incubated with 10 µg of DNA for 1h at RT in DNA binding buffer (150 mM NaCl, 50 
mM Tris pH 8.0, 0.1% NP40). After washing, the beads with coupled DNA were 
incubated with 400 µg U937 nuclear extract and 10 µg poly(dI-dC) competitor DNA 
(Sigma) for 2h at 4°C in protein binding buffer (150 mM NaCl, 50 mM Tris pH 8.0, 
0.25% NP40, 0.5 mM DTT, and complete protease inhibitors –EDTA (Roche)). Beads 
were washed extensively and bound proteins were eluted in SDS PAGE loading buffer 
and processed for mass spec analyses. 
 
3.4.6 Mass spectrometry 
Proteins eluted from the GFP-nanotrap beads were neutralized using Tris (pH 8.5) and 
subsequently digested with LysC (Wako) using the FASP protocol [31]. Proteins 
precipitated during the DNA pull-down were separated by SDS PAGE and subjected to 
in-gel trypsin digestion as described [27]. Collected peptides were desalted using 
StageTips [32] and measured on an LTQ-Orbitrap mass analyzer essentially as 
described [27]. Raw data were analyzed using the MaxQuant software package [22]. 
The DOC-1-GFP pull-down ratio vs ratio plot was generated using the open software 
package R.  
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3.4.7 Cloning 
To generate a DOC-1-Gal4-DBD construct, the stop-codon between the HindIII 
cleavage site and the transcription start site in plasmid pCMV-DBD [33] was mutated 
into a glycine codon using primers 5’CCAAGCTTCCGGAAAGATGAAGC3’ 
(forward) and 5’AGGTGACACTATA3’ (reverse). The point mutation in the forward 
primer is underlined. The PCR product was ligated into the backbone vector. Full-
length DOC-1 was amplified from a pCMX-DBD vector using primers 
(5’CCCAAGCTTATGTCTTACAAACCGAACTTG3’) and (5’ 
CCCAAGCTTGGGATCTGGCATTCCGTTCC3’). This fragment was then ligated 
into the mutated CMV-DBD vector, to obtain a C-terminal Gal4-DBD-fusion.  
 
3.4.8 Luciferase assay 
HEK293 cells were seeded in 12-well plates on day 1, transfected on day 2 (when 
confluency was ~30-40%). Transfection was done in triplicates, using 1.5 µl Fugene6 
reagent (Roche), 15 ng pCMV-Renilla, 200 ng Gal4-TK-luciferase and 50/100 ng 
pCMV DBD; 50/100 ng pCMV DOC-1-DBD; 100 ng pCMX DBD-MBD2 or 20 ng 
pGal4-Ash2L per well. Cells were lysed by applying 150 µl 1x Passive lysis buffer 
(Dual-luciferase assay kit (Promega)) and incubation for 20 min at RT. 50 µl lysate was 
used for measurement in a 96-well Berthold LB96V MicroLumat Plus luminometer.  
25 µl of Gal4-DBD, Gal4-Ash2L and Gal4-MBD2 and 12,5 µl of Gal4-DOC-1 lysate 
was applied to SDS-PAGE to check protein expression by anti-Gal4 western blotting.   
 
3.4.9 Confocal immunofluorescence microscopy 
NIH-3T3 cells were seeded on coverslips in 12-well plates. At ~40% confluency, cells 
were transfected with 1 µg stII-3HA-MBD2 plasmid [7] using PEI (Polysciences). At 
~80% confluency cells were fixed with 4% v/v paraformaldehyde. Permeabilization 
was performed by incubation with  0.2% Triton X-100 in PBS for 5 minutes at RT. 
Cells were then blocked with 1% Bovine Serum Albumin (Sigma) in PBS 
supplemented with 0.1% Triton X-100 for 30 minutes and subsequently incubated with 
the primary antibodies  (DOC-1 and HA, (Santa Cruz Biotechnology, 12xA5)) in 
blocking buffer for at least 1 hour. This was followed by incubation with secondary 
antibodies (GαR Alexa 488 and GαM Alexa568 (Invitrogen)) for 1 hour in blocking 
buffer. DNA was stained using 10 µg/mL DAPI (4'-6-Diamidino-2-phenylindole). A 
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Zeiss 510 Meta confocal microscope with a 63X/1.4 Oil DIC Plan-ApoChromat 
objective was used for microscopic analysis.  
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Abstract 
Zinc-fingers and homeoboxes 1 (ZHX1) is a multidomain protein that contains two 
tandem C2H2 zinc-fingers (ZNF) and five tandem homeodomains (HD). Its family 
members ZHX2 and ZHX3 are closely related and can form homodimers and 
heterodimers with ZHX1 and each other. Although ZHX1 functions as a 
transcriptional repressor in reporter assays and the structures of various domains 
have been resolved, its recruitment to DNA in vitro and in vivo has so far been unclear. 
We and others identified ZHX1 as a methylation-dependent binder to DNA 
sequences in methyl-CpG pull-down/SILAC experiments in vitro [1-2]. We here 
show that ZHX1 binds directly to methylated DNA in vitro in a sequence-specific 
manner via its homeoboxes. Generation of genome-wide ZHX1 binding and DNA 
methylation maps in HCT116 cells by ChIP-seq and MethylCap-seq, respectively, 
showed that in vivo ZHX1 occupies CpG-dense sites that are unmethylated. 
Moreover, the ZHX1 binding pattern in HCT116 cells was not affected by 
DNMT1,DNMT3b knockout. Lack of methylation of ZHX1 binding sites was 
confirmed by bisulfite sequencing of ZHX1 ChIP DNA (ChIP-BS-seq).  Finally we 
show that in vivo ZHX1 is associated with active chromatin. 
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4.1 – Introduction 
The Zhx1 (zinc-fingers and homeoboxes 1) gene was first identified in 1996 when the 
ORF was cloned from a mouse bone marrow stromal cell line [3]. Two tandem C2H2 
zinc-fingers (ZNF) at the amino region and five tandem homeodomains (HD) were 
identified in ZHX1 [3]. In addition, an arginine-rich domain (RR) and a C-terminal 
acidic amino acid rich region (AR) were identified. Human ZHX1 was later isolated in 
a yeast two-hybrid screen for proteins interacting with NF-Y [4-5]. The HD1 and HD2 
regions of ZHX1 were found to be essential for the interaction with NF-Y. In search for 
other ZHX1 interacting proteins using yeast two-hybrid screening, the ZHX1 family 
members ZHX2 and ZHX3 were identified [6-7]. It appeared that all ZHX family 
members have the ability to form homo- and heterodimers via the region containing 
HD1. A high degree of sequence conservation was observed among ZHX family 
members.  
Expression of ZHX1 has been detected in various tissues [3-4,8]. Its biological 
functions remain largely unclear at present. ZHX1 has been shown to interact with 
DNMT3B [9] and BS69 [6,10]. In luciferase reporter assays ZHX1 functioned as a 
transcriptional repressor [6,9,11]. The domain responsible for transcriptional repressor 
activity was mapped to the acidic region, and dimerization was found to be prerequisite 
for full repressor activity [11]. Liu et al. reported a role for ZHX proteins in the 
regulation of podocyte gene expression during the development of nephrotic syndrome 
[12]. ZHX3 knock-down in mesenchymal stem cells indicated a role for this factor in 
osteogenic differentiation [13]. Roles for ZHX2 in neural progenitor maintenance [14] 
and regulation of liver gene expression [15-19] have been described. Finally, ZHX2 
has been shown to be deregulated in Hodgkin lymphoma [20-21].   
Recently, the structure of the tandem zinc-finger region of ZHX1 has been 
determined by NMR spectroscopy [22], and it was shown that both zinc-fingers adopt 
canonical C2H2 ββα-folds. C2H2 zinc fingers generally bind double-stranded DNA in 
the major groove, however, from the overall surface charge distribution of ZNF1 this 
zinc-finger was predicted to be unable to bind DNA. ZNF2 on the other hand was 
predicted to have potential DNA binding capacity. The structures of ZHX1 HD4 and 
ZHX2 HD2 have been determined from crystal structures [23]. In ZHX2 HD2 the 
functional DNA binding fold is disrupted by an altered conformation, whereas ZHX1 
HD4 has potential DNA binding capacity. Structures of the remaining ZHX1 HDs have 
not been resolved thus far.  
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Until recently, DNA binding had not been (directly) established for any of the 
ZHX proteins. A recent study, however, showed that ZHX family members are 
specifically recruited to methylated DNA in vitro [2]. In that study, SILAC-based 
screening was performed to identify proteins whose binding to DNA and nucleosomes 
is regulated by DNA or histone methylation. DNA/nucleosome interacting proteins 
were purified from SILAC-labeled nuclear extracts and their ratios of enrichment on 
unmethylated versus methylated DNA/nucleosomes were subsequently determined in 
mass spectrometry. Interestingly, all ZHX family members showed specific recruitment 
to methylated DNA, in naked form as well as in reconstituted recombinant 
nucleosomes. We found methylation-dependent recruitment of ZHX1 to the GSTP1 
CpG-island DNA sequence in vitro in a methyl-CpG pull-down/SILAC experiment [1].  
We here further investigated in vitro and in vivo ZHX1 DNA binding and 
dependency on methylation. We show that in vitro methylation-dependent DNA 
binding by ZHX1 is direct, sequence-specific and occurs via the homeoboxes. On the 
contrary, genome-wide binding profiles showed that in vivo ZHX1 is present at 
unmethylated, transcriptionally active CpG-island promoters. We show by various 
approaches that DNA methylation-dependent binding of ZHX1 does not occur in vivo. 
 
4.2 – Results 
4.2.1 ZHX1 specifically binds methylated DNA in a sequence-
specific manner in vitro 
We have previously used SILAC-based proteomic screening for the identification of 
proteins that bind specifically to methylated DNA [1]. Among known Methyl-CpG 
Binding Proteins (MBPs) and subunits of the MBD2/NuRD complex, we identified 
ZHX1 as a methylation-dependent binder to the GSTP1 CpG-island pull-down DNA. 
ZHX1 was also recovered in methyl-CpG pull-downs by Bartke et al.; they found that 
ZHX1, and family members ZHX2 and ZHX3, bind nucleosome positioning sequences 
in a methylation-dependent manner. Ratios of enrichment on methylated DNA and 
sequences to which methylation-dependent binding was observed, are indicated 
(Table1 and TableS1).  To validate methylation-dependent binding of ZHX1 to GSTP1 
DNA, we now used western blot analysis with anti-MBD2 and anti-ZHX1 antibodies 
of captured proteins from pull-downs with methylated and unmethylated DNA. Both 
MBD2 (positive control) and ZHX1 were specifically pulled down with the 
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methylated, but not unmethylated DNA (Fig.1A, right, upper and middle panel). To 
exclude that ZHX1 is recruited to the methylated DNA via protein-protein interactions, 
we used cleared lysate of E. coli expressing GST-tagged human ZHX1 as input for the 
pull-downs. Binding of ZHX1 to methylated DNA was observed (Fig.1A, right, lower 
panel). Purified GST-ZHX1 was then used in electrophoretic mobility shift assays 
(EMSAs), and was shown to shift methylated but not unmethylated DNA (Fig.1A, 
left). Together these results demonstrate that ZHX1 binds directly and methylation-
dependently to the GSTP1 CpG-island sequence.    
  To examine whether ZHX1 binds sequence-specifically to methylated DNA, we 
used four different DNA fragments in methyl-CpG pull-downs (Fig.1B). MBD2 bound 
all DNA fragments when methylated. On the contrary ZHX1 only bound methylated 
GSTP1 part2. Therefore, we conclude that ZHX1 binds methylated DNA in a 
sequence-context specific manner. To identify the domains responsible for methyl-
DNA binding of ZHX1, we made recombinant proteins containing either the ZHX1 Zn-
finger and dimerization domains (GST-ZNF1-2-dim), or the ZHX1 homeoboxes (GST-
HD1-5), and tested proteins in methyl-CpG pull-downs with GSTP part2 DNA 
(Fig.1C). We found that GST-HD1-5, but not GST-ZNF1-2-dim, bound methylated 
DNA. We conclude that ZHX1 binds methylated DNA in a sequence-context specific 
manner and that the ZHX1 homeoboxes region is involved in binding to this 
methylated DNA sequence in vitro.   
 
Table 1. ZHX family members in methyl-CpG pull-downs. 
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Figure 1. ZHX1 binds methylation-dependently and sequence-specifically to a CpG-island 
sequence in vitro. (A) ZHX1 binds methylation-dependently and directly to GSTP1 CpG-island 
DNA. Left: EMSAs were performed with recombinant GST-tagged human ZHX1 and GSTP1 CpG-
island DNA, as indicated. Right: Methyl-CpG pull-down experiments were performed, using 
western blotting as a read-out. Upper and middle panel: pull-down with U937 nuclear extract and 
probing for MBD2 (positive control) and ZHX1. Lower panel: pull-down with a cleared lysate of E. 
coli expressing GST-tagged human ZHX1 and probing for ZHX1. (B) Binding of ZHX1 to 
methylated DNA is sequence-specific. ZHX1 binds to the second part of the methylated GSTP1 
CpG-island DNA, and not to methylated GAM4. Methyl-CpG pull-downs were performed with U937 
nuclear extract and different DNA fragments as indicated. In GSTP1-del the double CpG is 
replaced by a single CpG. Western blotting was used as a read-out, and MBD2 was probed as a 
positive control. (C) ZHX1 homeoboxes region binds specifically to methylated GSTP1 CpG-island 
DNA. Recombinant GST-ZNF1-2 and GST-HD1-5 (schematically depicted below), consisting of 
ZHX1 zinc fingers and dimerization domain, and ZHX1 homeoboxes region, respectively, were 
tested for (methylated) GSTP1 CpG island DNA binding by pull-down/western experiments and 
probing with anti-GST antibody. 
A
B
Me+
+
-+-
+-- GST-ZHX1
ZHX1 bound
free probe
5-AAgcagacactggcaggtttCGGCGGGAGTCCGCGGGACCCTCCAGAAGAGCGGCCGGCGCCGTGACctaaggctaaggctcata-3
cgtctgtgaccgtccaaaGCCGCCCTCAGGCGCCCTGGGAGGTCTTCTCGCCGGCCGCGGCACTGgattccgattccgagtatTT
GSTP1-1 GSTP1-2
GAM4: 5-AAGATGATGACGACGACGACGATGATG-3
C
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M3 Enrichment: 5.10   ROC-AUC: 0.76
M2 Enrichment: 3.16   ROC-AUC: 0.62
M4 Enrichment: 5.36   ROC-AUC: 0.61
M1 Enrichment:15.64   ROC-AUC: 0.69
M5 Enrichment: 43.16   ROC-AUC: 0.58
M6 Enrichment: 4.79   ROC-AUC: 0.69
M7 Enrichment: 8.36   ROC-AUC: 0.72
M8 Enrichment:11.11   ROC-AUC:   0.72
M10 Enrichment: 6.90   ROC-AUC: 0.76
M9 Enrichment: 5.96   ROC-AUC: 0.74
M11 Enrichment: 9.47   ROC-AUC: 0.72
M12 Enrichment: 4.21   ROC-AUC: 0.77
A
B
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Figure 2. ZHX1 genomic binding sites have high CpG-densities but lack DNA methylation. 
(A) The majority of ZHX1 sites is associated with genes and CpG-islands. Bar diagram showing 
genomic distribution of ZHX1 binding sites and intersection with CpG-islands. In total 933 ZHX1 
binding sites were detected in HCT116 colorectal carcinoma cells. TSS regions are defined 5kb 
upstream to 2kb downstream from TSS. (B) Motifs identified within ZHX1 binding sites using the 
GimmeMotifs de novo motif prediction pipeline. Indicated are the identified motifs, enrichment over 
a matched genomic background, area under the curve (AUC) of receiver operator characteristic 
(ROC) curves of sensitivity versus specificity, and positional preference plots displaying motif 
positions relative to the ZHX1 peak summits. (C) ZHX1 sites have high CpG-densities but low DNA 
methylation levels as determined by MethylCap-seq. Examples of ZHX1 and H3K4me3 ChIP-seq 
and MethylCap-seq data of HCT116 cells. (D) Heatmaps and average plots of CpG-densities and 
MethylCap tag densities in 10 kb regions around the centre of ZHX1 peaks and MethylCap peaks. 
C
D
MethylCap (CpGdensity)       MethylCap (MethylCap counts)
ZHX1 (CpGdensity)                 ZHX1 (MethylCap counts)
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4.2.2 Genome-wide profiling of ZHX1 shows binding to 
unmethylated CpG-islands in vivo 
To investigate ZHX1 methylation-dependent DNA binding in vivo, we generated 
genome-wide ZHX1 binding maps with HCT116 colorectal carcinoma cells by ChIP-
seq (TableS2). Expression of ZHX1 in these cells was validated by western blotting 
(Fig.S1). We identified 933 ZHX1 binding sites (peaks) using the MACS peak calling 
algorithm [24]. A major fraction of these binding sites (758, 81%) was associated with 
genes (located near TSS, exonic or intronic), of which 646 sites (69%) overlapped with 
transcription start sites (5kb upstream to 2kb downstream) (Fig.2A). All genomic 
categories of ZHX1 binding sites showed substantial overlap with CpG-islands as 
annotated by UCSC; in particular the ZHX1 sites at transcription start sites, of which 
520 (80%) overlapped with CpG-islands (Fig.2A). Individual examples of ZHX1 
binding at CpG-island promoters are shown (Fig.2C).  
We used the GimmeMotifs pipeline [25] for de novo motif prediction on the 
ZHX1 binding sites detected with ChIP-seq. Various significant motifs were detected 
that all contained one or more CpGs (Fig.2B). The partially overlapping motifs M1, 2 
and 3 showed resemblance to the CREB1 motif (TGACGT). Motif M4 equaled the 
YY1 consensus sequence. Both CREB1 and YY1 motifs are well known promoter 
motifs [26]. Additional motifs were detected that did not show resemblance to known 
motifs. Motifs M6-M12 were remarkably C-,G- and T-rich.    
To determine the overlap of ZHX1 binding with DNA methylation, genome-wide 
DNA methylation patterns of HCT116 cells were generated using capturing of 
methylated DNA by MethylCap followed by deep sequencing [27]. This method 
utilizes a Methyl-CpG Binding Domain (MBD) for capturing of methylated DNA and 
subsequent step-wise salt elution [27]. Using MACS peak calling, we detected 134171 
MethylCap peaks corresponding to methylated regions in HCT116 cells. Visual 
inspection of ZHX1 and MethylCap profiles showed that ZHX1 peaks did not coincide 
with DNA methylation peaks (examples in Fig.2C). We then determined MethylCap 
read densities and CpG densities in 10 kb genomic regions around the centre of ZHX1 
peaks and MethylCap peaks, and visualized the results in heatmaps and average plots 
(Fig.2D). As expected, MethylCap peaks displayed elevated CpG-densities and high 
MethylCap read densities. ZHX1 sites showed high CpG-densities, corresponding with 
the observed overlap with CpG-islands. However, MethylCap read densities were not 
enriched over ZHX1 peaks, indicating that ZHX1 sites lack DNA methylation. We 
conclude that ZHX1 recruitment to DNA in vivo occurs to regions of high CpG density, 
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however, these regions appear to lack DNA methylation as determined by MethylCap 
experiments.  
The usage of HCT116 cells enabled us to analyze the impact of loss of DNA 
methylation on ZHX1 binding patterns, using DNMT1,DNMT3b double knockout 
HCT116 cells [28]. The DNMT1 and DNMT3b genes are genetically disrupted in these 
cells, resulting in a 95% reduction of genomic DNA methylation [28]. We generated 
ZHX1 binding patterns in HCT116 DKO by ChIP-seq. We found that ZHX1 binding 
was not disrupted in the DKO cells, as evident from heatmaps of ZHX1 ChIP-seq 
densities in the WT and DKO cells (Fig.3A). Individual examples are shown in Fig.3B. 
Thus, these results corroborate and extend that methylation dependent binding of 
ZHX1 does not occur in vivo in HCT116 cells. 
 
Figure 3. ZHX1 binding is not disrupted in DNMT1,DNMT3b double knockout cells. (A) 
Heatmaps representing read densities of ZHX1 ChIP-seq experiments in WT and DKO cells in 
ZHX1 peaks. (B) Examples of ZHX1 peaks in HCT116 WT and DKO cells from ChIP-seq 
experiments. 
A
B
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Figure 4. ZHX1 genomic binding sites contain unmethylated CpGs. (A) Examples of ZHX1 
ChIP-BS-seq data, showing DNA methylation data per covered CpG. Percentage methylation for 
each covered CpG is color coded as indicated. (B) Histograms showing methylation status of CpGs 
within ZHX1 peaks (left) and of genomic DNA (right) as derived from ChIP-BS-seq data. Only 
CpGs with a coverage of at least 5 were considered. Genomic DNA was derived from sonicated 
chromatin without a ChIP enrichment step. 
4.2.3 ChIP-BS-seq shows that CpGs within ZHX1 bound chromatin 
are unmethylated 
MethylCap affinity purification of methylated DNA is only effective in regions with a 
high local density of methylated CpGs. To definitively exclude or determine 
methylation-dependent binding of ZHX1, we applied ChIP-BS-seq [29] to determine 
A
B
0      100%Me
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DNA methylation within ZHX1 peaks. In this approach ChIP-captured DNA is directly 
subjected to bisulfite conversion and deep-sequencing. In contrast to MethylCap-seq 
that generates global DNA methylation patterns, ChIP-BS-seq yields DNA methylation 
information at base resolution for the captured regions of interest. For each CpG within 
the ZHX1 peaks, the methylation status was derived from the ZHX1-ChIP-BS-seq data. 
We found that CpGs within ZHX1 peaks were unmethylated (examples in Fig.4A); 
more than 95% of CpGs within ZHX1 sites displayed methylation levels below 10% 
(Fig.4B left panel). A minority of CpGs (less than 3%) showed methylation levels 
above 80%. These CpGs were localized in ZHX1 bound CpG-islands that were 
partially or fully methylated, however, such binding sites represented a very minor 
fraction of ZHX1 peaks. Control genomic DNA (derived from sonicated chromatin) 
showed substantial methylation (Fig.4B right panel). In conclusion, bisulfite 
sequencing data showed that ZHX1 binding sites lack DNA methylation. 
 
4.2.4 ZHX1 is associated with active chromatin in vivo  
Finally, we asked whether the ZHX1 binding sites are associated with transcriptionally 
active or repressive chromatin states. Therefore, we determined the overlap with 
trimethylated histone H3 lysine 4 (H3K4me3), acetylated histone H3 (H3K9K14ac) 
and trimethylated histone H3 lysine 27 (H3K27me3) ChIP-seq profiles. H3K4me3 and 
H3K9K14ac are known to predominantly mark promoters of active genes [30], 
whereas H3K27me3 is linked to gene repression [31]. We found that ZHX1 genomic 
sites are enriched for H3K4me3 and H3K9K14ac, but not H3K27me3, as evident from 
heatmaps and average plots of histone mark read densities in 10kb regions around 
ZHX1 peaks (Fig.5). Also, in HCT116 DKO cells ZHX1 binding sites showed similar 
enrichments for active histone marks (Fig.S2), indicating that ZHX1 binding as well as 
local chromatin states are maintained in the DKO cells. We conclude that in vivo ZHX1 
is associated with active chromatin. 
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Figure 5. ZHX1 binding sites overlap with active histone marks. Heatmaps and average plots 
showing read densities around ZHX1 binding sites of ZHX1, H3K4me3, H3K9K14ac and 
H3K27me3 ChIP-seq experiments. 
4.3 – Discussion 
The usage of affinity purifications combined with SILAC-based quantitative mass 
spectrometry to identify factors that are specifically enriched with DNA methylation 
has been extensively described before [1-2,32-33]. Using this approach we identified 
ZHX1 as a potential new DNA methylation reader in line with results from Bartke et 
al. [1-2] (Table1). Ratios of enrichment of ZHX1 on methylated DNA were in the same 
range as those of known MBPs. In this study we went to great length to investigate 
whether ZHX1 binds DNA in a methylation- and/or sequence-dependent manner in 
vitro and in vivo. All of our in vitro experiments validated the finding of previous 
work: ZHX1 binds methylation-dependently to DNA in vitro. Pull-down experiments 
with recombinant ZHX1 fragments showed that the ZHX1 homeoboxes are responsible 
for methylated DNA binding in vitro. Notably, the observation that homeoboxes can 
mediate methylation-dependent DNA binding has not been described before.  
We found that ZHX1 binds to the second part of methylated GSTP1 CpG-island 
DNA, but not to the first part or a methylated CAG-repeat containing sequence. In the 
study by Bartke et al. ZHX1 was shown to bind to methylated 601 and 603 nucleosome 
positioning sequences. We could not identify common sequences in the GSTP1 CpG-
island sequence and the nucleosome positioning sequences (TableS1), suggesting that 
ZHX1                                          H3K4me3
H3K9K14ac                                  H3K27me3
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ZHX1 can bind a variety of methylated sequences in vitro. A systematic approach, for 
example using a methyl-SELEX procedure as described in [34], would be required to 
identify this variety of sequences. Notably, Bartke et al. demonstrated that ZHX1 also 
binds to methylated DNA in the context of nucleosomes [2] (Table1). Only 603 DNA, 
but not 601 DNA, retained methylation-dependent binding of ZHX family members 
when assembled in nucleosomes. ZHX1 ratios of enrichment for methylated DNA 
binding slightly decreased when 603 DNA was assembled in nucleosomes compared to 
naked DNA. This was not the case for either ZHX2 or ZHX3.  
Surprisingly, our in vivo findings did not support the in vitro observed DNA 
methylation dependent binding of ZHX1. Genomic binding patterns showed ZHX1 
recruitment to unmethylated CpG-dense regions. Lack of DNA methylation within 
ZHX1 binding sites was derived from MethylCap-seq data. Moreover, genomic ZHX1 
binding was not lost in DKO HCT116 cells that show a 95% reduction in genomic 
DNA methylation. We note that the number of unmethylated CpG-islands occupied by 
ZHX1 did not increase either in the DKO HCT116 cells. Finally and most 
conclusively, bisulfite sequencing of ZHX1 ChIP-captured DNA did not reveal DNA 
methylation.  
De novo motif searches using GimmeMotifs [25] identified CREB-like motifs as 
well as the YY1 motif, that are all well-known promoter motifs. Additional C-,G- and 
T-rich motifs were detected. Apparently, ZHX1 is recruited to various sequences in 
vivo. Surprisingly, motifs M2, M4, M5, M6 and M10 showed only weak ZHX1 binding 
compared to methylated GSTP1 DNA in pull-down experiments in vitro (data not 
shown).  
Further work is required to elucidate how ZHX1 is recruited to its genomic sites, 
either direct or indirect, and which domains and interactions are involved. Interactions 
with other factors may affect and/or establish genomic occupancies of ZHX1. Various 
interactors of ZHX1 have been identified in yeast-two-hybrid screenings, including 
other ZHX family members, NF-Y and DNMT3B. We did not detect the NF-Y motif in 
ZHX1 binding sites. However, other (unknown) factors may be involved in ZHX1 
recruitment to chromatin. Interestingly, we find ZHX1 sites coincide with active 
histone marks in HCT116 cells. The role ZHX1 accomplishes at these active marked 
unmethylated CpG-islands remains to be determined in future investigations. 
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4.4 – Materials and Methods 
4.4.1 Cell culture 
U937 cells (ATCC) were cultured in RPMI medium supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin (Gibco/Invitrogen) at 37 °C in 5% CO2 
atmosphere. HCT116 WT and HCT116 DKO (DNMT1
-/-
, DNMT3b
-/-
) cells [28] were 
grown similarly in McCoy’s 5A medium (Gibco/Invitrogen). 
4.4.2 Nuclear extracts and methyl-CpG pull-down assay 
Oligos used in pull-down experiments are listed in TableS3. Preparation of nuclear 
extracts and methyl-CpG pull-downs were performed as described [1,33]. 
4.4.3 Western blotting 
Western blotting was performed according to standard procedures. The following 
antibodies were used: anti-MBD2 (Everest, EB07538), anti-ZHX1 (Abcam, Ab19356) 
and anti-GST (Santa Cruz, B-14, sc-138). 
4.4.4 Cloning and recombinant proteins 
pDEST15-GST-ZHX1 plasmid for bacterial expression of human full length GST-
ZHX1 has been described before [9]. To amplify the ZHX1 Zn-fingers plus 
dimerization domain (ZNF1-2-dim) the following primers were used:  
5’-AGACTTCCCGGGAAATCAGCAAAATAAAAAAGTTGAAGG-3’ (forward) 
5’-AAGTCTCCCGGGTCATTGCTCTTTTGTCTTTTTTGC-3’(reverse).  
To amplify the ZHX1 homeoboxes (HD1-5) the following primers were used: 
5’-AGACTTGGATCCAATTCTAATTTGATTCCCAAAGTCT-3’(forward) 
5’-AAGTCTGAATTCTCATCAGTCATCTGATTTAGACAG-3’ (reverse).  
PCR products were digested and cloned in the SmaI site (ZNF1-2-dim), and BamHI 
and EcoRI sites (HD1-5) of pGEX-2T, for bacterial expression of GST-ZNF1-2-dim 
and GST-HD1-5, respectively. Expression and GST purification of recombinant 
proteins were performed as described in [35]. For methyl-CpG pull-down experiments, 
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crude E. coli lysates were used, in which case the purification procedure was followed 
up to the addition of Glutathione Sepharose beads. For EMSAs, purified proteins were 
used. 
 
4.4.5 EMSA 
DNA oligos used in EMSAs are listed in TableS3. EMSAs were performed as 
described in [33]. 
4.4.6 ChIP-seq and ChIP-BS-seq 
Chromatin harvesting and ChIPs were performed as described [36]. The following 
antibodies were used: anti-H3K27me3 (Millipore, 07-449) [37], anti-H3K4me3 
(Diagenode), anti-H3K9K14ac (Millipore, 06-599) and anti-ZHX1 (Abcam, Ab19356). 
ChIP DNA was prepared for Illumina sequencing according to manufacturer's 
protocols (Illumina). For ChIP-BS-seq, ChIP-DNA was processed as described [29]. 
4.4.7 MethylCap-seq 
MethylCap-seq was performed on sonicated genomic DNA from HCT116 WT and 
DKO cells according to the procedure described in detail in [27]. 
 4.4.8 Bioinformatic analyses 
ZHX1 peaks were called by MACS (version 1.4.Orc2) [24] with pvalue=1e-10, 
mfold=5 and an input control track. Peaks with tag counts below 100 were discarded. 
MethylCap peaks were called by MACS (version 1.3.3) with pvalue=1e-06 and 
mfold=4. MethylCap LOW, MEDIUM and HIGH fractions were used individually for 
peak calling, after which peaks were merged. Further data analyses were performed in 
LINUX shell, Python, Perl and R, using in-house generated scripts. Gene annotations 
were based on RefSeq (hg18), CpG islands annotations were based on UCSC 
(http://genome.ucsc.edu/). 
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4.7 – Supplemental Figures and Tables 
 
Figure S1. ZHX1 protein expression in U937, HCT116 WT and HCT116 DKO cells. Nuclear 
extracts from U937 cells (used in methyl-CpG pull-downs) and HCT116 WT and DKO cells (used in 
ChIP-seq experiments) were analyzed by western blotting and probing with anti-ZHX1 antibody. 
Purified GST-ZHX1 was used as a positive control. 
 
Figure S2. ZHX1 binding sites in HCT116 DKO cells overlap with active histone marks. 
Heatmaps and average plots showing read densities around ZHX1 binding sites of ZHX1, 
H3K4me3, H3K9K14ac and H3K27me3 ChIP-seq experiments in HCT116 DKO cells. 
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Abstract 
Cross-talk between DNA methylation and histone modifications drives the establishment of 
composite epigenetic signatures and is traditionally studied using correlative rather than direct 
approaches. Here we present sequential ChIP-bisulfite-sequencing (ChIP-BS-seq) as an approach 
to quantitatively assess DNA methylation patterns associated with chromatin modifications or 
chromatin-associated factors directly. A chromatin-immunoprecipitation (ChIP)-capturing step is 
used to obtain a restricted representation of the genome occupied by the epigenetic feature of 
interest, for which a single-base resolution DNA methylation map is then generated. When 
applied to H3 lysine 27 tri-methylation (H3K27me3), we found that H3K27me3 and DNA 
methylation are compatible throughout most of the genome, except for CpG islands, where these 
two marks are mutually exclusive. Further ChIP-BS-seq-based analysis in Dnmt triple-knock-out 
(TKO) embryonic stem cells revealed that total loss of CpG methylation is associated with 
alteration of H3K27me3 levels throughout the genome: H3K27me3 in localized peaks is 
decreased while broad local enrichments (BLOCs) of H3K27me3 are formed. At an even broader 
scale, these BLOCs correspond to regions of high DNA methylation in wild-type ES cells, 
suggesting that DNA methylation prevents H3K27me3 deposition locally and at megabase scale. 
Our strategy provides an unique way of investigating global interdependencies between DNA 
methylation and other chromatin features.  
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5.1 – Introduction 
Epigenetic regulation, involving DNA methylation and histone modifications, is 
fundamental to a multitude of biological processes such as transcription, DNA 
replication and repair. The different modifications do not act independently of each 
other. Instead, cross-talk between different modifications plays an important role in 
establishment of chromatin diversity within the genome. Interdependent deposition and 
mutual exclusion of various marks result in complex modification patterns with 
different functional outcomes [1-3]. Classically, such patterns are determined by 
parallel genomic mapping of the various modifications within the same samples, using 
chromatin immunoprecipitation and deep sequencing (ChIP-seq) [4-5]. However, the 
analysis of cross-talk through independent profiling experiments is complicated by cell 
population heterogeneity, cell cycle effects, and allele-specific marking of chromatin 
such as in imprinting or X-inactivation. 
Here we present a method for the integrated analysis of histone modification or 
transcription factor deposition patterns and the underlying DNA methylation. In our 
approach, termed ChIP-BS-seq, ChIP capturing is followed by bisulfite conversion and 
deep sequencing to directly assess DNA methylation levels in captured chromatin 
fragments. While the use of whole-genome bisulfite shotgun sequencing is limited by 
the cost of the required sequencing depth, a restricted genomic representation obtained 
by ChIP capturing allows to reach adequate coverage at routine-scale sequencing, 
providing increased quantitative accuracy of DNA methylation measurements within 
captured regions. 
 We used ChIP-BS-seq to study the global cross-talk between H3K27me3 
and DNA methylation, which are both linked to repression. Polycomb Repressive 
Complex 2 (PRC2) catalyzes H3K27me3 methylation via the SET domain of EZH2, 
while Polycomb Repressive Complex 1 (PRC1) is recruited to the H3K27me3 mark 
and is involved in gene silencing [6]. The DNA methyltransferases DNMT3A/B and 
DNMT1 are responsible for the establishment and maintenance of the DNA 
methylation mark, respectively [2]. The interplay between DNA methylation and 
H3K27me3/Polycomb has been subject to extensive studies, and different phenomena 
have been described [2]. Direct interactions between Polycomb and the DNA 
methylation machinery have been reported, suggesting that H3K27me3 and DNA 
methylation co-occur [7]. Co-occurrence was further supported by ChIP experiments 
analyzing DNA hypermethylated promoters in cancer cells [8-9]. Whereas H3K27me3  
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Figure 1. Integration of capturing methods and bisulfite deep sequencing: ChIP-BS-seq and 
MethylCap-BS-seq. (A) Schematic outline of the ChIP-BS-seq and MethylCap-BS-seq 
procedures. Capturing of genomic regions of interest is achieved by the MethylCap procedure or 
ChIP with an antibody of interest. Captured DNA is processed as indicated. Shown intermediate 
products and final PCR fragments indicate the fate of unmethylated as well as methylated 
cytosines throughout the procedure. (B) Examples of conventional MethylCap-seq and MethylCap-
BS-seq data of normal (N) and tumor (T) colon tissues. For each covered CpG, percentage 
methylation as derived from the MethylCap-BS-seq data is indicated by color (yellow, 0%; blue, 
100%). CpG islands and a CpG density profile (CpG/bp) are shown in green. (C) Average profiles 
of DNA methylation and coverage in MethylCap peaks of normal colon tissue, as determined by 
MethylCap-BS-seq. Percentage DNA methylation, blue; CpG coverage, magenta; read density, 
brown. (D) MethylCap-BS-seq analysis of differentially methylated regions from normal/tumor colon 
tissue. Regions that gain DNA methylation in tumor tissue show increased CpG coverage (x-axis) 
and read-density (y-axis). Color-code depicts absolute changes in percent methylation of these 
regions, as determined by bisulfite sequencing. Blue, increase; yellow, decrease. 
A B
C D
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has been shown to 'prime' gene promoters for later DNA methylation [9-13], several 
reports have shown antagonism or mutual exclusiveness between H3K27me3 and DNA 
methylation [14-17]. Although the different observations are not necessarily 
incompatible, the co-occurrence of both marks is still a subject of debate. Using ChIP-
BS-seq we addressed the overlap of H3K27me3 and DNA methylation directly on a 
genome-wide scale. Our results unequivocally show that DNA methylation and 
H3K27me3 generally co-occur, but are mutually exclusive in CpG-dense regions. This 
mutual exclusivity is found in both a cancer cell line as well as in mouse ES cells. Loss 
of DNA methylation in ES cells is associated with the formation of H3K27me3 
patterns previously described as broad local enrichments (BLOCs), and at an even 
larger scale, H3K27me3 appears in megabase-sized regions that were marked by high 
DNA-methylation in wild-type cells. 
 
5.2 – Results 
5.2.1 Establishment of the strategy 
An outline of our strategy, which we named ChIP-BS-seq, is shown in Figure 1A. ChIP 
is used to capture a genomic sub-fraction associated with a specific histone 
modification or transcription factor. Similarly, such sub-fraction can be obtained by 
capture of methylated DNA using a methyl-CpG binding domain (MBD). Captured 
DNA fragments are subjected to end-repair, adapter ligation using methylated adapters, 
bisulfite conversion, PCR-amplification, and deep-sequencing (Fig.1A). In this way the 
levels of DNA methylation can be quantitatively assessed at base-resolution within the 
genomic sub-fraction of interest.  
 To provide technical proof-of-principle of our strategy we used capturing of 
methylated DNA by MethylCap [18-19], followed by bisulfite-deep sequencing 
(MethylCap-BS-seq). In MethylCap, an MBD domain is used to capture methylated 
DNA [19]. Genomic DNA isolated from normal and tumor colon tissues was used for 
MethylCap-BS-seq as well as for conventional MethylCap-seq experiments. Sequence 
reads were mapped as described in Methods (see also TableS1). Read densities across 
the entire genome of MethylCap and MethylCap-BS-seq experiments correlated well 
(Pearson R = 0.833, Fig.S1A), which is comparable to technical replicates of 
conventional MethylCap samples (Pearson R ≤ 0.85, unpublished). This indicated that 
the same genomic sub-fraction was captured and sequenced in both procedures. Within 
each sequencing read, cytosines within a CpG context were scored for their 
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methylation status by counting the percentage of bisulfite-induced mutations. As a 
control for bisulfite conversion efficiency we assessed DNA methylation within 
mitochondrial DNA which was present at low levels due to its cellular abundance. 
Mitochondrial DNA is known to be completely unmethylated, and conversion was 
calculated to be 99.91%. In addition, efficient conversion of 99.7% was found in 
genomic CHG/CHH context. 
Next, we focused on the captured genomic sub-fraction. Visual inspection of 
individual peaks showed that they were mostly hypermethylated (Fig.1B and Fig.S1B). 
This was confirmed on a global scale (Fig.1C); mean methylation was 87% within 
MethylCap peaks. At boundaries, methylation showed a sharp drop that continued 
further with increasing distance from peaks. This was accompanied by decreases in 
read densities and thus CpG coverage. When focused exclusively on regions inside the 
MethylCap peaks we found that 85% and 79% of the CpGs were at least 80% 
methylated in normal and tumor, respectively (Fig.S1C).  
Differential methylation between normal and tumor as observed by conventional 
MethylCap-seq was confirmed by MethylCap-BS-seq; differentially methylated 
regions showed corresponding alterations in CpG coverage and absolute CpG 
methylation (Fig.1B, bottom panel, Fig.S1B, middle panel). The same was observed on 
a global scale: regions that gained DNA methylation in tumor compared to normal 
tissue (color-coded in Fig.1D) showed increased coverage and methylation levels in 
MethylCap-BS-seq, whereas the opposite was observed for regions that lost 
methylation. Taken together, MethylCap-BS-seq showed hypermethylation of 
MethylCap-captured DNA, and differences observed between normal and tumor tissue 
could be corroborated and extended using MethylCap-BS-seq. These experiments 
demonstrate the successful integration of capturing experiments with bisulfite deep 
sequencing.  
 
5.2.2 H3K27me3-ChIP-BS-seq 
We next applied our approach to ChIP-captured DNA (ChIP-BS-seq) for analysis of 
DNA methylation patterns associated with specific chromatin modifications. 
H3K27me3 and DNA methylation are both involved in gene silencing, but their 
interplay is under debate and has not been directly investigated. We performed ChIP-
BS-seq on H3K27me3, using HCT116 colon carcinoma cells. For comparison we also 
generated conventional ChIP-seq profiles for H3K27me3. Read densities of the 
conventional H3K27me3 ChIP-seq and ChIP-BS-seq experiments correlated well 
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(Pearson R = 0.854, Fig.S2A), showing that the bisulfite/mapping procedure did not 
alter the H3K27me3 patterns. The H3K27me3 genome-wide profile showed 
H3K27me3 enrichments over broad regions, comprising genes and intergenic regions 
(Fig.2A, Fig.S2C, Suppl. Fig.3C). This pattern resembled the H3K27me3 'BLOCs' 
profile in mouse and human fibroblast cells [20-21], and differs from H3K27me3 
patterns in mouse ES cells, where the mark is present in focal areas at silent promoters 
[5,22-24] (see also below). As described before, genes that were located within the 
H3K27me3 BLOCs were generally silent, whereas genes outside BLOCs had a 
significant higher average expression level (Fig.S3A).  
To rule out that crosslinking/de-crosslinking of chromatin interfered with bisulfite 
conversion, we performed bisulfite sequencing on 12 independent PCR fragments 
amplified from genomic DNA isolated directly or after crosslinking/de-crosslinking 
(Fig.S2B). None of the fragments showed altered DNA methylation patterns after 
crosslinking/de-crosslinking, showing that ChIP-derived DNA did not affect -bisulfite 
conversion. 
 
5.2.3 DNA hypomethylation in H3K27me3-enriched high CpG 
density regions 
We then interrogated the DNA methylation status of captured H3K27me3-marked 
chromatin. H3K27me3-marked chromatin coincided mostly with fully methylated 
CpGs, with smaller patches of lower methylation occurring in between (Fig.2A, 
Fig.S2C). Strikingly, CpG-rich promoter regions marked with H3K27me3 contained 
exclusively unmethylated CpGs. For example, the SERTAD4, SMAD7 and OVOL2 
genes were located within H3K27me3 BLOCs (Fig.2B and Fig.S2D) and were mostly 
DNA methylated, except for the CpG islands encompassing their gene promoters; these 
were completely hypomethylated.  
To analyze DNA methylation of the H3K27me3-enriched fraction on a genome-
wide scale, DNA methylation was determined in 300-bp windows throughout 
H3K27me3 BLOCs, and windows were subsequently categorized according to their 
genomic function (intergenic, intron, exon, non-CpG island promoter, CpG island 
promoter). Histograms displaying DNA methylation levels are shown in Fig.2C. 
Within a window size of 300 bp, the DNA methylation pattern was clearly bimodal, as 
shown previously [25]. Genes, intergenic regions and non-CpG island promoters 
enriched for H3K27me3 generally contained unmethylated as well as methylated DNA, 
although methylated DNA was prevalent. In contrast, CpG island promoters marked 
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Figure 2. H3K27me3 enriched CpG island promoters are devoid of DNA methylation. (A-B) 
Examples of H3K27me3 ChIP-BS-seq data of HCT116 cells. H3K27me3 ChIP-BS-seq profiles are 
shown, as well as the derived DNA methylation data per covered CpG and per 200-bp window. 
Percentage methylation is color coded as in Figure 1B. (C) Histograms showing the distribution of 
mean methylation in 300 bp windows throughout H3K27me3 enriched regions, as derived from 
H3K27me3 ChIP-BS-seq results. Windows were categorized according to functional genomic 
elements (intergenic, intron, exon, non-CpG island promoter or CpG island promoter). (D) Average 
profiles of DNA methylation (blue), H3K27me3 (red), and CpG density (green) in regions flanking 
H3K27me3-enriched CpG islands, as determined from H3K27me3 ChIP-BS-seq data. 
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Figure 3. H3K27me3 is locally depleted at hypermethylated CpG islands. (A) Examples of the 
genome-wide H3K27me3 ChIP-seq and MethylCap-seq data, demonstrating hypermethylated CpG 
islands within H3K27me3 BLOCs, and concomitant local depletion of H3K27me3. H3K27me3-
enriched BLOCs and MethylCap peaks are indicated as red and blue rectangles, respectively. (B) 
Density maps of MethylCap-seq and H3K27me3 ChIP-seq read densities in 20-kb regions 
surrounding MethylCap peaks that reside in H3K27me3 BLOCs and overlap with CpG islands. 
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with H3K27me3 contained only hypomethylated DNA. Since this exclusively applied 
to CpG island containing promoters, we also categorized windows according to CpG 
density (Fig.S2E). While low-CpG dense windows (<0.06 CpGs/bp) contained mostly 
DNA hypermethylation, high CpG-density windows (>0.06 CpGs/bp) were exclusively 
hypomethylated. We next focused in more detail on H3K27me3-captured CpG islands. 
Median DNA methylation from 5 kb outside to 0.5kb within these CpG islands was 
plotted along with CpG-density and H3K27me3 levels (Fig.2D). A clear and sharp 
decrease in DNA methylation took place at CpG island borders, resulting in an almost 
perfect inverse correlation between DNA methylation and CpG-density. Inside CpG 
islands H3K27me3 was consolidated. Taken together, our results show that H3K27me3 
and DNA methylation generally co-occur in low CpG-density regions, i.e. the bulk of 
the human genome. Within H3K27me3-marked regions of high CpG-density, such as 
CpG islands, DNA is exclusively hypomethylated. We conclude that H3K27me3 and 
DNA methylation are mutually exclusive in CpG-dense regions. 
 
5.2.4 Hypermethylated CpG-islands show local H3K27me3 
depletion within H3K27me3 BLOCs 
The results obtained by H3K27me3 ChIP-BS-seq clearly demonstrate the existence of 
mutual exclusiveness of H3K27me3 with DNA methylation in CpG islands. To further 
confirm the relevance of this observation, we analyzed genome-wide profiles for 
H3K27me3 and DNA methylation generated by conventional ChIP-seq and 
MethylCap-seq. Using this approach we could test whether DNA methylation also 
excludes H3K27me3. Obviously, the latter could not be directly shown by ChIP-BS-
seq as regions lacking H3K27me3 were not captured and thus not available for DNA 
methylation measurements.  
To test our hypothesis we examined DNA-methylated CpG islands within 
H3K27me3 BLOCs. We detected 6,456 H3K27me3 BLOCs with a median length of 
77 kb (Fig.S3B). 8,781 out of the total 28,226 annotated CpG islands (31%, 
http://genome.ucsc.edu/) were located within H3K27me3 BLOCs. 6,473 of these CpG 
islands contained MethylCap peaks. Visual inspection of such methylated CpG islands 
within H3K27me3 BLOCs revealed local depletions of H3K27me3 (Fig.3A and 
Fig.S3C). To assess this at a genome-wide scale, we generated density maps 
representing read densities of MethylCap and H3K27me3 ChIP around BLOCs-
contained methylated CpG islands (Fig.3B). A clear local depletion of H3K27me3 was 
evident over methylated CpG islands. To exclude that this local depletion of 
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H3K27me3 was due to a local drop in nucleosome density, we used publicly available 
DNaseI hypersensitivity data from HCT116 cells (ENCODE). MethylCap peaks were 
not enriched for DNaseI hypersensitivity, and are thus unlikely to represent 
nucleosome-depleted regions (Fig.S3D). Taken together, our data show that DNA-
hypermethylated CpG islands present within H3K27me3 BLOCs are locally depleted 
for H3K27me3. This corroborates and extends the above findings on mutual 
exclusiveness of DNA methylation and H3K27me3 in regions of high CpG density. 
 
5.2.5 Mutual exclusiveness of H3K27me3 and DNA methylation in 
mouse ES cells 
To extend our observations to non-cancerous cells, we applied our H3K27me3-ChIP-
BS-seq strategy to mouse embryonic stem (mES) cells. Regions of H3K27me3 
enrichment were smaller than in HCT116, representing the typical more peak-like mES 
pattern described before [5,22-24]
 
(Fig.4A and Fig.S4A). About one third of these 
H3K27me3 peaks overlap with CpG islands or transcription start sites encompassing 
CpG islands (32%, Fig.S4B). Importantly and as in HCT116 cells, these CpG-rich 
regions contained exclusively unmethylated CpGs. For example, the Htra4/Plekha2, 
and Lmx1b genes were mostly DNA methylated, except for the CpG islands underneath 
the H3K27me3 peaks (Fig.4A). We generated average profiles for H3K27me3 peaks 
over CpG islands and accompanying DNA methylation from H3K27me3-ChIP-BS-seq 
(Fig.4B). Whereas DNA methylation on the flanks of CpG islands was 80%, this 
dropped to zero in CpG islands. This decrease appeared to be instigated at least 0.5 kb 
away from CpG islands, where CpG density is elevated but by far not maximal. To 
further relate DNA methylation–H3K27me3 mutual exclusiveness to high CpG 
density, we applied a 300-bp sliding window approach over all H3K27me3 peaks, 
categorized these windows according to their CpG density, and inferred their DNA 
methylation status from the ChIP-BS-seq data (Fig.4D). Up to a CpG density of 0.05 
CpG/bp, H3K27me3 and DNA methylation co-occurred within the same windows. 
This CpG density corresponds to that encountered at the borders ('shores') of CpG 
islands (http://genome.ucsc.edu/). Within windows of higher CpG density (>0.05 
CpG/bp) DNA methylation was virtually absent, confirming the antagonism between 
H3K27me3 and DNA methylation. Together, these data clearly confirm and extend our 
findings on mutual exclusiveness of DNA methylation and H3K27me3 in regions of 
high CpG density to mES cells. 
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Figure 4. Localized peaks of H3K27me3 in wild-type mES cells over CpG islands. (A) 
Screenshots of localized H3K27me3 peaks (red). Per covered CpG, percentage methylation as 
derived from the H3K27me3-BS-seq data is indicated in color. (B-C) Average profiles of DNA 
methylation (blue), H3K27me3 (red), and CpG density (green) in H3K27me3 peaks over CpG 
islands, as determined from H3K27me3-ChIP-BS-seq. (D) Histograms showing the distribution of 
methylation in 300 bp windows through H3K27me3 peaks, as inferred from H3K27me3 ChIP-BS-
seq. Windows were categorized according to CpG density. (E) H3K27me3 changes in CpG islands 
that were either hypermethylated (>90%, left) or hypomethylated (<10%, right) in wild-type mES 
cells. Readcounts shown are from conventional H3K27me3 ChIP. 
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As an extension to our observations with H3K27me3, we performed ChIP-BS-seq 
using H3K9me3, a repressive mark that has classically been linked to DNA 
hypermethylation. Indeed, examples of H3K9me3 peaks such as in the imprinting 
control region (ICR) upstream from H19 [26-28] showed that this mark was associated 
with hypermethylated DNA in mES cells (Fig.S5A). Of all detected H3K9me3 peaks, 
over 90 percent of them were associated with hypermethylated DNA (Fig.S5B). This is 
in sharp contrast with H3K27me3 peaks, under which there is a more equal subdivision 
of hypomethylated and hypermethylated DNA (Fig.S5B), corresponding to high-CpG 
density and low-CpG density sequences, respectively (see Fig.4D). These data show 
that histone marks other than H3K27me3 may display different DNA methylation 
properties, which extends and confirms the validity of the ChIP-BS-seq strategy. 
 
5.2.6 H3K27me3 changes upon loss of DNA methylation 
We next addressed the question what happens to the H3K27me3 distribution upon 
removal of DNA methylation. Therefore we performed H3K27me3-ChIP-BS-seq on 
Dnmt[1kd,3a-/-,3b-/-] (TKO) mES cells [29]. DNA methylation in virtually all of the 
captured/sequenced CpGs had disappeared (Fig.S5B).  
We first focused on CpG islands and created average profiles for H3K27me3 
peaks over CpG islands (Fig.4C). DNA methylation had disappeared, and the 
H3K27me3 signal over CpG islands that was generally high in wild-type cells had also 
decreased in TKO cells. It should be noted that hypermethylated CpG island in wild-
type mES cells are scarce and not captured by H3K27me3 ChIP due to the observed 
antagonism, so their contribution to these average profiles is almost zero. To enable 
analysis of H3K27me3 changes in hypermethylated CpG islands we subselected such 
CpG islands using publicly available data [30] and plotted the changes in H3K27me3 
from conventional ChIP data. In case of antagonism between DNA methylation and 
H3K27me3 we expected that hypermethylated CpG islands would gain H3K27me3 in 
TKO cells, which was indeed the case (Fig.4E). The opposite effect, although to a 
lesser magnitude, occurred at hypomethylated CpG islands. These CpG islands – 
containing high H3K27me3 – displayed a loss in H3K27me3 in TKO cells (Fig.4E). 
Thus, antagonism between DNA methylation and H3K27me3 was clearly observed in 
hypermethylated CpG islands, but appeared to be absent in unmethylated CpG islands, 
where loss of DNA methylation caused a concomitant decrease of H3K27me3. 
The H3K27me3 changes described above concern mainly the sharp and localized 
peaks of H3K27me3 typical of mES cells. An additional and striking observation in 
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TKO cells was the appearance of large regions of H3K27me3 enrichment, resembling 
the typical BLOCs (Fig.5A). To analyze the co-occurring changes of peaks and BLOCs 
in more detail, we plotted the fold change of H3K27me3 BLOCs against the fold 
change of the localized peaks within these BLOCs (Fig.5B). In 43% of the cases, the 
increase in H3K27me3 in BLOCs was accompanied by a decrease of H3K27me3 in 
localized peaks within the same BLOCs (Fig.5B, quadrant II). In another 18% of the 
cases, BLOCs appeared but the peaks of H3K27me3 in these BLOCs were maintained 
(Fig.5B, quadrant I). The observed changes of H3K27me3 in TKO cells  – decrease in 
peaks and accumulation in BLOCs –  could be clearly confirmed using targeted ChIP-
qPCR. 10 out the 12 tested peaks showed decrease and 8 out of the 9 tested BLOCs 
showed increase (Fig.S6). These results not only validated our genome-wide analyses, 
but also excluded the possibility that decrease of H3K27me3 peaks was a technical 
artifact due to a higher complexity of the TKO sequencing libraries by accumulation of 
H3K27me3 throughout a larger part of the genome.  
A possible explanation for accumulation of H3K27me3 BLOCs could be a 
compensatory repressive effect instigated by the loss of DNA methylation. If this were 
the case, H3K27me3 BLOCs elevated in TKO cells are expected to represent genomic 
regions with high DNA methylation in wild-type cells. We made use of our 
H3K27me3-ChIP-BS-seq data to assess the DNA methylation status in TKO-BLOC 
regions in wild-type cells (Fig.5C). Indeed, in cases where BLOCs became more 
prominent (Fig.5C, quadrants I & II), DNA methylation in wild-type mES cells was 
significantly higher as compared to regions where H3K27me3 was lost (Fig.5C, 
quadrants I vs. IV, p = 2.8e-68; quadrants II vs. III, p = 1.5e-137 , Mann–Whitney U 
test).  These data suggest that large chromosomal regions with high DNA methylation 
become more susceptible for accumulation of H3K27me3 upon removal of DNA 
methylation. To analyze H3K27me3 changes instigated by loss of DNA methylation at 
an even larges scale and independent of BLOC-like patterns, we generated a 
MethylCap DNA methylation profile for wild-type mES cells. A sliding window of 0.5 
Mb was applied (Fig.S7A). We found that H3K27me3 in TKO cells resembled the 
MethylCap profile of wild-type (Fig.S7B). Correlation between H3K27me3 and 
MethylCap profiles increased from 0.41 in wild-type to 0.71 in TKO (Pearson 
correlation, Fig.S7C).  
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Figure 5. Changes in H3K27me3 patterns upon loss of DNA methylation in Dnmt triple-
knockout (TKO) mES cells. (A) Examples of H3K27me3 BLOCs appearing in TKO cells, and 
concomitant loss of H3K27me3 in localized peaks. Per covered CpG, percentage methylation as 
derived from H3K27me3-ChIP-BS-seq is indicated in color. (B) Scatterplot of H3K27me3 changes 
in peaks (x-axis) vs. BLOCs (y-axis). H3K27me3 peaks were matched against BLOCs in which 
they reside. I-IV indicate the four quadrants of the plot, as determined by log2 fold changes 
deviating from zero. (C) Histograms of percent DNA methylation in the BLOCs of each quadrant of 
(B), as deduced from H3K27me3-ChIP-BS-seq in wild-type mES cells. (D) Density maps of 
H3K27me3 through BLOC transition regions detected in TKO mES cells. Average profiles are 
shown on top.  
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To analyze the consequence – if any – of H3K27me3 accumulation in BLOCs at 
the level of gene expression, we categorized RefSeq genes according to their position 
within or outside BLOCs and plotted their expression levels in wild-type and TKO 
cells (RNA-seq data from  [31]). Genes located outside BLOCs were expressed at 
higher levels than genes located within BLOCs (Fig.S8A), which is in line with 
observations made by others [20] and us in HCT116 cells (see Fig.S3A). Strikingly, in 
wild-type mES cells these differences were already evident, even though BLOCs are 
less prominent as in TKO cells. As shown before [31], loss of DNA methylation did 
not cause massive deregulation, and the expression levels of most genes were stably 
maintained. Only 190 transcripts were found to be deregulated (Fig.S8B, FDR of 0.05, 
minimal 2-fold change).  
A closer inspection of H3K27me3 patterns in wild-type mES cells revealed that 
BLOCs of TKO cells could already be distinguished in wild-type cells, although 
signals were much weaker (Fig.5A). This was confirmed by plotting density maps of 
all BLOC transition regions in both wild-type and TKO cells (Fig.5D): the same BLOC 
boundaries were present in wild-type cells as in TKO cells. Taken together, total 
removal of DNA methylation caused an accumulation of H3K27me3 signal in BLOC-
like patterns with boundaries that had been set in wild-type cells. This suggests that 
besides the local antagonism between the two marks at high-CpG dense regions, there 
is also antagonism between the two marks at a much larger scale in the genome. 
 
5.3 – Discussion 
Various methods for the generation of genome-wide DNA methylation maps exist. An 
extensive comparison of the most frequently used bisulfite- and enrichment-based 
technologies has recently been performed [18,32]. In our strategy, we integrated 
MethylCap and ChIP-capturing procedures with bisulfite-based DNA methylation 
analysis. Although similar strategies have been used to interrogate DNA methylation 
within a limited number of preselected regions [33-34], our strategy allows to obtain 
base-resolution DNA methylation information within all fragments obtained by a 
capturing step. Any subset of the genome occupied by a specific feature can be directly 
assessed for DNA methylation, provided that the feature of interest can be enriched for 
or captured. Not only does this open up the possibility to assess cross-talk between 
DNA methylation and other chromatin features, it also allows for the analysis of DNA 
methylation within binding sites of transcription factors that are dependent or excluded 
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by DNA methylation. In addition, it allows for detection of allele-specific marking of 
chromatin such as in imprinting or X-inactivation.  
We used MethylCap-BS-seq as a proof-of-principle for our strategy and showed 
that DNA fragments obtained by MethylCap represent a highly methylated fraction of 
the genome. In addition, differences in methylation between normal and tumor tissue as 
detected by conventional MethylCap-seq were corroborated and extended by 
MethylCap-BS-seq. ChIP-BS-seq was successfully established using H3K27me3 and 
H3K9me3 as the epigenetic marks of interest. Depending on CpG density, H3K27me3 
and DNA methylation co-occur or are mutual exclusive, whereas H3K9me3 and DNA 
methylation coincide.  
Upon loss of DNA methylation in TKO cells we observed two notable effects, (1) 
accumulation of H3K27me3 in BLOC patterns and (2) a decrease (flattening) of sharp 
localized H3K27me3 peaks. Thus, depending on whether one regards BLOCs or 
smaller peaks, the effects of DNA methylation loss appear to be different. Our data 
strongly suggest that the increase in H3K27me3 BLOCs is related to antagonism 
between H3K27me3 and DNA methylation, since regions where H3K27me3 
accumulates in BLOC patterns have elevated methylation already in wild-type mES 
cells. Decrease of H3K27me3 in peaks occurs mostly in unmethylated CpG islands; 
likely surrounding DNA methylation normally constraints H3K27me3 to unmethylated 
CpG islands in wild-type cells, which is lost in TKO cells. This constraint probably 
relates to the same antagonism as observed elsewhere in the genome and as such limits 
the spread of H3K27me3 into neighboring chromatin. Thus, although the H3K27me3 
changes observed in BLOCs and peaks are different, they may result from the same 
antagonism between DNA methylation and H3K27me3. We have ruled out that the 
decrease in peaks is a technical artifact caused by increased complexity of sequencing 
libraries as a larger part of the genome is enriched for H3K27me3 (Fig.S6).  
 How the observed mutual exclusiveness of H3K27me3 and DNA 
methylation within regions of high CpG density is achieved mechanistically is not yet 
clear, but several studies have described an antagonism between H3K27me3 and DNA 
methylation. In SILAC nucleosome affinity purifications, DNA methylation of 
nucleosome positioning sequences impeded PRC2 binding to H3K27me3-modified 
nucleosomes [16]. The CpG density of the nucleosome positioning sequences (“601” 
and “603”) was 0.09 CpG/bp. At this density we observed mutual exclusiveness of the 
H3K27me3 and DNA methylation marks in both HCT116 as well as in mES cells (see 
Fig.S2E and Fig.4D). Therefore, one explanation for our observations may be 
obstruction of PRC2 recruitment at DNA methylated CpG-dense regions. Such 
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obstruction may also be involved in epigenetic switching as described for prostate 
cancer cells [12]. Genes initially silenced by Polycomb in normal prostate cells, 
acquired DNA methylation and lost H3K27me3 in the PC3 cancer cells.  
 The appearance of H3K27me3 BLOCs in TKO cells suggests that DNA 
methylation more globally antagonizes accumulation of H3K27me3, which is 
alleviated in TKO cells. Still, the resulting BLOCs occur in specific genomic regions 
that importantly are pre-set in wild-type mES cells, indicating that there are positional 
restraints on the deposition of H3K27me3. It is possible that these regions and their 
boundaries are characterized by other (epi)genetic features such as over-representation 
of genomic elements like certain repeat classes, CpG islands, gene density, lamina-
associated domains [35] or transcriptional factor binding. We anticipate that the two-
dimensional information obtained using ChIP-BS-seq will provide new insights in the 
composition of different types of chromatin and their biological roles. 
 
5.4 – Methods 
5.4.1 ChIP-seq, MethylCap-seq and RNA-seq 
HCT116 cells were cultured in McCoy’s 5A medium supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin (all Gibco/Invitrogen) at 37 °C in 5% 
CO2 atmosphere. Mouse ES cells were cultured as described in [29]. Chromatin 
harvesting and ChIPs were performed as described [36]. The following antibodies were 
used: anti-H3K27me3 (Millipore, 07-449) [37] and anti-H3K4me3 (Diagenode). 
MethylCap-seq was performed as described [19]. For RNA-seq total RNA was isolated 
using Trizol (Invitrogen) according to the manufacturer's recommendations. 100µg 
total RNA was subjected to two rounds of poly(A) selection (Oligotex mRNA Mini 
Kit, QIAGEN), followed by DNaseI treatment (QIAGEN). 100 ng mRNA was 
fragmented by hydrolysis (5x fragmentation buffer: 200mM Tris acetate, pH8.2, 
500mM potassium acetate and 150mM magnesium acetate) at 94°C for 90 s and 
purified (RNeasy MinElute Cleanup Kit, QIAGEN). cDNA was synthesized using 5µg 
random hexamers by Superscript III Reverse Transcriptase (Invitrogen). ds-cDNA 
synthesis was performed in second strand buffer (Invitrogen) according to the 
manufacturer's recommendations and purified (MinElute Reaction Cleanup Kit, 
QIAGEN). ChIP and MethylCap DNA and ds-cDNA were prepared for Illumina 
sequencing according to manufacturer's protocols (Illumina). 
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5.4.2 ChIP-BS-seq and MethylCap-BS-seq 
100 ng ChIP DNA or 10 ng MethylCap DNA from the HIGH fraction [19] was 
prepared for bisulfite deep sequencing. DNA was first subjected to end-repair in a 30 
µl reaction containing 6 units T4 DNA polymerase, 2.5 units DNA Polymerase I 
(Large Klenow Fragment), 20 units T4 Polynucleotide Kinase (all New England 
Biolabs), dATP, dCTP, dGTP and dTTP (0.125 mM each), and 1x T4 Ligase buffer 
with ATP for 30 min at 20°C. Illumina sequencing generates sequences corresponding 
to the 5’-ends of the input DNA fragments (see also Fig.1A). Therefore, fill-in of 5’-
overhangs did not alter sequenced DNA methylation patterns. Purification was 
performed using a standard phenol:chloroform:isoamyl alcohol (25:24:1) protocol and 
ethanol precipitation as described previously [38]. DNA was then adenylated in a 20 µl 
reaction containing 10 units Klenow Fragment (3’→5’ exo-) (New England Biolabs), 
0.5 mM dATP and 1x NEB buffer 2 for 30 min at 37°C. After phenol extraction and 
ethanol precipitation, Illumina genomic DNA adapters containing 5-methylcytosine 
instead of cytosine (atdbio, Southampton), preventing deamination during bisulfite 
conversion, were ligated. In a 20 µl reaction, DNA was incubated with 1.5 µM pre-
annealed adapters, 2000 units T4 DNA Ligase (NEB) and 1x T4 Ligase buffer with 
ATP, for 16-20 h at 16°C.  
 Adapter-ligated DNA fragments were subsequently purified by phenol 
extraction and ethanol precipitation, and size-selected on gel. 50 ng sheared and 
dephosphorylated E.coli K12 genomic DNA was added to adapter-ligated DNA as 
carrier during size-selection and bisulfite conversion. DNA was run on 2.5% Nusieve 
3:1 Agarose (Lonza) gels. Lanes containing marker (50 bp ladder New England 
Biolabs) were stained with SYBR Green (Invitrogen), and size regions to be excised 
were marked with toothpicks. To obtain 80-280 bp (low) and 280-430 bp (high) insert 
sizes, adapter-ligated DNA fragments from 200-400 and 400-550 bp, respectively, 
were excised. The Illumina adapters cause the fragments to run slower, presumably due 
to the forked structure, as has been described before [38]. Note that after PCR, dsDNA 
libraries appear at 140-340 bp and 340-490 bp, in accordance with exact sizes. DNA 
was isolated from gel using the MinElute Gel Extraction kit (QIAGEN). The low and 
high libraries were kept separate in subsequent steps.  
Analytical PCRs were performed to check ligation efficiency and sizes of the 
libraries. Amplifications were performed in 10 µl reactions containing 0.3 µl template 
DNA (from 20 µl eluted after size-selection), 0.5 units Pfu Turbo Cx Hotstart DNA 
Polymerase (Stratagene), Illumina primers LPX 1.1 and 2.1 (0.3 µM each), dNTPs 
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(0.25 mM each), 1x Turbo Cx buffer, under the following thermocycler conditions: 
94°C for 5 min,  n x (94°C for 30 s, 65°C for 30 s, 72°C for 1 min) and 72°C for 7 min. 
We tested three different cycle numbers (n) –  10, 15 and 20 –  and analyzed PCR 
products on 4-20% TBE Criterion precast gels (BioRad) using SYBR Green staining.  
 Adapter-ligated and size-selected DNA was subjected to two subsequent 5h 
bisulfite treatments using the EpiTect Bisulfite kit (QIAGEN) following the 
manufacturer's protocol for DNA isolated from FFPE tissue samples. After bisulfite 
conversion, analytical PCRs were performed as before to determine the minimum 
number of cycles required in the final amplification step for each sample. In this case, 
tested cycle numbers were several cycles higher as before bisulfite conversion; 15, 19 
and 22 PCR cycles were performed. The minimum cycle number for final large-scale 
amplification was determined as the lowest cycle number that generated enough PCR 
product of the desired size range to be visualized on analytical gels as above. Large-
scale amplification was performed in 8 reactions of 25 µl, each containing 3 µl DNA 
(from 40 µl bisulfite-converted DNA, the remainder was stored at -80°C as back-up), 
1.25 units Pfu Turbo Cx Hotstart DNA Polymerase (Stratagene), primer LPX 1.1 and 
2.1 (0.3 µM each), dNTPs (0.25 mM each), 1x Turbo Cx buffer and thermocycler 
conditions as above. Amplified libraries were purified with the MinElute PCR 
Purification kit (QIAGEN), and subsequently purified from gel essentially as described 
above; whole gels were stained with SYBR Green and no carrier DNA was added. 
Final libraries were analysed on analytical 4-20% TBE Criterion precast gels (BioRad), 
and measured by Quant-iT dsDNA HS Assays (Invitrogen). The protocol for 
preparation of captured DNA for bisulfite deep sequencing was adapted from [38-40]. 
Sequence reads were generated on the Illumina Genome Analyzer IIx or the 
HiSeq2000 using a standard 36-base protocol. After sequencing low and high library 
reads were combined. 
 
5.4.3 Bisulfite sequencing of PCR fragments 
Cultured cells (SKNO-1) were either untreated or crosslinked directly in culture 
medium by the addition of 1% formaldehyde for 15 min. at room temperature. 
Chromatin harvesting, de-crosslinking and DNA isolation were done as described 
previously [36]. Bisulfite conversion was performed using the EpiTect Bisulfite kit 
(QIAGEN) following the manufacturer's standard protocol. For each sample, PCR 
amplicons of the appropriate size were excised from agarose gel, pooled, and subjected 
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to end-repair as above. Pooled fragments were subsequently concatamerized by ligation 
in the presence of 17% PEG3350,   and sonicated using a Bioruptor (Diagenode) at 
high power for 30 min. in a final volume of 300 µl. The obtained DNA fragments were 
subjected to library preparation according the standard procedure (Illumina). Index 
sequences were introduced by using in-house generated single-read adapters that 
contained a six-base barcode directly after the sequence primer binding site. The two 
samples (untreated and crosslinked/de-crosslinked) were pooled and sequenced on the 
Illumina Genome Analyzer IIx using a standard 36-base protocol. 
 
5.4.4 ChIP-seq and MethylCap-seq data analysis 
MethylCap peaks in HCT116 and H3K27me3 peaks in mES cells were called by 
MACS [41], with mfold=4 and pvalue=1e-06 and 1e-10, respectively. MethylCap 
LOW, MEDIUM and HIGH fractions [19] were used individually for peak calling, 
after which peaks were merged. Identification of H3K27me3 enriched regions 
(BLOCs) was performed using the RSEG algorithm [42], which models the read counts 
with a negative binomial distribution after correcting for the effect of genomic 
deadzones. Subsequently, it uses a two-state HMM for segmentation the genome into 
foreground domains and background domains. We used a binsize of 500 bp in 
combination with default RSEG settings. These include that the posterior probability of 
each bin obtained by HMM decoding is larger than 0.95, and that the mean read counts 
within a region is above the top 90% percentile of foreground emission distribution.  
BLOCs within 20 kb proximity were merged, and BLOCs smaller than 20 kb were 
discarded. 
 
5.4.5 ChIP-BS-seq and MethylCap-BS-seq data analysis 
Initial data processing and base-calling was done using the Illumina pipeline software. 
Mapping of bisulfite-converted sequence reads was done using a custom-made pipeline 
using a strategy similar to that in Lister et al. [43]. To reduce PCR artifacts, a 
maximum of three identical sequence reads was allowed. To perform mapping 
independently of DNA methylation status, sequence reads were in silico bisulfite-
converted (C to T), and subsequently mapped to two different in silico converted hg18 
genome sequences; one C to T converted genome and one G to A converted genome. 
Reads mapping to both genomes were discarded, which typically represented a very 
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minor fraction of all reads. Mapping was done using the Burrows-Wheeler Aligner 
(BWA) [44], with default settings allowing a single mismatch. Percentages of uniquely 
mapped reads ranged from 78% to 50% for the 80-280 bp and 280-430 bp libraries, 
respectively (see TableS1 for details). The obtained mapping positions were used to 
align unconverted sequence reads with their corresponding unconverted genomic 
sequence and to subsequently determine the methylation status of each sequenced 
cytosine within a CpG context, both on the forward strand as well as on the reverse 
strand. The mapping and CpG methylation scoring procedure was driven by a custom-
generated Perl script. Further data analysis was done using in-house generated scripts 
written in LINUX shell, Python, Perl, and R. Gene annotations were based on RefSeq 
(hg18), CpG islands annotations were based on UCSC (http://genome.ucsc.edu/)  
 
5.5 – Data access 
The data generated for this work have been deposited in NCBI's Gene Expression 
Omnibus and are accessible through GEO Series accession number GSE28254 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28254). 
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5.8 – Supplemental Figures and Tables 
 
 
Figure S1. (A) Scatter-plot showing MethylCap versus MethylCap-BS-seq read densities within 5 
kb windows covering the genome. (B) Additional examples of normal MethylCap-seq and 
MethylCap-BS-seq data of normal (N) and tumor (T) colon tissues. Per covered CpG, percentage 
methylation as derived from the MethylCap-BS-seq data is indicated in color. (C) Histograms 
showing the distribution of methylation in MethylCap peaks, as derived from MethylCap-BS-seq of 
normal and colon tissue. 
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Figure S2. (A) Scatter-plot showing H3K27me3 ChIP-seq versus ChIP-BS-seq read densities 
within 5 kb windows covering the genome. (B) Bisulfite sequencing of individual PCR fragments 
amplified from genomic DNA from either untreated or crosslinked/decrosslinked cells (SKNO-1) as 
in ChIP. CpGs were sequenced to a median coverage of over 300-fold (see Methods). (C) Example 
of H3K27me3 ChIP-BS-seq data of HCT116 cells, showing DNA methylation throughout 
H3K27me3 BLOCs. Percentage methylation is color coded. (D) Examples of H3K27me3 ChIP-BS-
seq data of HCT116 cells, displaying DNA hypomethylation within H3K27me3-enriched CpG 
islands. (E) Histograms showing the distribution of methylation in 300 bp windows throughout 
H3K27me3 enriched regions, as established from H3K27me3 ChIP-BS-seq results. Windows were 
categorized according to CpG density. 
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Figure S3. (A) Boxplot showing expression levels of genes contained within H3K27me3 BLOCs 
and genes outside BLOCs. RPKM, Reads Per Kilobase of exon model per Million mapped reads. 
The p-value was calculated using the Mann-Whitney U test. (B) Density plot showing the 
distribution of H3K27me3 BLOCs sizes. (C) Upper panel, 0.7-Mb overview of the genome-wide 
H3K27me3 ChIP-seq and MethylCap-seq data of HCT116 cells. Positions of H3K27me3 BLOCs 
and MethylCap peaks are indicated as red and blue rectangles, respectively. RNA-seq data are 
included (black profile). Middle and lower panel, additional examples of H3K27me3 ChIP-seq and 
MethylCap–seq data demonstrating hypermethylated CpG islands within H3K27me3 BLOCs, and 
concomitant local depletion of H3K27me3. (D) Boxplot showing that MethylCap peaks are not 
associated with DNaseI hypersensitivity. DNaseI hypersensitivity was measured within DNaseI 
peaks (defined by ENCODE), MethylCap peaks and random genomic regions of equal size. 
DNaseI-seq data for HCT116 cells were retrieved from ENCODE (DNaseI Hypersensitivity by 
Digital DNaseI from ENCODE/University of Washington). 
 
 
 
 
 
Figure S4. (A) Density plot showing the length distribution of H3K27me3 BLOCs and localized 
H3K27me3 peaks in mES cells. (B) Genomic distribution of localized H3K27me3 peaks in mES 
cells. TSS, transcription start sites (here defined the region from -500 to +500 bp). 
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Figure S5. H3K9me3 peaks of mES cells are associated with DNA hypermethylation. (A) 
Screenshots of H3K9me3 peaks (orange) at H19 and the Meg3 and Gbr10 genes. The H3K9me3 
peak upstream of H19 colocalizes with the imprinting control region (ICR) upstream of H19 ([26-
28]). Per covered CpG, percentage methylation as derived from the H3K9-BS-seq data is indicated 
in color. (B) Histograms showing the distribution of methylation in 300 bp windows through peaks of 
H3K9me3 in wild-type mES cells, and peaks of H3K27me3 in wild-type and TKO mES cells, as 
inferred from ChIP-BS-seq. 
 
Figure S6. ChIP-qPCR validation of observed changes in H3K27me3 peaks (decrease) and 
H3K27me3 BLOCs (increase) in TKO mES cells. 
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Figure S7. Megabase-scale genome profiles reveal resemblance between H3K27me3 of TKO 
mES cells and MethylCap DNA methylation of wild-type mES cells. A 0.5-Mb windowing was 
applied over the complete mouse genome, and read counts within these windows were calculated 
to generate megabase-scale profiles for H3K27me3 and MethylCap. (A) Profiles for chromosomes 
1, 3, and 10. Grey highlights represent regions with highest correlation between H3K27me3-TKO 
and MethylCap-wild-type (increase of at least 0.4, to a minimum of 0.8, Pearson correlation). (B) 
Example of a 36-Mb region in chr10qD, as indicated by the red arrow in (A). (C) Overall Pearson 
correlation between  megabase-scale genome profiles. 
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Figure S8. (A) Boxplot of gene expression changes in wild-type and TKO mES cells, inside and 
outside of H3K27me3 BLOCs. RPKM, Reads Per Kilobase of exon model per Million mapped 
reads. (B) MA-plots of gene expression changes in TKO relative to wild-type mES cells. Blue, 
unchanged genes; red, upregulated genes; green, downregulated genes. Deregulated genes were 
detected using the DESeq package [45] at an FDR of 0.05 and with an additional threshold of 2-
fold change. 
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Abstract 
Notch signaling plays crucial roles in mediating cell fate choices in all metazoans largely by 
specifying the transcriptional response of one cell in response to a neighbouring cell [1]. The 
DNA-binding protein RBPJ is the principle effector of this pathway in mammals, and together 
with the transcription factor moiety of Notch (NICD) it regulates the expression of target genes 
[2]. The prevalent view presumes that RBPJ statically occupies consensus binding sites while 
exchanging repressors for activators in response to NICD. We performed chromatin 
immunoprecipitation and high-throughput sequencing to identify global binding of RBPJ, its 
coactivator p300, and NICD in myogenic cells under active or inhibitory Notch signaling 
conditions. Unexpectedly, our results demonstrate dynamic binding of RBPJ in response to 
Notch activation at essentially all sites co-occupied by NICD. Additionally, we identify a distinct 
set of sites where RBPJ recruits neither NICD nor p300, and binds DNA statically, irrespective 
of Notch activity. These findings significantly modify our views on how RBPJ and Notch 
signaling mediate their activities and consequently impact on cell fate decisions. 
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6.1 – General introduction Notch signaling and RBPJ 
6.1.1 The Notch signaling pathway 
The Notch pathway [3-4] is a highly evolutionary conserved signaling pathway with 
pleiotropic actions. It operates not only in a wide spectrum of species but also in many 
cell types and at various stages during development [5]. It is essential in processes of 
stem cell maintenance, cell proliferation, differentiation and death during for example 
myogenesis, neurogenesis, gliogenesis, skin/hair formation and lymphoid development. 
Disturbances in the Notch pathway lead to developmental defects and diseases in 
human. For example, mutations in JAG1 and NOTCH2 genes resulting in 
haploinsufficiency cause Alagille syndrome [6]. NOTCH3 mutations cause CASADIL 
syndrome [7]. Also, deregulated oncogenic Notch signaling is associated with cancer, 
for example in T-cell acute lymphoblastic leukemia (T-ALL), breast and colon cancer 
types [8-9]. Oncogenic Notch signaling in T-ALL has been intensively studied [8-10]. 
Various truncations or mutations in the NOTCH1 gene have been described that cause 
constitutive active Notch signaling inducing T-ALL.  
Notch signaling is triggered by the binding of transmembrane Notch receptors to 
transmembrane ligands on neighboring cells (Fig.1). Mammals have four Notch 
receptors (NOTCH1-4) and five canonical ligands (DELTA-LIKE 1 (DLL1), DLL3, 
DLL4, JAGGED1 (JAG1) and JAG2). Ligand stimulation results in intramembrane 
proteolysis of Notch receptors and release of the Notch intracellular domain (NICD). 
NICD localizes to the nucleus, where it directs transcriptional programs engaging the 
DNA binding transcription factor Recombination signal sequence-Binding Protein 
Jkappa (RBPJ, or SUH in Drosophila, LAG-1 in C.elegans, and CSL to denominate 
the orthologous proteins). Apart from the here described canonical Notch signaling, 
non-canonical Notch signaling occurs, in which for example non-canonical ligands are 
involved, or Notch signaling is RBPJ-independent and involves interactions with other 
signaling pathways upstream of the NICD-RBPJ interaction [11-12].  
According to the current model of Notch signaling RBPJ is constitutively 
associated with its targets, either in a transcriptional repressive complex in the absence 
of Notch signaling or in an activating complex following Notch activation. A diversity 
of RBPJ corepressor complexes has been identified [13]. The RBPJ interacting protein 
SPEN is thought to serve as an adaptor in the recruitment of different corepressor 
complexes, including CtBP, SMRT/NCoR and ETO [14-17]. Recently, roles for the 
histone H3K4 demethylase KDM5A [18] and the H4K16 deacetylase SIRT1 in 
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complex with H3K4 demethylase LSD1 and CoREST1-CtBP [19] in RBPJ targeted 
silencing have been reported. According to the model the NICD, together with 
Mastermind-like (MAML), displaces the co-repressors and recruits co-activators to 
RBPJ, eliciting a transcriptional switch. The histone acetyl transferases (HATs) p300 
[20-22] and GCN5 [23] have been shown to associate with the NICD containing 
complex. Furthermore, interactions of the Notch activating complex with the 
transcriptional coregulator SKIP [24] and CDK8 [25] have been reported, the last being 
involved in ubiquitin ligase mediated degradation of the NICD. 
 
 
Figure 1. The Notch signaling pathway. Schematic depiction of the canonical Notch signaling 
pathway in mammals. Ligand binding to a Notch receptor induces proteolytic cleavage of the 
receptor, resulting in the release of the Notch intracellular domain (NICD). NICD translocates to the 
nucleus and binds to the transcription factor RBPJ. According to the current model, RBPJ recruits 
co-repressor complexes to Notch target genes in the absence of NICD. Indicated are the adaptor 
protein SPEN and NCoR-HDAC complex. Binding of NICD and co-activator MAML to RBPJ 
replaces the co-repressor complexes and results in the recruitment of other co-activators, such as 
p300. The RBPJ-NICD activation complex activates Notch target gene transcription.      
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6.1.2 The RBPJ transcription factor 
RBPJ was originally identified in nuclear extracts from a mouse pre-B cell line as a 
protein that binds the immunoglobulin Jx type V(D)J recombination signal sequence 
[26-27]. Subsequently, the RBPJ recognition sequence was determined as 5’-
ag/ccGTGGGAActa/t-3’, of which the middle hepta-nucleotide sequence is the core 
recognition motif [28]. RBPJ was found to be identical to the Drosophila SUH factor 
[29-30], and genetic analyses in Drosophila led to the discovery that it functions 
downstream of Notch signaling [31-32]. Indeed, the Drosophila Notch target gene 
Enhancer of split (E(spl)) m8 was found to be directly regulated by SUH [33-34]. 
Hes1, the mammalian homologue of Hairy and E(spl), was then identified as 
RBPJ/Notch target [2,35]. The Hairy and Enhancer of Split-Related (HESR) genes, 
comprising HES and HEY genes, are the best characterized genes activated downstream 
of Notch signaling [36]. They encode basic helix-loop-helix (bHLH) transcriptional 
repressors that are essential in many Notch-dependent processes where they repress key 
cell fate determinants and cell cycle regulators [36].  
RBPJ consists of three integrated domains: N-terminal and C-terminal Rel 
homology domains and a central β-trefoil domain [37]. The N-terminal domain plus the 
β-trefoil domain bind DNA in a cooperative manner via specific interactions with DNA 
base pairs and the formation of a positively charged surface that interacts non-
specifically with the DNA backbone, as derived from the crystal structure [37]. 
Structural studies have also been performed on the NICD-RBPJ and NICD-RBPJ-
MAML complexes (reviewed in [38-39]). The RAM domain of NICD interacts with 
the β-trefoil domain of RBPJ [40-43]. The ANK repeats of NICD primarily bind to the 
C-terminal domain of RBPJ, although a number of contacts are made between ANK 
and the N-terminal RBPJ domain as well. The interaction between the ANK repeats 
and the RBPJ C-terminal domain results in the formation of a docking site for the 
transcriptional co-activator MAML [40-43]. Binding of NICD induces substantial 
conformational changes within RBPJ. However, RBPJ DNA binding is unaltered: 
RBPJ alone and RBPJ-NICD-MAML ternary complexes share an invariant RBPJ-DNA 
interface in crystal structure determinations [37,41-42].  
A number of known Notch responsive targets contains sequence-paired binding 
sites (SPS) in their proximal promoters. SPSs consist of two RBPJ motifs that are 
oriented head to head with a spacer of 15-20 bp in between [44-45]. Nam et al. found 
that assembled Notch activation complexes cooperatively dimerize on SPSs [46]. The 
structure of a dimeric Notch complex loaded on the paired site from the HES1 
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promoter has been resolved [47]. It was speculated that the dimer interface allows for 
some flexibility in spacer lengths between sites. Notably, cooperative assembly of 
dimeric Notch complexes also occurred on a cryptic paired site from the Hes5 
promoter, in which one RBPJ binding sequence substantially diverges from the 
consensus, indicating that cooperative binding may also play a role at divergent SPSs 
[47]. Via transductions of  normal NICD or dimerization-defective NICD into T-ALL 
cells and various isolated primary cells, Liu et al. found that the formation of dimeric 
Notch complexes is required for T-cell maturation and leukemic transformation, but 
not for specification of the T-cell fate  [48]. They stated that this differential 
requirement for dimerization arises from the differential dependencies of various target 
genes on Notch dimerization.   
In a search for Rbpj related genes, Minoguchi et al. found the Rbpj paralogue 
Rbpj-like (Rbpjl) [49]. The RBPJL protein exhibits 48% overall identity to RBPJ. It 
binds the same DNA consensus sequence as RBPJ [49]. However, RBPJL does not 
interact with any of the four mammalian Notch proteins [49]. RBPJL expression is 
largely confined to the pancreas, lung and cerebral cortex [49-51], in contrast to the 
ubiquitous expression of RBPJ. Rbpjl homozygous mutant mice are morphologically 
normal and fertile [50]. An in vivo function of RBPJL  was revealed with the finding 
that it resides in a PTF1 complex in the pancreas [51] (see below). It has been 
suggested that RBPJL has evolved to specialize in Notch-independent functions in the 
pancreas and insulate PTF1A from interference by Notch signaling competing for 
RBPJ binding [52]. However, this hypothesis will need further investigation.   
Apart from its functions downstream of Notch signaling, Notch-independent 
functions have been described for RBPJ. Most of the phenotypes of Notch conditional 
knockout mice, i.e. abnormalities in the T/B cell lineages, marginal zone B cells, and 
αβ T-cell development, are also observed in RBPJ conditional knockout mice [53-58]. 
However, pancreas-specific deletion of Rbpj in mice results in a severe phenotype, that 
is not observed with double deletion of Notch1 and Notch2 [59]. Nakhai et al. stated 
that RBPJ plays a Notch-independent role in the development of the pancreas. In line 
with this, P48/PTF1A, a transcription factor essential for pancreas development, has 
been shown to interact with RBPJ [60]. P48/PTF1A, RBPJ and a class A bHLH protein 
form a trimeric complex that activates pancreas-specific gene transcription [51]. 
Notably, the RBPJ paralogue RBPJL can replace RBPJ in the PTF1 complex [51]. In 
mature acinar cells, the PTF1 complex exclusively contains RBPJL. The transcriptional 
activities of the RBPJ and RBPJL containing PTF1 complexes are independent of 
Notch signaling; P48/PTF1A occupies the NICD docking site on RBPJ and RBPJL is 
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known to lack NICD binding capacity. P48/PTF1A, RBPJ and RBPJL are essential for 
pancreas growth and pancreas-specific gene transcription [51,61-62]. Besides this, the 
P48/PTF1A-RBPJ interaction is essential for specification of the GABAergic neurons, 
indicating Notch-independent functions for RBPJ in development of the nervous 
system as well [63]. Here Neurog2 was identified as a direct target of the PTF1 
complex [64]. Beres et al. noted that additional Notch-independent RBPJ functions 
may exist, as other transcription factors contain peptides related to the RBPJ-
interacting motifs of NICD and P48/PTF1A [51]. 
 
6.1.3 Notch signaling in muscle cells 
The Notch pathway is a crucial regulator of myogenesis in cultured myogenic cells, in 
vertebrate embryos and in postnatal regenerating muscle [65-66]. It positively regulates 
muscle progenitor cell maintenance and inhibits myogenic differentiation. 
Overexpression of NICD or exposure to Notch ligands has been shown to inhibit 
myoblast differentiation and MyoD-mediated fibroblast conversion in vitro by various 
reports [67-72]. How Notch represses myogenic differentiation has remained 
controversial though [66]. Kopan et al. suggested that NICD targets the transcriptional 
activity of MyoD [67]. It was then found that Hes1 is directly activated by NICD and 
that HES1 overexpression inhibits myogenic conversion similarly to NICD [2,69], 
leading to the model that Notch signals through Hes1 to inhibit muscle differentiation. 
However, other in vitro and in vivo data did not support such role for HES1 [70,73]. 
Buas et al. described a role for the Notch target HEY1 in repression of myogenesis 
[71]. Forced expression of HEY1 was sufficient to recapitulate inhibitory effects of 
Notch signaling on differentiation in vitro [72]. Buas et al. found that HEY1 inhibits 
myogenesis by associating with and repressing expression of key myogenic targets 
[71]. Notably, the same group reported that multiple pathways exist for inhibition of 
myogenesis by Notch [72]. In expression analyses of ligand-stimulated myoblasts, 82 
genes were identified whose expression was activated by Notch signaling. MyoR was 
further analyzed and found to be sufficient to inhibit differentiation as well when 
constitutively expressed. However, siRNA-mediated knockdown of Hey1, MyoR or a 
combination of both, was ineffective at rescuing myogenic differentiation in the 
presence of Notch signaling, indicating that Notch acts via multiple pathways.   
The role of the Notch signaling pathway in myogenesis is critical for normal 
muscle development in vivo. Schuster-Gossler et al. analyzed Dll1 hypomorph mice –
circumventing embryonic lethality caused by homozygous null mutation in Dll1 [74] -, 
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that survived until birth but displayed severe defects in the skeletal muscle lineage [75]. 
Mutant mice showed premature myoblast differentiation, depletion of progenitor cells 
and severe muscle hypotrophy. Similarly, conditional deletion of Rbpj in mice resulted 
in premature differentiation, depletion of progenitor cells and lack of muscle growth 
[76]. These studies indicated that Notch signaling, involving DLL1 ligand and RBPJ, is 
essential for maintaining a resident pool of myogenic progenitor cells and preventing 
their differentiation during muscle development in vivo. Finally, Notch signaling is 
involved in muscle regeneration in adult mice [77]. Conboy et al. showed that muscle 
injury results in the induction of Dll1, which promotes the proliferation of muscle stem 
cells, known as satellite cells. Subsequent induction of Numb, an inhibitor of Notch 
signaling, correlates with differentiation of the expanded satellite cell pool into 
myotubes. Aging mice display reduced Dll1 expression and inadequate Notch signaling 
resulting in the loss of regenerative potential of muscle [78]. 
 
The next sections describe the analysis of genome-wide RBPJ binding profiles in 
mouse C2C12 myoblasts. We initially identified RBPJ in our methyl-CpG pull-down 
assays as a methylation-dependent and sequence-specific DNA binding protein 
(chapter 2). We continued working on this factor and explored its in vivo binding 
patterns under Notch on and Notch off conditions using ChIP-seq. By means of the 
generated data we identified confident RBPJ targets in mouse myoblasts, defined the 
RBPJ binding motif from its in vivo binding sites, and analyzed RBPJ binding 
dynamics under various Notch signaling conditions, as described hereupon. 
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6.2 – Introduction 
Notch signaling influences a wide spectrum of stem and progenitor cell fate choices, 
and perturbations of this pathway lead to congenital defects, vascular disorders and 
cancer [79]. Notch is a plasma membrane receptor, but its cleaved intracellular domain 
(NICD) is also a transcription factor [80-82]. NICD interacts with RBPJ, a potent 
DNA-binding transcription factor that associates with a large number of chromatin 
regulators, corepressors and coactivators [2,4]. Dissecting the mode of transcriptional 
regulation by RBPJ and identifying its direct targets is fundamental for understanding 
how RBPJ regulates diverse processes in response to Notch signaling, but also 
independent of it. The current model states that RBPJ is statically bound to DNA and 
acts as an interaction platform that can be switched from a repressor to an activator 
complex upon binding to NICD. This dual activity of RBPJ has been clearly 
demonstrated genetically in flies for specific target genes [83-88], however, it remains 
largely untested in vivo in vertebrates.  
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Figure 2. Genome wide RBPJ binding sites in mouse myogenic cells. (A) Activation of 
Notch signaling (Notch ON) was induced by exposure to immobilized Delta-like1-Fc or by 
transfection of intracellular Notch1 (NICD-GFP). Block of Notch signaling (Notch OFF) was 
accomplished by incubation with the γ-secretase inhibitor DAPT. ChIP was performed using two 
independent RBPJ antibodies (Ab1 and Ab2), an anti-p300, and an anti-GFP antibody for the 
NICD-GFP fusion. A representative example of the retrieved tracks is shown (bottom). (B) Genomic 
distribution of RBPJ peaks (antibody#1, Ab1) in C2C12 cells. TSS regions were defined from 5kb 
upstream to 2kb downstream of TSS. (C) De novo motif search on the RBPJ peaks using 
GimmeMotifs. Upper panel: identified motif and histogram displaying the distribution of motif 
positions within the RBPJ peaks (0 is the peak summit as defined by the MACS peak calling 
algorithm). Lower panel: RBPJ motif as present in the TRANSFAC database and histogram 
displaying the distribution of motif positions detected with this matrix. (D) Examples of RBPJ (pink) 
and p300 (green) binding sites associated with the known Notch pathway target genes Hey1 and 
Hes1. Higher RBPJ binding, accompanied by p300, can be observed in the cells cultured in the 
presence of the Notch ligand Dll1-Fc compared to DAPT. 
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6.3 – Results and Discussion 
To address the mode of action of RBPJ in the context of activated and repressed Notch 
signaling and to identify novel targets, we conducted a genome-wide temporal analysis 
of RBPJ binding by performing ChIP-sequencing (ChIP-seq) in mammalian myogenic 
cells. We complemented this analysis by conducting ChIP-seq for targets of NICD and 
the histone acetytransferase p300 that is a member of the RBPJ/NICD transcriptional 
activation complex [89] (Fig.2A) (TableS1). RBPJ and p300 occupancies were 
compared in cells exposed to immobilized ligand Delta-like1 (Dll1) to activate Notch 
[90] or treated with the γ-secretase-inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-
S-phenylglycine t-butyl ester (DAPT) to block Notch signaling, at different time 
intervals (Fig.2A; n = 2). Efficiency of induction by Dll1 and inhibition by DAPT were 
assessed by RT-qPCR (Fig.S1A). 
 Analysis of the RBPJ ChIP-seq profile from cells exposed to Dll1 for 6 hours (6h, 
Dll1) and an input control, yielded 158 RBPJ peaks using MACS peak calling 
algorithm [91]. Of these, 78 RBPJ sites (49%) were within or near genes (exonic, 
intronic or around TSS) and 80 sites (51%) were intergenic (Fig.2B). Of note, only a 
small fraction of peaks (16%) was present near transcription start sites (TSS). De novo 
motif prediction in the 158 RBPJ peaks using GimmeMotifs [92], identified a highly 
enriched motif in 79% of all binding sites that corresponds to the known RBPJ binding 
consensus (Fig.2C). However, the RBPJ motif Position Weight Matrix (PWM), as 
defined using our dataset, differs slightly from that in TRANSFAC (Su(h), M00234) 
[93] (Fig.2C and Fig.S1B). In positional preference plots RBPJ motifs were localized at 
the peak summits (Fig.2C), indicating binding specificity of the RBPJ antibody 
(hereinafter Ab1) used in ChIP-seq. Ab1 specificity was further demonstrated using 
wild type and Rbpj
—/—
 mouse embryonic fibroblasts (MEFs) in ChIP-qPCR (Fig.S1C) 
and by indirect immunofluorescence (Fig.S1D). We did not find statistically significant 
enriched motifs for REST, CREB and ETS, as previously described in mouse T-ALL 
RBPJ profiles [94], and PWM scan analysis corroborated this observation (Fig.S1E).   
We then analyzed RBPJ peaks for the presence of motifs located in tandem. 
Additional RBPJ motifs (GimmeMotifs matrix with cutoff 0.90 or 0.85) showed a 
preference for 11-21bp spacing to the first RBPJ motif (Fig.S1F). In addition, in 22 out 
of 26 of these peaks (containing 11-21bp spaced motifs) the motifs were oriented head-
to-head, as it has been described for some RBPJ targets, including Hes1 [46]. 
Therefore, this head-to-head genomic arrangement is found only in a small fraction of 
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total RBPJ binding sites, yet it is a more likely configuration when more than one motif 
is present. RBPJ binding was observed adjacent to several known Notch targets, 
including Hey1, Nrarp, Jagged-1, and Hes1. Surprisingly, with the exception of Hes1, 
the RBPJ peaks were not detected at the proximal promoters of these genes, but far 
away at presumed enhancer sites (at 50, 25 and 30 kb, respectively; Fig.2D and data 
not shown).  
 Comparison of the RBPJ binding sites in cells with activated or inhibited Notch 
signaling identified two classes of peaks. Unexpectedly, for the majority of RBPJ sites 
(95 out of 158), binding was in response to Notch activity, with low or undetectable 
RBPJ occupancy in Notch-off cells and high occupancy in Notch-on cells (“inducible” 
sites; Fig.3A-D). The RBPJ site 50 kb upstream of Hey1 is representative of targets 
where RBPJ binding was greatly increased upon Notch activation (Fig.2D and Fig.S2A 
for additional examples from 6h and 24h samples). Strong inducibility was also 
observed for the platelet derived growth factor receptor beta (Pdgfrβ) at 6h post Notch 
activation (Fig.3B), and this binding was reproducibly and strongly diminished after 
24h exposure to the ligand (Fig.S2A), representing a case of dynamic as well as 
temporal RBPJ binding.  
 A second class of peaks, comprising 63 sites, displayed constitutive RBPJ binding 
in all conditions independent of Notch activity (“constant” sites; Fig.3A-D and 
Fig.S2B). For example, the RBPJ binding site 13kb upstream of Apobec3 showed 
constant levels of RBPJ binding (Fig.3C). The constant and inducible classes were 
clearly distinguishable in heatmap representations (Fig.3A) and average graphs, 
showing RBPJ ChIP-seq read densities at 6 hours (Fig.3D in pink) and 24 hours 
(Fig.S2C). Similar results were obtained in replicate experiments (Fig.S2D).   
 Notably, using an independent polyclonal RBPJ antiserum (hereinafter Ab2) [94-
95] for ChIP-seq on cells exposed to Dll1 or DAPT for 6h, similar results were 
obtained within the defined constant and inducible sites, thereby corroborating the 
specificity of our analysis (Fig.S3A). However, using this polyclonal antibody, 388 
additional sites were detected, highly enriched for the motif of the zinc-finger 
transcription factor REST, but not for the RBPJ motif (Fig.S3B). ChIP experiments 
with anti-RBPJ Ab2 on wild type and Rbpj null MEFs showed specific signal loss at 
the RBPJ sites in the Rbpj null MEFs, but not at sites with a REST-motif, 
demonstrating that the additional 388 peaks are likely due to antibody cross-reactivity 
(Fig.S3C,D).  
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Figure 3. Identification of two classes of RBPJ binding sites based on dynamic and 
static behaviour in response to Notch activity. (A) Heatmaps of RBPJ ChIP-seq read 
densities in the inducible and constant sites from cells cultured for 6h in the presence of Dll1-Fc 
(left) or DAPT (right). (B) Inducible RBPJ (pink) and p300 (green) binding in response to Notch in 
the first Intron of the growth factor receptor Pdgfrb. (C) Constant RBPJ (pink) and p300 (green) 
binding upstream of the predicted gene D730005E14Rik and Apobec3. (D) Average tag densities 
of RBPJ (pink) and p300 (green) ChIP-seq in 5kb regions around the inducible and constant sites 
for the various conditions. (E) Isolated primary myoblasts transduced with NICD-GFP expressing 
lentivirus. NICD-GFP (green) accumulated in subnuclear bodies that co-localise with endogenous 
RBPJ (red). Scale 5µm. (F) ChIP using anti-Rbpj (Ab1) on primary myoblasts expressing GFP or 
NCID-GFP. Significantly increased binding in the NICD-GFP expressing cells is indicated by an 
asterisk (* p<0.05, ** p<0.01). Bars on histograms indicate s.d; n=3/genotype. (G) Scatter plots of 
ratios 6hDll1/6hDAPT of RBPJ binding versus p300 binding for the inducible sites (upper panel) 
and constant sites (lower panel). The accumulation in the upper right quadrant indicates correlation 
between p300 and RBPJ specifically at the inducible sites. 
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Figure 4. Transcriptional regulation of genes associated with inducible and constant sites. 
(A) For all inducible and all constant RBPJ sites, the nearest gene was assigned and analysed. 
Ratios of RPKMs (Dll1/DAPT at 6 and 24 hours) extracted from RNA-sequencing are represented 
in the heatmap. Genes that are induced at least two-fold upon 6h or 24h Notch activation and that 
have a minimal average RPKM value in 6h and 24h Dll1 (in both biological replicates) are 
indicated. (B) Assessment by RT-qPCR of candidate genes in primary myoblasts from postnatal 
day 10 mice expressing activated Notch1 (NICD-GFP). Relative transcript levels are shown as 
ratios of normalised values of NICD-GFP over GFP-expressing cells (2
-∆∆Ct
). Samples are classed 
as inducible and constant, reflecting RBPJ binding behaviour after Notch activation. Results are 
presented as relative gene expression ±s.d. (n=3 biological replicates).  
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Continuation from previous page. (C) Muscle sections showing GFP marked satellite cells 
stained with anti-RBPJ (Ab1, red). Conditional deletion of Rbpj in quiescent satellite cells was 
achieved using a tamoxifen inducible Tg:Pax7-CreERT2 line (control: Tg:Pax7-
CreERT2::Rbpj
flox/+
::R26R
mT/mG/+
 and Rbpj null: Tg:Pax7-CreERT2::Rbpj
flox/—
::R26R
mT/mG/+
). 
Depletion of RBPJ results in the decrease of the Notch target transcripts Hey1 and HeyL and in the 
upregulation of Myogenin as measured by RT-qPCR. Histograms are 2
-∆Ct
 and error bars indicate 
s.d. (n=3 mice/genotype); scale bar=15µM. (D) Measurements of transcripts of candidate Notch 
targets in control and Rbpj null purified satellite cells by RT-qPCR. Targets are classed as inducible 
(upper plot) and constant (lower plot) reflecting RBPJ binding behaviour after Notch activation 
(n=3). Red dotted line indicates no change (2
-∆∆Ct
=1). Bars on histograms indicate s.d. (n=3 
mice/genotype). 
 The dynamic binding of RBPJ was also validated on primary myoblasts 
expressing activated Notch1 (NICD-GFP; Fig.3E) or control GFP. In ChIP 
experiments, increased RBPJ binding was observed for a number of sites in response to 
Notch activation, including those associated with the known Notch targets Hey1, Hes1 
and Nrarp. In contrast, RBPJ binding at the constant sites was unaffected by NICD 
(Fig.3F).  
 Taken together, our analysis clearly demonstrates that the association of RBPJ to 
DNA is highly dynamic and strongly induced by NICD. However, at a subset of sites, 
RBPJ is constitutively bound to DNA. Notably, at several of the inducible sites, RBPJ 
was barely detectable by two different antibodies (Ab1: monoclonal, Ab2: polyclonal) 
when Notch signaling was inhibited, suggesting that in this context silencing by a 
repressive RBPJ complex may not be predominant mode of action. 
 To extend our analysis, we generated ChIP-seq profiles for the histone 
acetytransferase p300 that is a member of the RBPJ/NICD transcriptional activation 
complex and marks enhancer regulatory elements [89,96]. To determine if p300 
binding can discriminate between inducible and constant RBPJ sites in the context of 
Notch-on and –off states, we analysed p300 ChIP-seq profiles from the same chromatin 
samples described above. We found that at the inducible sites, p300 behaved similarly 
to RBPJ, showing increased occupancies upon activation with Dll1 (Fig.3B-D, 3G and 
Fig.S2A, Fig.S4A,B). In contrast, RBPJ constant sites generally displayed low tag 
counts for p300 and modulations of Notch activity did not result in changes in p300 
binding intensities (Fig.3B-D, 3G and Fig.S2B, Fig.S4A,B). Furthermore, Notch 
activation did not affect p300 occupancy (tag counts) at 10.207 peaks (Fig.S4C) that 
did not overlap with either inducible or constant RBPJ sites, thereby reinforcing the 
notion that the increase of p300 at inducible RBPJ peaks following Notch activation is 
highly significant and specific.   
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To determine the functional relevance of the inducible and constant groups, peaks 
were correlated with changes in gene expression in the Notch-off and Notch-on states. 
Transcript levels were measured by RNA-seq analysis that was validated by the 
identification of the known Notch targets Hey1, HeyL, Nrarp and Jag1 (indicated in 
color in scatter plots, Fig.S5A), consistent with earlier findings in muscle cells [72,97]. 
For each RBPJ peak the nearest gene was assigned without a threshold on distance. 
Ratios of RPKMs (Reads Per Kilobase of exon model per Million mapped reads) of the 
two groups were visualized in heatmaps (Fig.4A) and MA plots (distribution of RPKM 
ratios versus RPKM averages) (Fig.S5B). Overall, genes associated with constant 
RBPJ sites did not significantly change with Notch activation. For the inducible cluster, 
a fraction of the genes showed increased expression associated with Notch signaling 
(Fig.4A), and this was linked with high Dll1/DAPT p300 ratios (Fig.S5C). These 
observations were reproducible in the replicate experiment (Fig.S5D).  
 The transcript levels of target genes identified in C2C12 cells were also measured 
in primary myogenic cells isolated by FACS from perinatal mice, with activated Notch 
(NICD-GFP) compared to control (GFP). Significant induction of several of the 
inducible associated genes was obtained in the cells expressing NICD, whereas the 
expression of the tested constant genes remained unaffected (Fig.4B). We note that the 
fraction of differentially expressed genes could be greater than assessed here if some of 
the RBPJ peaks assigned to the closest gene act instead to a more distally located locus. 
We also scored the transcript levels of candidate target genes in vivo, in purified adult 
muscle stem (satellite) cells null for Rbpj compared to control cells (see Methods). 
Satellite cells were selected for the loss-of-function studies, as Notch signaling is active 
in these cells and is required for their maintenance [97-98]. In cells lacking RBPJ 
(Fig.4C), a significant number of inducible targets was downregulated (Fig.4D). 
Instead, out of 14 genes linked to constant RBPJ sites 3 were significantly 
downregulated in the Rbpj null satellite cells (Vav3, Tgfb1, and Rps6ka1), but none 
were upregulated (Fig.4D), suggesting that RBPJ at the constant sites might act mainly 
as an activator.  
 The differential RBPJ occupancy and p300 recruitment upon Notch activation at 
static and dynamic sites, suggested that RBPJ and NICD can also act autonomously of 
one another. To obtain a more comprehensive view of how Notch-RBPJ signaling 
operates, we determined NICD genomic occupancies in myogenic cells and its 
association with RBPJ inducible and constant sites. A tetracycline inducible expression 
system was used to conditionally express an NICD-GFP fusion protein or GFP control. 
The functionality of the NICD-GFP fusion protein was validated by the induction of 
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HeyL protein (Fig.S6A). NICD and RBPJ genome-wide profiles were generated using 
anti-GFP and anti-RBPJ antibodies on NICD-GFP expressing cells 8h after 
doxycycline induction (Fig.5A). In addition, both antibodies were used on DAPT 
treated cells expressing GFP as a control. 
 We performed MACS peak callings on both RBPJ and NICD-GFP tracks, 
combined the peaks, and analyzed RBPJ and NICD occupancies in Notch-on and -off 
conditions. Individual examples of NCID-GFP occupancy at inducible and constant 
RBPJ sites are shown in Fig.5A. Out of 241 sites, 199 inducible sites (83%) were 
identified that displayed NICD-GFP and RBPJ binding in the Notch-on cells and no or 
weak RBPJ binding in Notch-off cells, as revealed by intensity plots and average 
profiles (Fig.5B,C). A small group (20 sites) consisted of constant RBPJ sites that did 
not display NICD-GFP binding (Fig.5C, Fig.S6B). The larger fraction of inducible 
sites, as opposed to constant sites identified in the NICD-GFP compared to the Dll1-
stimulated cells, might be due to a more robust induction achieved with the NICD-GFP 
overexpression. We note that the increase in the number of inducible sites does not 
originate from switching of constant to inducible sites; they comprise new additional 
inducible sites. We speculate that additional inducible sites represent lower affinity 
sites that are manifested by high levels of NICD expression. The nature of the 14 
NCID-GFP sites displaying RBPJ-independent binding and 8 sites displaying inducible 
RBPJ binding without NICD-GFP signal remains to be further characterized (Fig.S6B).  
 De novo motif prediction on the RBPJ/NICD overlapping sites identified the 
RBPJ motif with a similar Position Weight Matrix as defined above (Fig.5D). Using 
Position Weight Matrix scans, we found that all categories of RBPJ sites (inducible and 
constant) displayed high enrichments of the RBPJ motif (Fig.S6C), corroborating the 
veracity of these RBPJ sites. Thus, by using different tools to activate Notch signaling 
we consistently identified RBPJ inducible (with NICD) and constant (without NICD) 
sites, thereby extending our observations. 
 Few studies have challenged the view of static association of RBPJ with its target 
enhancers. A more dynamic model was suggested mainly from work in Drosophila, 
where an increase of Su(H) (fly RBPJ) occupancy on specific E(spl) genes was noted 
following Notch activation [85]. In mouse, dynamic RBPJ binding has been reported 
on the Hes1 [25] and cyclinD3 [99] promoters, corresponding to Notch activity. In the 
present study, using two different RBPJ antibodies (a rat monoclonal and a rabbit 
polyclonal), we uncovered dynamic RBPJ occupancy on specific DNA sequences in 
response to Notch activity using a genome-wide approach. Taken together, these data 
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strongly suggest that RBPJ occupancy at cognate DNA sequences is altered with Notch 
activity.  
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Figure 5 (Previous page). RBPJ inducible sites, but not RBPJ constant sites, display NICD 
binding. (A) Upper panel: Examples of inducible RBPJ binding sites displaying NICD-GFP binding. 
Lower panel: examples of constant RBPJ binding sites showing no NICD-GFP recruitment. Shown 
tracks were generated with an anti-RBPJ (Ab1, pink) or anti-GFP (blue) antibody. Both antibodies 
were used for ChIP on GFP (control) and NICD-GFP expressing cells. (B) Heatmaps of RBPJ and 
NICD-GFP or GFP ChIP-seq read densities in the RBPJ/NICD overlapping sites for the various 
conditions. (C) Average tag densities of anti-RBPJ (pink) and anti-GFP (blue) ChIP-seq in 5kb 
regions around the inducible and constant sites for the various conditions. (D) Positional Weight 
Matrix of the motif identified in the RBPJ/NICD-GFP overlapping sites using GimmeMotifs. 
 
 
 
Figure 6. Model of RBPJ binding to DNA at inducible and constant sites. Upon receptor 
activation and cleavage, the intracellular domain of Notch (NICD, green) translocates into the 
nucleus. There it binds to RBPJ (red) and both are recruited to the RBPJ/NICD binding targets, 
where together with p300 (purple) and Mastermind-like (blue) they regulate gene expression (black 
arrow). In the absence of NICD, RBPJ is weakly or not bound to those “inducible” binding targets. 
In constrast, RBPJ is statically bound to DNA on target sequences that are not regulated and co-
occupied by NICD (“constant” sites) nor p300. Constant sites contain the same RBPJ binding motif 
as the inducible sites, hence binding is likely to be specified by diverse partners (grey). 
Chapter 6 
 170
Given the discrepancies in phenotypes between Notch and Rbpj null mutants [52], 
it has been postulated that these factors might also function independently. To date, 
only an atypical RBPJ/PTF1A activation complex that does not contain NICD has been 
described during the generation of GABAergic neurons [63]. In this study we uncover 
a distinct set of RBPJ binding sites that are not co-occupied by NICD. The nature of the 
binding partners of RBPJ, and the extent to which they are conserved amongst these 
sites, remains largely unknown.  
 Our results are consistent with a dynamic model of RBPJ/NICD binding and 
provide the first empirical, genome-wide evidence in vertebrates for distinct modes of 
transcriptional regulation by RBPJ (Fig.6). The lack of RBPJ binding in the absence of 
Notch signaling also questions the universality of the default repression model for 
mammalian cells as a mechanism to maintain genes transcriptionally silent in the 
absence of signaling. In addition, we identify a large group of RBPJ sites that do not 
contain NICD, and where RBPJ is statically bound to DNA. Our findings lead us to 
propose that the inducible and constant RBPJ peaks do not represent two distinct ways 
to respond to NICD, but rather the existence of Notch-dependent and -independent 
complexes. These findings modify significantly our current understanding of how 
Notch signaling, in conjunction with RBPJ, regulate gene expression and consequently 
how this impacts on cell fate decisions. Future work will show whether RBPJ dynamics 
define a general phenomenon during the transduction of Notch signaling.  
 
6.4 – Materials and Methods 
6.4.1 Cell culture and treatments 
C2C12 mouse myoblast cell line was cultured in DMEM supplemented with 20% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen) at 37°C in 5% CO2 
atmosphere. Mouse Rbpj
—/—
 (OT11) and wild type (OT13) fibroblast cell lines were 
obtained from RIKEN BRC [100] and were grown in high-glucose DMEM 
supplemented with 10% FBS and 100 U/ml of mouse IFN-γ (Millipore) per ml at 33°C 
in 5% CO2 atmosphere. For ligand-dependant activation of Notch signaling, cells were 
grown in the presence of the extracellular domain of Delta-like 1 fused to the Fc 
fragment of human IgG [90] (kindly provided by N.Gupta upon permission from 
G.Weinmaster). As a control, cells were grown in the presence of the Fc fragment only 
(kindly provided by T. Kadesch). Culture dishes were first coated with 10 µg/ml anti-
Fc antibody (Jackson ImmunoResearch, #109-005-098) for 1h at RT. Dishes were then 
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incubated with conditioned medium from stably transfected 293T cells expressing the 
fusion proteins, for 1h at RT. C2C12 cells were plated in fresh medium and grown for 
6h or 24h on the immobilized-ligand containing dishes. To inhibit Notch signaling, 
DAPT dissolved in DMSO (Calbiochem) was added to Fc only dishes at a final 
concentration of 20µM. For NICD induced activation, NICD-GFP fusion was obtained 
by cloning the intracellular domain of human Notch1 (amino acids 1,757 to 2,555) in 
the pEGFP-N3 plasmid in frame with the EGFP sequence (kindly provided by U. 
Lendahl). EGFP or NICD-GFP coding sequences were subcloned in a tet-inducible 
viral vector. The reverse transactivator rtTA3 expressed under the control of the 
Ubiquitin C promoter was cloned in a separate lentivector. All vectors were based on 
pTRIP∆U3 [101]. Viral particles were generated in 293T cells using psPax2 and 
pMD2.g second-generation packaging plasmids (Addgene #12260 and #12259). 
Multiplicity of infection (MOI
HCT116
) of 20 and 200 were used on primary myoblasts 
and C2C12 cells, respectively. Expression of NICD-GFP or EGFP was induced by 
exposing cells to 1µg/ml Doxycycline (Sigma-Aldrich) for the indicated time. 
 
6.4.2 Mice and tamoxifen injections 
Tg:Pax7-nGFP mice were used to isolate postnatal skeletal muscle stem/progenitors 
[102]. Generation of the Tg:Pax7-CreER
T2
 was described previously [97]. For the 
generation of Rbpj null satellite cells, compound mice were used: Tg:Pax7-CreER
T2
, a 
conditional GFP reporter transgene (R26R
mT/mG
) [103] purchased from Jackson 
Laboratories (Stock 007576), a conditional knock-out (cKO) allele of Rbpj (Rbpj
flox
) 
kindly provided by Prof. T.Honjo [53]. Control mice were Tg:Pax7-
CreER
T2
::Rbpj
flox/+ 
::R26R
mT/mG
 and Rbpj null mice Tg:Pax7-CreER
T2
::Rbpj
flox/—
::R26R
mT/mG
. Injection of tamoxifen resulted in efficient induction of GFP in the 
satellite cells and deletion of the DNA-binding encoding domain of Rbpj gene in 
satellite cells. Comparisons were done between age-matched littermates using 7-9 week 
old mice. Animals were handled as per European Community guidelines. Tg:Pax7-
CreER
T2
 mice were injected twice (13 to 16 hours apart) intraperitoneally with 
tamoxifen (250 to 300 µl, 20mg/ml; Sigma #T5648) diluted in sunflower seed oil/5% 
ethanol. 
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6.4.3 ChIP-sequencing 
Chromatin harvesting and ChIPs were performed as described [104]. The following 
antibodies were used: rat monoclonal anti-RBPJ antibody clone 1F1 (Ab1) [105] 
(provided by E.Kremmer via Ascenion), rabbit polyclonal anti-RBPJ (Ab2) [94-95] 
(kindly provided by E.Kieff and collaborators), rabbit polyclonal anti-p300 antibody C-
20 (sc-585, Santa Cruz) [96], and goat polyclonal anti-GFP antibody (kindly provided 
by M. Vermeulen). ChIP DNA was prepared for Illumina sequencing according to 
manufacturer's protocols (Illumina) or used for ChIP-qPCR assay. 
 
6.4.4 RNA-seq (strand-specific) 
Total RNA was extracted using RNeasy Mini and Micro kit (Qiagen) following the 
manufacturer instruction. Ribosomal RNA was removed from 200ng total RNA using 
the Ribo-Zero rRNA Removal Kit Low Input for Human/Mouse/Rat (Epicentre 
Biotechnologies), according to the manufacturer’s protocol. RNA was subsequently 
fragmented in fragmentation buffer (40 mM Tris-Ac pH8.2, 100 mM KAc, 30 mM 
MgAc) for 90s at 95ºC and purified by ethanol purification. cDNA was synthesized 
using random hexamers by Superscript III Reverse Transcriptase (Invitrogen), in 
presence of 6 ng/µl ActinomycinD. cDNA was purified (MinElute Reaction Cleanup 
Kit, QIAGEN) and subjected to second strand synthesis by E.Coli DNA Polymerase I 
(Invitrogen) and E.Coli DNA Ligase (New England Biolabs) in the presence of 
RNaseH (Ambion). For second strand synthesis dUNTPs were used, containing dUTP 
instead of dTTP. ds-cDNA was purified (MinElute Reaction Cleanup Kit, QIAGEN) 
and prepared for Illumina sequencing according to standard procedures. Before final 
PCR amplification uracil containing second strand DNA was removed by USER 
enzyme (New England Biolabs) for 15min at 37ºC followed by 10min at 95ºC in 1x 
Phusion Buffer (Finnzymes). 
 
6.4.5 RT-qPCR and ChIP-qPCR 
Quantitative PCR was performed using SYBR Green based mix (Invitrogen) and 
analysis was performed using the 2
-∆∆CT
 method [106]. Transcripts of HeyL, Hey1 and 
Myogenin were measured using TaqMan primers and FastStart Probe Master mix 
(Roche, 13098600). Primers used in this study are listed in TableS2. 
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6.4.6 Bioinformatic analyses 
RBPJ, p300 and NICD peaks were called by MACS (version 1.4.Orc2) [91] with 
pvalue=1e-8 and mfold=5, and an input control. Inducible peaks were defined by a 
decrease in tag counts to 60% or below in DAPT compared to Dll1 conditions. 
Constant peaks were defined as peaks that maintained tag counts higher than 60% in 
DAPT compared to Dll1. GimmeMotifs was used for de novo motif prediction using 
default settings [92]. Motif occurrences were determined by PWM scans with cut-off 
0.9. For calculation of motif enrichments over background, a set of random genomic 
sequences with a similar genomic distribution as the peak sequences was used. Further 
data analyses were performed in LINUX shell, Python, Perl and R, using in-house 
generated scripts. Gene annotations were based on RefSeq (mm9). 
 
6.4.7 Statistical analysis of primary cell samples 
For comparison between two groups, two-tailed Student’s t test was performed to 
calculate p values and to determine statistically significant differences (* p < 0.05, ** 
p<0.001, *** p<0.0001). All statistical analyses were performed with PRISM and 
Excel softwares. 
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6.7 – Supplemental Figures and Tables 
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Figure S1 (Previous page). RBPJ antibody specificity and motif analysis of RBPJ sites. (A) 
Verification of Dll1-Fc and DAPT reagents used for activation and block of Notch signaling, 
respectively. For Notch activation, myogenic C2C12 cells were cultured for 18h in the presence of 
immobilised Dll1-Fc ligand or the Fc fragment alone as control. For inhibition, cells were incubated 
in the presence of the γ-secretase inhibitor DAPT (20µM) or DMSO used as carrier. Relative 
mRNA levels of Hey1 (2
-∆∆Ct
) are presented, normalised to Fc DMSO control (basal activity). Note 
complete inhibition of the Dll-Fc induction (second column) by DAPT (third column). Data represent 
average values ± s.e.m of three independent experiments. (B) ROC curves (receiver operator 
characteristic curves of sensitivity versus specificity) for the GimmeMotifs and TRANSFAC RBPJ 
motifs in the RBPJ ChIP-seq dataset (antibody#1, Ab1). (C) ChIP qPCR using anti-RBPJ (Ab1) on 
OT13 (wt) and OT11 (Rbpj-/-) cells. The absence of enrichment in RBPJ null cells confirms the 
specificity of the signal detected in the ChIP-Seq dataset with Ab1. (D) Specificity of the RBPJ 
antibody as demonstrated by the absence of signal in Rbpj knock-out MEF cells (OT-11). In wild 
type (WT) MEFs (OT-13) RBPJ is readily detected concentrated in subnuclear bodies of all cells. 
(E) Upper panel: presence of the RBPJ, REST, CREB and ETS motifs in C2C12 RBPJ peaks 
detected with Ab1. Pwm-scans were performed with cut-off 0.90 and indicated matrixes. For 
detection of RBPJ motifs, both the GimmeMotifs defined matrix and the TRANSFAC matrix 
M00234 were used, as indicated. For each peak one best motif was reported, if above cutoff. For 
calculation of enrichments, motif occurrences were compared to those in a set of genomic 
sequences with a similar genomic distribution as the peaks. Lower panel: histograms showing the 
distribution of motif positions within the peaks (0 is the peak summit). (F) Histograms showing the 
distribution of additional RBPJ motif positions relative to the position of the one best RBPJ motif per 
peak. Sequences surrounding the RBPJ motifs (100bp upstream and 100bp downstream) were 
analyzed for the presence of additional RBPJ motifs using pwm-scans with the GimmeMotifs matrix 
and cutoff 0.9 or 0.85. The asterisk (*) indicates distances of 20-30 bp (centre to centre) between 
double motifs, corresponding to spacer lengths 11-21bp. 
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Figure S2 (Previous pages). Classification of RBPJ sites as constant levels of RBPJ binding, 
and inducible, Notch activation-dependent RBPJ binding. (A) Additional examples of inducible 
RBPJ sites at 6h and 24h Dll1 and DAPT, displaying low levels of RBPJ and p300 in the DAPT 
treated cells and increased RBPJ and p300 binding in Dll1 treated cells. (pink, anti-RBPJ; green, 
anti-p300). Note the temporal RBPJ binding on Pdgfrb only present at 6h (upper left track). (B) 
Additional examples of constant RBPJ sites at 6h and 24h Dll1 and DAPT. Upper panel: examples 
of constant RBPJ sites that lack p300. Lower panel: examples of constant RBPJ sites that overlap 
with p300 binding (independent of treatment). (C) Average tag densities of RBPJ (pink) and p300 
(green) ChIP-seq in 5kb regions around the inducible and constant sites for the various conditions 
at 24h post induction (See Figure 2 for the 6h time point). (D) RBPJ binding properties at constant 
and inducible sites are reproducible in a biological replicate experiment. Upper panel: heatmaps of 
RBPJ ChIP-seq read densities of the replicate experiment in inducible and constant RBPJ sites as 
defined and ranked in experiment 1 (see Figure 2a). Lower panel: graphs showing the average tag 
densities of the replicate RBPJ ChIP-seq experiment in the inducible and constant sites for the 
various conditions. 
 
 
Figure S3 (Next pages). Comparison of RBPJ ChIP-seq profiles in C2C12 cells with two 
different antibodies. (A) RBPJ binding properties at constant and inducible sites are reproducible 
with an independent RBPJ polyclonal Ab (Ab2). Upper panel: heatmaps of RBPJ Ab1 (Red) and 
RBPJ Ab2 (Brown) ChIP-seq read densities in inducible and constant RBPJ sites as defined in 
experiment1. Heatmaps are ranked according to the Ab1 RBPJ intensities. Lower panel: graphs 
showing the average tag densities of the Ab1 and Ab2 RBPJ ChIP-seq experiment in the inducible 
and constant sites for the 6hDll1 and 6hDAPT conditions. (B) Upper panel: Motif identified within 
the RBPJ Ab2-only sites using GimmeMotifs. Middle panel: presence of the RBPJ, REST, CREB 
and ETS motifs in Ab2-only sites. Pwm-scans were performed with cut-off 0.90 and indicated 
matrixes. For detection of RBPJ motifs, both the GimmeMotifs defined matrix and the TRANSFAC 
matrix M00234 were used, as indicated. For detection of REST motifs the GimmeMotifs defined 
matrix was used. For each peak one best motif was reported, if above cutoff. For calculation of 
enrichments, motif occurrences were compared to those in a set of genomic sequences with a 
similar genomic distribution as the peaks. Lower panel: histograms showing the distribution of motif 
positions within the peaks (0 is the peak summit). (C) ChIP-qPCR performed with Ab2 on sites 
bound by RBPJ (Ab1) show specific enrichment only in OT13 cells (wt) and not in OT11 cells 
(Rbpj-/-). (D) ChIP-qPCR on Ab2-only sites identified in C2C12 ChIP-seq and harbouring a REST 
motif on OT13 (wt) and OT11 (Rbpj-/-). Using Ab1, no enrichment was detected on these sites in 
both cell types, whereas using Ab2, an enrichment is observed in wt and also Rbpj null cells. The 
tested peaks were selected for presence with Ab2 but not Ab1 in the ChIP-Seq experiments, 
presence in both C2C12 and T-ALL dataset and they also contained the REST motif. 
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Figure S4. Inducible sites are associated with high p300 occupancy in Notch-on cells. (A) 
Boxplot of p300 tag counts within all p300 peaks, inducible RBPJ sites, and constant RBPJ sites 
(derived from the ChIP-seq on 6hDll1 treated cells). p300 tag counts in constant sites are 
significantly lower than p300 tag counts in inducible sites (Mann-Whitney U test). (B) Scatter plots 
of ratios 24hDll1/24hDAPT of RBPJ binding versus p300 binding for the inducible sites (upper 
panel) and constant sites (lower panel) as shown in Figure 2g. (C) Heatmap of p300 ChIP-seq read 
densities in all p300 peaks. 
 
 
 
Figure S5 (Next pages). RBPJ inducible sites, but not RBPJ constant sites, are associated 
with Notch induced gene activation. (A) Scatter plots of RPKMs of all genes in Dll1 versus DAPT 
conditions. Upper panel: experiment1. Lower panel: experiment 2. Housekeeping genes Actb and 
Tuba1a, the known Notch responsive genes Heyl, Hey1 and Nrarp, and the Notch ligand Jag1 are 
indicated in color. (B) MA plots of all genes for the 6h and 24h treatments. The genes assigned to 
inducible and constant RBPJ sites are indicated in red and green, respectively. (C) Boxplots 
showing p300 ratios (Dll1/DAPT) at inducible RBPJ sites associated with induced genes (box 1), 
the remainder of RBPJ inducible sites (box 2), and RBPJ constant sites (box 3). RBPJ inducible 
sites associated with gene induction show ratios (Dll1/DAPT) of p300 binding that are slightly 
elevated compared to the rest of inducible sites. p-values were calculated using the Mann-Whitney 
U test. (D) Heatmaps representing ratios of RPKMs (6hDll1/6hDAPT and 24hDll1/24hDAPT) of 
genes coupled to inducible RBPJ sites and genes coupled to constant sites, for both biological 
replicate experiments. Both heatmaps are ranked according to the sum of ratios (6h plus 24h) of 
experiment1.  
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Figure S6. Subclasses of NICD-GFP and RBPJ binding sites. (A) Induction of HeyL protein in 
C2C12 cells expressing NICD-GFP or GFP, 8h after doxycycline induction detected by Western 
blot analysis. Rabbit polyclonal anti-HeyL was kindly provided by Dr. So-Ichiro Fukada (1/250 
dilution). (B) Distribution of the 4 categories of peaks identified based on signal in RBPJ and GFP 
ChIP-seq tracks in Notch-on and -off conditions: NICD-GFP and RBPJ binding sites, RBPJ only 
constant sites, RBPJ only inducible sites and NICD-GFP only sites. (C) RBPJ motif occurrences in 
the four groups of binding sites. Pwm-scans were performed with the GimmeMotifs RBPJ matrix 
and cut-off 0.90. For each peak one best motif was reported, if above cut-off. For calculation of 
enrichments, motif occurrences were compared to a matched genomic background. Lower panel: 
histograms showing the distribution of motif positions within the peaks (0 is the peak summit). 
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Table S1. ChIP-seq and RNA-seq samples and number of mapped reads per sample 
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Table S2. Primers used for quantitative RT-PCR and ChIP-PCR 
 
ChIP-PCR primer sequence (5'→3') RT-PCR primer sequence (5'→3')
ChIP_Apobec3_F CCAGATGTATCACTCGTGACC RTqPCR_4533422C13Rik_F CCAACACCAGGGATAACCAG
ChIP_Apobec3_R AGCAAGGAAGCAGTCCTGAG RTqPCR_4533422C13Rik_R AGCAGAATAGCTGGGCTTTG
ChIP_Bmp6_F GCAAATCGGTCACTTCACAC RTqPCR_Ank2_F TCTTATCGTCTGAGCTGGGG
ChIP_Bmp6_R TCGCTCTGGTGATTCACTTC RTqPCR_Ank2_R GGGCATCCACCATAAAACTG
ChIP_cdh15_F GCTTCAAAGAGCCTGGGAAT RTqPCR_Bmp6_F CATGAGCTTTGTGAACCTGG
ChIP_cdh15_R GCCAGGCTGATGTCATCTGTA RTqPCR_Bmp6_R CCCTCAGGAATCTGGGATAG
ChIP_Col5a3_F ATGACCCTGAGGTTGTGTGA RTqPCR_Ccdc97_F GAGCCCGCTGTGGCGGTTAC
ChIP_Col5a3_R CCCAATTTCTGCTGAGTCTG RTqPCR_Ccdc97_R CTGGGCTCCACGCCGTCATT
ChIP_D630045J12Rik_F AGATCCTCCACTCCAGATCG RTqPCR_Col5a_F CCGGAGACTGGATCAGCTT
ChIP_D630045J12Rik_R GGACTTTGAGTTGGCTCCTC RTqPCR_Col5a1_F GCTACTCCTGTTCCTGCTGC
ChIP_Egf_F TTCTCCTGACTCCACCAACC RTqPCR_Col5a1_R TGAGGGCAAATTGTGAAAATC
ChIP_Egf_R CTTCCATGCTTCCCACCTC RTqPCR_Col5a3_R GCTTCCAGTACGTCCACAGG
ChIP_Egfr_F TTTTCATTGCCTCCTGGTTC RTqPCR_Col6a1_F TCGGTCACCACGATCAAGTA
ChIP_Egfr_R CTGGCTGTGAGAATGCTCTG RTqPCR_Col6a1_R TACTTCGGGAAAGGCACCTA
ChIP_Gm2694_F CATCTCTGGGCACCTCTTTC RTqPCR_Dicer1_F TGCCAAGTTTAGCCCAGCGGA
ChIP_Gm2694_R ACACACCAGGAAGTCGAAGG RTqPCR_Dicer1_R GGCGATCCTGTAGCTCCGGC
ChIP_Hes1_F TTTGGGAAGTTTCACACGAG RTqPCR_Dpf1_F CCCACCGCGGGCCTGGTTT
ChIP_Hes1_R TTATCAGCACCAGCTCCaGA RTqPCR_Dpf1_R CGTTTCTTCCTCCAACAGCGGGC
ChIP_Hey1_F AAATTCAATCTCCGTGTGACC RTqPCR_Dusp2_F GTGTGCTTCTTGCGAGGCGG
ChIP_Hey1_R TGGGATTGACGGTGTAAGTG RTqPCR_Dusp2_R GGCCTGGGCAGGAGCTTCAGA
ChIP_Itgb5_F CCTCAGGGAACGAAATCCTA RTqPCR_Egfr1_F GGCGTTGGAGGAAAAGAAAG
ChIP_Itgb5_R CAAGAAGATACGCTTGGGAAA RTqPCR_Egfr1_R ATCCTCTGCAGGCTCAGAAA
ChIP_Krt14_F CCACCACTGCATTTTCTTGA RTqPCR_Ehd3_F GATTTCGACAACAAGCCCAT
ChIP_Krt14_R AGCCTGTGAGTCATGTTTGG RTqPCR_Ehd3_R TCATGCCTGGAAAATCCTGT
ChIP_Lifr_F AGAGGAAGAGACAGGGGTGA RTqPCR_Eps15l1_F GGGCGGCTTTGGAGCTATGGATG
ChIP_Lifr_R CTCCCCAAAACTCTGGTCTC RTqPCR_Eps15l1_R GGGTCCTCAGCCTGGAAGGGG
ChIP_neg16_F TTCCTTCCCTATTTGCTGCT RTqPCR_Gipc1_F AAGCCGGGCGGAGTTTCGAG
ChIP_neg16_R CCCACCCCGTCTAACTTTTA RTqPCR_Gipc1_R ACTCTGGCTGGGAGACCTGCG
ChIP_Nrarp_F GCTGGAGCTCAGTGTTTGTT RTqPCR_Gm14005_F CTGGGAGCTGAAACAGGAAG
ChIP_Nrarp_R CGTGGGAAAGAGGAGAGTGT RTqPCR_Gm14005_R GATCAGCAGGCAGCAGGTAG
ChIP_Pdgfrb_F ATGTGGCCAAGATGGGTTAG RTqPCR_Gm2694_F CCCCAGGCAAAGCCACACCAT
ChIP_Pdgfrb_R TCGCAAGCACTCAGAGTTTC RTqPCR_Gm2694_R AGCTCCAGGGCTGATGCTCCA
ChIP_Rbms1_F CTCTGGCTGACCTTGTGAAA RTqPCR_Gpbar1_F TGCCAACTGCAGCTCCCAAGC
ChIP_Rbms1_R GCCTGAGAAACCCTTAGCTG RTqPCR_Gpbar1_R CCCACGGCAGGCAACAGGAG
ChIP_Rps6ka1_F GAAAAGCGACCTTCTTCTGG RTqPCR_Hes1_F ACACCGGACAAACCAAAGAC
ChIP_Rps6ka1_R TGCTTCTTTTCCCACACGTA RTqPCR_Hes1_R AATGCCGGGAGCTATCTTTC
ChIP_Runx1_F GGATTAGCATCGCCTAAGCA RTqPCR_Hey1_F CACCTGAAAATGCTGCACAC
ChIP_Runx1_R GATCCAGAACTGGTGGGAAC RTqPCR_Hey1_R ATGCTCAGATAACGGGCAAC
ChIP_Serinc5_F AAAGACTCCATCTGCTGTCTGA RTqPCR_Hspa12a_F GGAGGCTCCTTTCCCGGGCT
ChIP_Serinc5_R GCTGTCCTTTTGAGGAGCTT RTqPCR_Hspa12a_R TGGGGGCTGTTTCTCGGGGC
ChIP_Spata13_F TGAGGCTGCTCTATGAGTCCT RTqPCR_Irx3_F GTGCCTTGGAAGTGGAGAAA
ChIP_Spata13_R CTTGCGTCAGGGAAATGAAC RTqPCR_Irx3_R ATAAGACCAGAGCAGCGTCC
ChIP_Vav3_F GCACATGGGTTTGTCTTAGC RTqPCR_Klf2_F CCATGGCGCTCAGCGAGCCT
ChIP_Vav3_R CAAATGCTCCAGCTGTCAAT RTqPCR_Klf2_F GTTGCACTACGGGCCTCC
ChIP_REST_1_F TCCCGGCTTGTATTTTTCTC RTqPCR_Klf2_R TCATTTCGCGGCCAGCGCTCC
ChIP_REST_1_R ATATTTCAGCACCGTGGACA RTqPCR_Klf2_R GTGGCAGGTGGAGCCAAG
ChIP_REST_2_F TGTCCCCGGTCCTAAAATAG RTqPCR_Krt14_F GGAGAGGACGCCCACCTTTCA
ChIP_REST_2_R CAGTGACCGTTCAGAACCAG RTqPCR_Krt14_R CTTGGTGCGGATCTGGCGGT
ChIP_REST_3_F AAGAGGCTAGACGTGGCATT RTqPCR_Lifr_F AAGAACTGGCTCCCATTGTCGC
ChIP_REST_3_R GTCAGGAGCTCTCCAAGGTC RTqPCR_Lifr_R AGCCTCGGAGCTCTTCCACGG
ChIP_REST_4_F GTGTCCTGTTATGGACCGTG RTqPCR_Marcks_F GTCGCCTTCCAAAGCAAAT
ChIP_REST_4_R TCTCAGAAACGGCTTTCCTT RTqPCR_Marcks_R GTTGGCTTGCAGCTCCTC
ChIP_REST_5_F TCTTGGCAGTTGTACTTGGC RTqPCR_Nrarp_F TGTATCCAGCGTTGTGAAGG
ChIP_REST_5_R GAATTCCTGCCGCTATCCTA RTqPCR_Nrarp_R ATTGGGGAAGGCAGAAAGAG
ChIP_REST_6_F TTTAACACGCGACACACAGA RTqPCR_Pdgfrb_F TTGCCAGTTCCACCTTGAATGA
ChIP_REST_6_R TCAGCACCAGGGACAGTAAC RTqPCR_Pdgfrb_R AGTTGTGCCTCAGGCTCTGCTT
ChIP_REST_7_F AGCAAACCAAGCAGCTACAA RTqPCR_Rps6ka1_F CCGCTGGACCCGGAGAATGG
ChIP_REST_7_R TCTTGTGTGGAACCTTCAGC RTqPCR_Rps6ka1_R AGCCAGCCTTGACGTGGTGT
ChIP_REST_8_F CACTGCCCAAGAGGGTACTT RTqPCR_Runx1_F GGTGGACAGAGGAAGAGGTG
ChIP_REST_8_R GCATCTGGCAATAGGTGAAA RTqPCR_Runx1_R TTGCCACCTACCATAGAGCC
ChIP_REST_9_F TACAGTTACTCCGCAGGCAG RTqPCR_Serinc5_F GTGACTTGGCTGGGCACCCTT
ChIP_REST_9_R GCATCACTCCCTGCACTAGA RTqPCR_Serinc5_R CTGAAAGCCCACGAACCGGGC
ChIP_REST_10_F TGTCTCCTCTGAGCACAAGC RTqPCR_Slmap_F CCCAGCCGTTTTCATCGGCCT
ChIP_REST_10_R TCAGGACCACGGACAGTTAC RTqPCR_Slmap_R GCATCCAGGGCCAGGGTTTCTTT
ChIP_REST_11_F CATGGTGGCATAACATTTCC RTqPCR_Spata13_F CTTGGTCCAACCAGCAGCCAGG
ChIP_REST_11_R TTCATCACCTTGGACAGCTC RTqPCR_Spata13_R GTCCAGCCCGATGGGAGTGC
ChIP_REST_12_F TTCTTGTCCATGGTGCTGAT RTqPCR_TBP_F ATCCCAAGCGATTTGCTG
ChIP_REST_12_R ACAAGACCTACTTGGCCACC RTqPCR_TBP_R CCTGTGCACACCATTTTTCC
ChIP_REST_13_F CATGGTGCTGACCTGAAACT RTqPCR_Tgfb1_F GTGGACCGCAACAACGCCATCT
ChIP_REST_13_R AATAAGACAGGGTGGGGTGA RTqPCR_Tgfb1_R GCAATGGGGGTTCGGGCACT
ChIP_REST_14_F GAGCGCATAGAAAGACCCTC RTqPCR_Vav3_F GAGCCAGAACAGCCAGCtg
ChIP_REST_14_R CCTGCAAAGGCAAAGTATGA RTqPCR_Vav3_R tgtGGATGGAAACCAGCCC
ChIP_REST_15_F TTTAAGCAGACCTGGAAGGG
ChIP_REST_15_R CAAACCACGACCATTCTGAG Target gene TAQMAN assay #
ChIP_REST_16_F GGGAGGGAAACTTGAGTTGA Tbp1 Mm00446973_m
ChIP_REST_16_R GCACGGCTCACAGTACCTAA Myog Mm00446194_m1 
HeyL Mm00516555_m1
Hey1 Mm00468865_m1
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7.1 – Identification of Methyl-CpG Binding Proteins 
Methylated DNA is specifically recognized by MBPs, that belong to three different 
structural families in mammals; the MBD family, the KAISO family and the SRA 
domain proteins. The current view is that MBPs bind to methylated DNA and translate 
the DNA methylation signal into appropriate functional states through interactions with 
diverse partners [1]. Methyl-DNA binding activity in nuclear extracts was first 
described two decades ago in EMSAs and Southwestern assays [2-3]. MeCP2 [3], and 
later KAISO[4], were then purified by traditional biochemical approaches. Their 
family-members were identified via homology with the MBD domain or the KAISO 
Zinc-fingers [5-7]. UHRF1 was identified as binder of methylated DNA corresponding 
to the CpG-islands of intron 1 of the EGR2 gene in a DNA-protein pull-down assay 
with subsequent mass spectrometry analysis [8-9]. SRA containing proteins in plants 
were already known to be required for DNA methylation maintenance [10-11], and a 
similar role was then described for mammalian UHRF1 [12-13].    
Major developments in mass-spectrometry-based proteomics have changed 
methodology in protein research [14-16]. New technology employed in high 
throughput approaches enables the identification of thousands of proteins in complex 
mixtures. Moreover, quantitative strategies, for example SILAC-based, allow for single 
step low stringency purification schemes in rapid and sensitive screenings of protein 
interactions. We and others applied high-throughput ‘interactomics’ approaches for 
methyl-DNA interactome research. In chapter 2 we describe a methyl-CpG pull-down 
assay combined with SILAC based mass spectrometry, to identify potential novel DNA 
methylation readers. In this assay, fully methylated synthetic DNA is used as a bait for 
MBPs in a heavy-labeled nuclear extract, whereas unmethylated DNA is used in a light 
(normal) extract (or vice versa in a reverse experiment). Both pull-down fractions 
(heavy and light) are mixed, and proteins that - directly or indirectly - specifically bind 
to methylated DNA in vitro are identified by their heavy/light ratios in subsequent mass 
spectrometry analyses. Similarly, Bartke et al. investigated effects of DNA methylation 
and histone methylation on the chromatin interactome [17]. They used assembled 
nucleosomes as well as naked DNA in pull-downs. The usage of nucleosomes provided 
a more physiological substrate and allowed the identification of cross-talk between 
DNA methylation and histone methylation.  
In our methyl-CpG pull-downs we identified the known DNAme readers MBD2, 
KAISO, MeCP2, UHRF1 and MBD4, as well as almost all subunits of the 
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MBD2/NuRD complex as methyl-specific binders to our DNA, whereas CGGBP1 was 
found to be repelled by DNA methylation in line with previous reports [18-19]. 
Moreover, potential novel DNA methylation readers were identified. We performed 
further investigations on RBPJ and ZHX1 (chapters 2, 4 and 6) that were found to be 
sequence-context specific DNA methylation binders in vitro. Bartke et al. identified 
sequence-context specific DNA methylation binders as well, that showed methylation 
dependent binding to only one of the two nucleosome positioning elements [17]. When 
analyzing the DNA methylation binding factors for the presence of known domains 
they identified a striking number of zinc-finger containing proteins. The second most 
prevalent domain was the homeobox. The usage of various DNA sequences and 
extracts from diverse cell types is likely to identify a whole new group of (sequence-
context specific) methylation dependent binding proteins with diverse DNA  binding 
domains. However, we note that it remains of major importance to determine the 
relevance of in vitro findings by investigating the binding patterns and DNA 
methylation dependencies of such factors in vivo. 
 
7.2 – In vitro versus in vivo observations 
Using the methyl-CpG pulldown assay in combination with SILAC-based mass 
spectrometry we aimed to identify novel DNA methylation readers (chapter 2). 
Moreover, we were able to show that DOC-1 is a true subunit of the NuRD complex 
using this method (chapter 3). We performed further analyses on RBPJ and ZHX1 
(chapter2, 4 and 6), both identified as potential novel DNA methylation readers in 
methyl-CpG pull-downs.  
 
RBPJ showed direct and DNA methylation dependent binding in a sequence context-
specific manner in vitro. The RBPJ binding consensus has been described as 5’-
ag/ccGTGGGAActa/t-3’, of which the middle hepta-nucleotide sequence is the core 
recognition motif [20]. We found that RBPJ binds the mutated consensus sequence 5’-
GCGGGAA-3’ in a methylation dependent manner; when this consensus was 
unmethylated weak RBPJ binding was observed and when it was methylated strong 
RBPJ binding occurred. We speculate that the structural resemblance of thymine and 
methylcytosine allows for interchangeability of these residues, and the mode of binding 
by RBPJ is similar. Thymine and methylcytosine interchangeability in DNA binding 
sites has been described before for the MDBP/RFX [21-23] and ZBTB4 [24] 
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transcription factors. Whether this is a general phenomenon or only applies to specific 
factors remains to be investigated. To define RBPJ binding sites genome-wide in vivo 
we performed ChIP-seq experiments in mouse C2C12 cells that were either Notch 
activated with ligand or Notch inhibited with DAPT (chapter 6). Using the genome-
wide maps of RBPJ, we could examine whether the methylcytosine containing site is 
also used in vivo and if so whether it is amongst the top binding sites. Surprisingly, we 
did not detect RBPJ binding to methylcytosine containing consensus sites. The normal 
thymine-containing RBPJ consensus on the other  hand was present in the vast majority 
of the peaks. Of course we cannot exclude a role for the methylcytosine containing 
sequence in vivo, as binding to such a site may be restricted to one or very few loci 
within specific cell types and under specific conditions. 
A very small number of RBPJ binding sites was found in vivo, even though the 
consensus is abundant in the genome. Moreover, we found that RBPJ binding was 
dynamic at a large fraction of its sites: weak binding was observed in Notch off cells 
whereas binding drastically increased with Notch activation. Similar findings were 
reported in Drosophila [25]. Interestingly, recent isothermal titration calorimetry (ITC) 
binding experiments demonstrated that RBPJ has only moderate affinity for DNA with 
a dissociation constant at least 100-fold higher than previously considered [26]. 
Friedmann et al. therefore stated that cooperative mechanisms are likely to play an 
important role in recruitment of RBPJ to its targets [26]. Regarding these observations, 
we speculate that, apart from recognition of the consensus sequence, many other 
factors influence RBPJ occupancies at the DNA in vivo. This may involve effects of 
cofactor binding and of the local chromatin architecture. As such a normal RBPJ 
consensus site or a methylcytosine containing mutated consensus site by itself is not 
sufficient for RBPJ binding in vivo, additional regulation is required.   
 
ZHX1 was also shown to directly bind to specific DNA sequences in a DNA 
methylation dependent manner in vitro. Moreover, it was shown by others that it also 
binds to nucleosomal DNA in a methylation dependent manner in vitro [17]. We found, 
however, that in vivo DNA methylation dependent binding by ZHX1 did not occur. 
ZHX1 binding profiles and DNA methylation patterns in HCT116 cells, generated by 
ChIP-seq and MethylCap-seq, respectively, showed that ZHX1 occupied CpG-dense 
sites which are unmethylated. Using bisulfite-sequencing of ZHX1 ChIP DNA (ChIP-
BS-seq) the unmethylated state of ZHX1 binding sites was confirmed. Finally, ZHX1 
genomic binding patterns in DNMT1/DNMT3B knockout cells, that display a 95% 
reduction of genomic DNA methylation [27], were virtually identical to those of wild 
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type cells. Thus our in vivo findings did not support the in vitro observed DNA 
methylation dependent binding of ZHX1. 
ZHX1 is a protein with many domains: two tandem C2H2 zinc-fingers and five 
tandem homeodomains. Little is known about this factor and its biological functions. 
The structures of the tandem zinc-finger region and HD4 have been determined [28-
29]. ZHX1 ZNF2 and HD4, but not ZNF1, were predicted to have potential DNA 
binding capacity. Further work is required to elucidate how ZHX1 is recruited to its 
genomic sites. If ZHX1 binds directly to its genomic sites, it remains to be determined 
which domain(s) are responsible. Although in vitro the region containing the 
homeoboxes is responsible for methylated DNA binding (the exact domain was not 
further determined), the domains for in vivo DNA binding may be different and are 
unknown at this moment. On the other hand, genomic occupancies of ZHX1 may be 
affected/established by interacting proteins. Various interactors of ZHX1 have been 
identified in yeast-two-hybrid screenings, including other ZHX family members, NF-Y 
and DNMT3B. Their functions in relation to ZHX1 in vivo remain to be determined. 
Moreover, other (unknown) factors may be involved in ZHX1 recruitment to 
chromatin. 
 
The here reported discordance between our in vitro and in vivo binding site analyses 
may be a general problem when extrapolating in vitro binding studies to reflect the in 
vivo situation. Obviously, in vitro experiments do not reproduce properties of the 
nucleus, as outlined in [30-31]. The genome is not arranged homogeneously and not all 
sites are equally accessible to protein regulators in vivo [32-33]. This not only involves 
condensation and modifications of the chromatin, but also looping, (inter)chromosomal 
interactions and occupation of chromosome territories within the nucleus. Moreover, 
proteins often interact with other factors or complexes that modify location within the 
nucleus, genomic recruitment, properties and functions. Processes in the nucleus and 
the functional status of the genome are tightly regulated. Where in vitro protein-DNA 
interactions depend on the concentration of the interactors and the binding constants, 
the in vivo situation is considerably more complex.  
 
Known MBPs were defined as such based on their methylation-dependent DNA 
binding characteristics in vitro. As discussed before, we also recovered various known 
MBPs as methylation-dependent binders in our in vitro methyl-CpG pull-down/SILAC 
experiments, which provided proof-of-principle for our method. However, the in vivo 
binding characteristics of known MBPs have been investigated only to a limited extent. 
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Many studies have performed ChIP-QPCR experiments on MBPs, analyzing one or 
few loci (for example [34-39]). They mainly focused on specific CpG-island promoters 
that are hypermethylated in cancer. Few MBPs have been investigated on a larger scale 
in ChIP-array experiments or genome-wide in ChIP-seq experiments, as discussed in 
more detail below. It is remarkable that so few genome-wide profiles of MBPs have 
been published so far, while it is of major interest to clarify the interplay between DNA 
methylation and MBPs and the role MBPs play in interpreting the DNA methylation 
code in vivo. Possibly genome-wide analyses are hampered by technical issues, for 
example the availability of ChIP-grade antibodies for MBPs. We note here that we 
tested a variety of commercial and in house generated MBP antibodies in targeted 
ChIPs, but did not find ChIP-grade antibodies. In analyses of MeCP2 in vivo binding, 
Schmiedeberg et al. found that transient protein-DNA interactions escape detection by 
ChIP due to the inability of formaldehyde to fix such transient interaction [40]. 
However, it is unlikely that in vivo MBP-DNA interactions are generally too unstable 
to be captured. Notably, the genome-wide binding profile of MeCP2 led to a re-
evaluation of its function; MeCP2 is now postulated to be a global regulator of 
neuronal chromatin structure [41]. For the other MBPs the in vivo situation is largely 
unknown. It remains to be seen whether DNA methylation by itself is sufficient for 
MBP binding in vivo, or whether additional regulation is required. Also, the extent to 
which DNA methylation or other factors, for example DNA binding preferences of 
associated proteins/complexes, determine the genomic binding patterns of MBPs 
remains to be determined. The analyses of genomic MBP binding patterns, their co-
occurrence with DNA methylation, location to specific genomic elements and sequence 
preferences, would answer these questions.  
Skene et al. profiled MeCP2 binding in whole brain of mature mice [41]. They 
found that MeCP2 bound throughout the genome, tracking the presence of methyl-
CpGs. MeCP2 levels in neurons were very high: nearly as abundant as the histone 
octamer. The abundance and widespread recruitment suggested a specific structural or 
regulatory function for MeCP2 in neuronal chromatin. Indeed, lack of MeCP2 in 
neuronal nuclei led to global changes in chromatin structure, including elevated histone 
acetylation and a doubling of linker histone H1. Moreover, elevated transcription of 
repetitive elements was observed. Based on their findings, Skene et al. proposed that 
MeCP2 does not act as a gene-specific transcriptional repressor in neurons, but instead 
dampens transcriptional noise genome-wide in a DNA methylation dependent manner. 
This is also in line with previous reports showing that disrupted MeCP2 function does 
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not result in upregulation of a discrete set of genes but leads to subtle changes in the 
expression of thousands of genes in the brain [42-44].  
Yildirim et al. recently performed ChIP-seq on MBD3 in mouse embryonic stem 
cells after they found that several hundred genes were antagonistically regulated by 
BRG1 and MBD3  [45]. As mentioned before, MBD3 is not a bona fide MBP as it is 
known to lack methyl-CpG binding activity [6], but it is – at least biochemically – 
similar to MBD2 because of its association into the Mi2-NuRD complex. MBD3 
localized largely to promoters, was associated with a significant fraction of Polycomb-
bound genes and displayed significant overlap with BRG1. Surprisingly, MBD3 was 
proposed to play a central role in hydroxymethylcytosine biology. MBD3 genomic 
binding showed substantial overlap with TET1 binding patterns and 
hydroxymethylcytosine marking. Knockdown of TET1 abrogated MBD3 binding to its 
genomic targets. Using EMSAs Yildirim et al. showed that the MBD3/NuRD complex 
and MBD3 alone bind hydroxymethylated DNA probe. MBD3 as well as BRG1 
knockdown resulted in strong reduction in global hydroxymethylcytosine levels. The 
authors concluded that MBD3 is a novel effector of hydroxymethylcytosine that is both 
dependent upon this mark for chromatin binding as well as required for normal levels 
of this mark within the genome. We note, however, that the data quality of this study is 
extremely poor and that additional experiments are required. Shown results, including 
the EMSAs investigating MBD3 binding to hydroxymethylated DNA, are far from 
conclusive in our opinion. It was shown before that MBD1, MBD2, MBD4 and MeCP2 
do not bind hydroxymethylated DNA [46-47]. MBD3 lacks several important amino 
acids that are conserved in other MBD proteins [6], causing lack of methyl-CpG 
binding capacity. Whether and how this modified MBD fold specifically  recognizes 
hydroxymethylcytosine remains subject for structural investigations.    
MBD1, MBD2, MBD3 and MeCP2 were analyzed by ChIP-array experiments by 
Ballestar et al. [48]. They performed ChIPs in human breast cancer cells lines MCF7 
and MDA-MB-231 and hybridization on DNA microarrays containing a library of 7777 
CpG-islands. They found that 7.1% of the clones were positive for all four MBDs, 
while 24.2, 10.3, 9 and 5.8% were positive singly for MBD2, MBD3, MeCP2 and 
MBD1, respectively. A limited number of selected sites were then shown to be DNA 
methylated and associated with gene repression. This was, however, not investigated 
on a larger scale. Moreover, these findings could not be reproduced in our laboratory, 
using the same antibodies (personal communication A. Brinkman). Chatagnon et al. 
performed ChIP of MBD2 in HeLa cells followed by hybridization on arrays 
representing 25,500 promoter regions [49]. They found preferential localization of 
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MBD2 near TSSs. Motif analyses did not reveal specific sequence motifs; although 
CCG and CGC sequences seemed to be overrepresented. A linear relationship between 
MBD2 binding and DNA methylation was found, as derived from the number of 
probes from MBD2 ChIP and from MAP (methylated DNA precipitation by a 
recombinant protein consisting of four MBD domains) within a 50 bp sliding window 
throughout the genomic regions on the array. Notably, we found MBD2 occupancies at 
unmethylated enhancers in ChIP-seq analyses of a TTE-tagged MBD2 expressing cell 
line (unpublished results, R. Menafra and H. Stunnenberg), suggesting that other 
factors than DNA methylation are involved in MBD2 genomic targeting. This is 
currently further validated and analyzed via different approaches. Clearly, additional 
and more extensive analyses are required for the in vivo characterization of MBPs in 
general. 
 
7.3 – DNA methylation and H3K27me3 cross-talk 
Cross-talk between different epigenetic modifications is essential for the regulation of 
chromatin-based processes. The relationships between various chromatin modifications 
have been largely determined by correlative studies. However, the analysis of cross-
talk through independent profiling is complicated by cell population heterogeneity, cell 
cycle effects and allele-specific marking of chromatin such as in imprinting and X-
inactivation. One method for the direct measurement of chromatin cross-talk is 
sequential ChIP, in which chromatin of a first ChIP is eluted from beads and directly 
used in a second round of ChIP. This method specifically allows determining the co-
occurrence of histone modifications or factors that can both be captured by sequential 
ChIP. The implementation of proper controls is essential and ideally mononucleosomal 
DNA is used for the sequential ChIPs. The method has been used in targeted 
approaches, for example in the analyses of potentially bivalent promoters.   
In chapter 5 we described the ChIP-BS-seq method, that specifically allows for 
the direct assessment of DNA methylation cross-talk with other chromatin marks at 
genome-wide scale. Any chromatin feature or transcription factor that can be captured 
is suitable for ChIP-BS-seq analysis. The (ChIP) captured fragments are directly 
subjected to bisulfite conversion and deep sequencing, generating base resolution DNA 
methylation data for the genomic subset of interest. While the use of whole-genome 
bisulfite shotgun sequencing is limited by the cost of the required sequence depth, a 
restricted genomic representation obtained by ChIP capturing allows for more cost-
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effective sequencing. ChIP-BS-seq was implemented by us to analyze DNA 
methylation patterns associated with MethylCap captured DNA (chapter 5), 
H3K27me3 enriched DNA (chapter 5) and sites occupied by the ZHX1 transcription 
factor (chapter 4). We anticipate that the information obtained with ChIP-BS-seq will 
provide new insights in the composition of different chromatin types.  
 
H3K27me3 is mediated by Polycomb group proteins and is associated with 
transcriptional repression and silenced chromatin [50]. Polycomb Repressive Complex 
2 (PRC2) catalyzes H3K27 methylation via the SET domain of EZH2, whereas 
Polycomb Repressive Complex 1 (PRC1) is recruited to the H3K27me3 mark and 
executes gene silencing. The interplay between DNA methylation and 
H3K27me3/Polycomb has been subject to extensive studies, and various phenomena 
have been described [51].  
Viré et al. reported that EZH2 interacts with DNMTs in the context of PRC 
complexes, and that  EZH2 knockdown results in reduced H3K27me3 occupancy and 
an accompanying decrease in DNMT binding and DNA methylation at several EZH2-
target promoters [52]. In contrast with the earlier findings, McGarvey et al.  did not 
detect a reduction in DNA methylation nor increased expression of DNA 
hypermethylated tumor suppressor genes upon EZH2 knockdown [53]. Various studies 
have reported H3K37me3 marking at hypermethylated promoters in cancer cells, 
suggesting cooperation of both modifications in silencing [54-55]. On the other hand, 
antagonism or mutual exclusiveness between DNA methylation and H3K27me3 has 
been described. Kondo et al. found that genes enriched for H3K27me3 have no DNA 
hypermethylation and vice versa in PC3 and MCF7 cells [56]. Experimental 
manipulation of DNA methylation and H3K27me3 levels at the Rasgrf1 locus in mice, 
of which the paternal allele is normally DNA methylated and the maternal allele 
H3K27me3 enriched, showed antagonism of the marks; deposition of one mark 
prevented placement of the other [57]. In recent nucleosome affinity purifications 
enrichment of PRC2 components at H3K27me3 nucleosomes was obstructed by DNA 
methylation of the nucleosome positioning sequence, suggesting negative regulation of 
PRC2 by DNA methylation [17]. In mouse postnatal neural stem cells nonpromoter 
DNA methylation by Dnmt3a was found to counteract PRC2 binding, thereby 
facilitating transcription of neurogenic genes [58]. Finally, various studies have 
described a correlation between Polycomb marking and de novo (aberrant) DNA 
methylation: cancer-specific or neural differentiation –specific hypermethylated 
promoters were shown to be DNA methylation free but associated with 
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Polycomb/H3K27me3 in embryonic stem cells [54,59-61]. Similar observations were 
made in prostate cancer cells when compared with matching primary cells [62]. If and 
how Polycomb and H3K27me3 marking directly play a role in targeting DNA 
methylation in these cases has not been elucidated.  
 
We used ChIP-BS-seq to directly analyze the DNA methylation patterns associated 
with H3K27me3 (chapter5). We found that H3K27me3 and DNA methylation 
generally co-occur but are mutually exclusive in CpG-dense regions. CpG-density 
dependent mutual exclusiveness was observed in both the human colon cancer cell line 
HCT116 as well as in mouse embryonic stem cells. Furthermore, ChIP-BS-seq in Dnmt 
triple knockout (TKO) embryonic stem cells showed that total loss of DNA 
methylation resulted in changes of H3K27me3 genomic occupancies: H3K27me3 in 
localized peaks was decreased while broad local enrichments (BLOCs) of H3K27me3 
were formed. Since BLOCs corresponded to regions of high DNA methylation in wild 
type cells, we speculated that DNA methylation also antagonized H3K27me3 
deposition at megabase scale.  
Independently, the Clark lab investigated H3K27me3-DNA methylation cross-
talk using the same strategy [63]. Their method, called BisChIP-seq, involved similar 
processing of ChIP-captured DNA as ours. Differences with our method lie in the exact 
bisulfite treatment protocol, order of processing steps (size-selection after or before 
bisulfite treatment) and deep sequencing (single-end by Brinkman et al. versus paired-
end by Statham et al.). Statham et al. found that H3K27me3 and DNA methylation can 
co-occur in a genomic region dependent manner in normal and cancer prostate cells. In 
normal cells H3K27me3 enriched TSSs and CpG-islands showed bimodal DNA 
methylation profiles, with either fully methylated or unmethylated DNA, whereas 
exonic, intronic and intergenic H3K27me3 enriched regions primarily associated with 
methylated DNA. In cancer cells the co-dependency of the marks was largely 
redistributed. An increase in regions with the dual repressive marks at TSSs and CpG-
islands was observed. DNA methylation in H3K27me3 enriched exonic, intronic and 
intergenic regions decreased.  
The antagonism between H3K27me3 and DNA methylation that we observed fits 
with various previous observations, including the antagonism described for the Rasgrf1 
locus and the “epigenetic switching” in cancer cells, where genes initially silenced by 
Polycomb have acquired DNA methylation and lost H3K27me3. We speculated that 
obstruction of PRC2 recruitment at DNA methylated CpG-dense regions may cause 
mutual exclusiveness, which would fit with the observations by Bartke et al. that DNA 
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methylation interferes with PRC2 binding on assembled nucleosomes in vitro. It is very 
surprising, however, that Statham et al. did not find mutual exclusiveness of the marks 
at CpG-islands when using a similar approach. They even found an increase of CpG-
islands and TSSs containing both DNA methylation and H3K27me3 in cancer cells. 
Apparently, the mutual exclusiveness of the two marks at CpG-islands is cell type-
specific, even though we observed it in two different cell types (a human cancer cell 
line and mouse embryonic stem cells). Whereas in both studies a human cancer cell 
line was included, HCT116 by us and LNCap by Statham et al., findings therein were 
different. Furthermore, Statham et al. reported differences between normal and cancer 
prostate cells, as mentioned before. These findings argue against a universal 
mechanism for mutual exclusiveness of DNA methylation and H3K27me3 as we 
speculated to be the case. Future studies are required to reveal what is the predominant 
configuration of DNA methylation and H3K27me3 throughout the genome, and at 
CpG-islands specifically, in diverse cell types. 
 
7.4 – A new model for Notch-RBPJ signaling 
In chapter 6 we describe the analyses of genome-wide RBPJ binding profiles in mouse 
C2C12 myoblasts. Overexpression of NICD or exposure to Notch ligands is known to 
inhibit myogenic differentiation of these cells [64-67]. We found that RBPJ binds a 
very limited set of genomic targets in C2C12. Interestingly, at a large subset of targets 
RBPJ binding was dependent on Notch signaling status. At such inducible sites RBPJ 
displayed low occupancies in Notch off cells and high occupancies in Notch activated 
(Notch on) cells, treated with DAPT and Dll1 ligand, respectively. On the other hand, 
RBPJ binding at the remainder of sites was constant and independent of Notch status. 
We found that RBPJ inducible sites, but not constant sites, dynamically recruit p300 
and trigger gene activation upon Notch activation. NICD-GFP profiling revealed that 
inducible sites were associated with NICD, whereas NICD was not detected at RBPJ 
constant sites. Thus, constant RBPJ sites were not Notch regulated and represented 
sites regulated by RBPJ probably by unknown interactors. Inducible RBPJ sites 
represented Notch targets. Our results argue that Notch signaling does not involve 
repressive/activating complex switching at constitutive RBPJ sites, but instead that 
RBPJ is dynamically recruited to Notch targets in a RBPJ-NICD activating complex.  
RBPJ genomic binding has been studied before in human and mouse T-
lymphoblastic leukemia (TLL)  cells [68] and human lymphoblast cells (LCL) [69]. 
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Both cell types are characterized by deregulated RBPJ, either by aberrant Notch 
signaling in TLL cells or via the Epstein-Barr virus (EBV) oncoprotein EBNA2 that 
mimics NICD in LCL cells. The number of detected genomic RBPJ binding sites 
varied from 548 in mouse G4A2 cells up to 2776 in mouse T6E cells and 10,529 sites 
in human LCL cells [68-69]. We identified 158 and 227 RBPJ binding sites in Dll1 
treated and NICD-GFP expressing mouse C2C12 cells, respectively. Using the 
polyclonal anti-RBPJ antibody (Ab2) from the Kieff lab (used in [68-69]), we detected 
388 sites in Dll1 treated C2C12 cells in addition to the 158 sites detected by our 1F1 
anti-RBPJ antibody (Ab1). However, we found that these sites were highly enriched for 
the REST motif. When using the Ab2 antibody on Rbpj null mouse fibroblasts, REST 
motif containing peaks were still detected indicating cross-reactivity of the antibody. 
The finding of cross-reactivity of this antibody has implications for the interpretation of 
the previously published RBPJ genomic profiles [68-69]. The main observations, 
involvement of various cofactors and cross-talk with other signaling pathways, may be 
(partially) based on false peaks. The RBPJ sites described by us were confirmed by 
three independent antibodies (including Ab2), highly enriched for the RBPJ motif and 
coincided with NICD-GFP binding (at inducible sites), indicating that they were high 
confident, direct RBPJ targets. The small number of sites and the observation of 
inducible binding, indicated that RBPJ genomic recruitment is highly specific and 
tightly regulated.  
According to the model of Notch signaling, RBPJ is statically associated with its 
genomic targets and swaps interaction partners leading to a switch from transcriptional 
repression to activation upon Notch signaling. The switching model, however, had not 
been investigated at genome-wide scale so far. We found that RBPJ is not statically 
associated with Notch targets, but instead shows strong inducible binding upon Notch 
signaling. As RBPJ showed low/no occupancies at Notch targets in Notch inhibited 
cells, it is unlikely that RBPJ actively represses these sites in absence of Notch 
signaling. Inducible sites included well-known Notch targets, for example Hey1 and 
Pdgfrb associated sites. Notch dependent dynamics in RBPJ binding have been 
observed before in ChIP-QPCR experiments in Drosophila. SUH occupancies 
significantly increase at E(spl) Notch target genes in S2-N and DmD8 cells following 
Notch activation by EDTA treatment [25]. Increased SUH binding is transient and 
declines after activation has ceased. Our findings are very similar to the observations in 
Drosophila. Increased RBPJ occupancies at inducible sites following Notch signaling 
suggest that RBPJ is more strongly recruited and/or binds more stably as part of the 
Notch activating complex at these sites. Consistent with a dynamic nature of RBPJ 
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binding to DNA, recent isothermal titration calorimetry (ITC) binding experiments 
have demonstrated that RBPJ has only moderate affinity for DNA with a dissociation 
constant at least 100-fold higher than previously considered [26]. Friedmann et al. 
hence stated that cooperative mechanisms are likely to play an important role in 
recruitment of RBPJ to its targets. We propose that in the model of Notch signaling 
RBPJ is not a static DNA binding factor, but actively recruited to targets following 
Notch activation. At the transcriptional level, the Notch pathway thus acts in a different 
manner than previously thought.  
 
 
In this thesis, we describe an assay for the identification of novel DNA methylation 
readers, follow-up in vitro and in vivo analyses of potential novel DNA methylation 
readers, and a method to directly determine DNA methylation levels at base-resolution 
within genomic regions occupied by a transcription factor or histone mark of interest. 
We here emphasize the importance of in vivo analyses of in vitro identified methyl-
DNA binding proteins, as we found that DNA methylation dependent binding by RBPJ 
and ZHX1 does not hold true in vivo. In general, the in vivo binding patterns and DNA 
methylation dependencies of MBPs are largely unknown, while it is of major interest to 
clarify how the DNA methylation code is interpreted by MBPs. The here described 
ChIP-BS-seq assay may be used in future investigations to directly measure DNA 
methylation levels within MBP occupied genomic sites, provided ChIP-grade 
antibodies are available. Finally, we describe genome-wide analyses of the RBPJ 
transcription factor, and show that its genomic occupancies depend on the Notch 
signaling status. This is a new finding that changes our view on how the Notch 
signaling pathway functions at the transcriptional level. 
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Mammalian DNA methylation comprises the methylation of the carbon 5 of cytosine 
residues in genomic DNA and occurs predominantly in the context of CpG 
dinucleotides. It plays a crucial role in a variety of biological processes, including 
genomic imprinting, X chromosome inactivation and genome stability.The methylation 
mark is established and maintained by DNMTs. Mammalian genomes are globally 
methylated with the exception of CpG-islands that are generally unmethylated. Over 
the last decades DNA methylation has been subject of intensive research. Recent 
technical advances, including next generation sequencing technology, have accelerated 
the field. Chapter 1 provides a general introduction to DNA methylation and includes 
the latest findings of non-CpG methylation, hydroxymethylation and demethylation 
processes. Methylated CpGs are specifically recognized by MBPs. Three types of 
MBPs exist in mammals: MBD proteins, KAISO family proteins and UHRF1 family 
proteins. They have been found to execute specialized functions and many interaction 
partners have been identified for MBPs. We here set out to (1) identify potential new 
DNA methylation readers, (2) characterize potential new readers by in vitro and in vivo 
analyses, (3) develop a method for direct measurement of DNA methylation within 
genomic binding sites of transcription factors or sites occupied by epigenetic marks.  
Chapter 2 describes a methyl-CpG pull-down assay combined with SILAC for the 
purpose of identifying novel DNA methylation readers. In this assay proteins are 
captured from nuclear extracts by DNA coupled to beads and quantitatively analyzed 
by mass spectrometry. Methylated DNA is used in combination with heavy-labeled 
nuclear extract and unmethylated DNA with light extract or vice versa in a reverse 
experiment. Heavy/light ratios of proteins provide information about DNA binding: 
high ratios indicate methylation dependent binding whereas low ratios indicate 
repulsion by methylation (or vice versa in a reverse experiment). Proof-of-principle for 
this method was provided by the recovery of known MBPs and almost all subunits of 
the MBD2/NuRD complex as methylation-dependent binders. Interestingly, RBPJ, the 
transcription factor downstream of Notch signaling, was found to specifically bind 
methylated DNA. Follow-up experiments showed that methylation dependent binding 
was direct and sequence-context specific: RBPJ bound an atypical RBPJ binding motif 
(5’-GCGGGAA-3’) when this motif was methylated. The normal consensus RBPJ 
binding motif is 5’-GTGGGAA-3’. We concluded that within the RBPJ consensus 
motif, thymine is interchangeable with methylcytosine.  
In chapter 3 we show analyses of the MBD/NuRD complexes. It was described 
previously that MBD2 and MBD3 assemble in mutually exclusive distinct NuRD 
complexes, MBD2/NuRD and MBD3/NuRD. In the same study DOC-1 peptides were 
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identified in MBD2/NuRD and MBD3/NuRD complex purifications, indicating that 
this protein may be an interactor or novel subunit of the NuRD complex. We here 
showed by purification of GFP-tagged DOC-1 complex and SILAC-based mass 
spectrometry analysis that DOC-1 is a bona fide subunit of the NuRD complex; 
virtually all known NuRD complex subunits, including both MBD2 and MBD3, co-
purified with DOC-1. Using the previously described methyl-CpG pull-down approach 
in combination with SILAC-based mass spectrometry, it was shown that the 
MBD2/NuRD complex and DOC-1 were specifically enriched on methylated DNA. 
Moreover, DOC-1 repressed transcription in luciferase reporter assays and co-localized 
with MBD2 in mouse NIH-3T3 nuclei in immunofluorescence experiments. Thus, 
using a variety of approaches it was shown that DOC-1 is a bona fide subunit of the 
MBD2/NuRD and MBD3/NuRD complexes.   
Chapter 4 describes experiments on in vitro and in vivo methyl-DNA binding 
properties of ZHX1. ZHX1 is a multidomain protein that contains two tandem C2H2 
zinc-fingers and five tandem homeodomains. We and others identified ZHX1 as a 
methylation-dependent binding protein in methyl-CpG pull-down assays. It was shown 
to bind naked as well as nucleosomal DNA in a methylation dependent manner in pull-
down assays. We here showed that in vitro methylation-dependent DNA binding by 
ZHX1 is direct, sequence-specific and occurs via the homeoboxes. Surprisingly, our in 
vivo findings did not support the in vitro observed DNA methylation dependent binding 
of ZHX1. Generation of genome-wide ZHX1 binding and DNA methylation maps in 
HCT116 cells by ChIP-seq and MethylCap-seq, respectively, showed that in vivo 
ZHX1 occupies CpG-dense sites that are unmethylated. By additional approaches, 
namely by bisulfite sequencing of ZHX1 ChIP DNA (ChIP-BS-seq) and by ZHX1 
genome-wide mapping in DNMT1,DNMT3b knockout HCT116 cells, we showed that 
DNA methylation dependent binding of ZHX1 does not occur in vivo. Finally we found 
that in vivo ZHX1 is associated with active chromatin. 
In chapter 5 we report on a new method for direct measurements of DNA 
methylation within genomic sites occupied by an epigenetic modification or 
transcription factor of interest. In this method, called ChIP-BS-seq, ChIP-capturing of 
DNA occupied by the modification or factor of interest is followed by bisulfite 
conversion and deep sequencing. The ChIP-capturing step results in a reduced 
representation of the genome, for which then single-base resolution DNA methylation 
maps are generated. This methods allows for direct assessment of cross-talk between 
DNA methylation and other marks, instead of using correlative studies. Moreover, due 
to the reduced genomic representation, it provides sufficient sequencing depth with 
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relatively low requirements for total number of reads compared to whole genome 
sequencing. We provided proof-of principle by first performing MethylCap-BS-seq, 
which demonstrated successful integration of capturing experiments with bisulfite deep 
sequencing. We then showed, using ChIP-BS-seq in human HCT116 cells and mouse 
ES cells, that H3K27me3 and DNA methylation are compatible throughout most of the 
genome, except for CpG-islands, where these two marks are mutually exclusive. 
Analyses of Dnmt triple-knockout ES cells revealed that total loss of DNA methylation 
is associated with global alterations of H3K27me3 patterns: H3K27me3 localized 
peaks decrease while broad regions of H3K27me3 enrichment are formed. The new 
ChIP-BS-seq approach provides a new way for investigating such interdependencies.       
Finally, in chapter 6 we continued investigations on the RBPJ transcription factor, 
initially identified in our methyl-CpG pull-downs as a methylation-dependent and 
sequence-specific DNA binding protein. This factor is known to regulate Notch-
dependent transcription programs. According to the current model, RBPJ is statically 
associated with its genomic targets and swaps interaction partners leading to a switch 
from transcriptional repression to activation upon Notch signaling. Using ChIP-seq, we 
investigated genomic occupancies of RBPJ under Notch on and Notch off conditions. 
We found that at a large fraction of its binding sites, RBPJ behaved dynamically: 
displaying weak binding in Notch off conditions and strong binding upon Notch 
activation. In contrast, the remaining RBPJ sites showed constant RBPJ binding 
independent of Notch status and were termed constant sites. We found that RBPJ 
inducible sites displayed similar p300 binding dynamics and were associated with 
Notch responding genes. Using GFP-tagged NICD overexpression, it was shown that 
RBPJ dynamic sites overlapped with NICD binding, whereas RBPJ constant sites did 
not and represented Notch-independent RBPJ sites. Altogether, our results indicated 
that, contrary to current models, RBPJ is a dynamic binding factor in the Notch 
signaling pathway and needs Notch activation conditions to strongly bind Notch 
targets. Chapter 7 gives a general discussion of all findings of the work described in 
this thesis. 
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DNA methylatie in zoogdieren vindt plaats op de koolstof 5 positie van cytosine 
residuen in genomisch DNA en vindt vrijwel alleen plaats binnen de context van CpG 
dinucleotiden. Het speelt een belangrijke rol in tal van biologische processen, 
waaronder genomische imprinting, X-chromosoom inactivatie en het behoud van 
genomische stabiliteit. De methylgroep wordt afgezet door specifieke enzymen, 
genaamd DNMTs. Het genoom van zoogdieren is globaal gemethyleerd, dat wil zeggen 
de meeste CpGs zijn gemethyleerd. De uitzondering zijn CpG-eilanden, korte regio’s in 
het genoom met een relatief hoge concentratie CpG dinucleotiden, welke over het 
algemeen methylatie-vrij zijn. DNA methylatie is de afgelopen decennia onderwerp 
geweest van intensief onderzoek. Nieuwe technische ontwikkelingen, bijvoorbeeld de 
ontwikkeling van next-generation sequencing, hebben het onderzoek versneld. 
Hoofdstuk 1 van dit proefschrift geeft een algemene introductie over DNA methylatie 
in zoogdieren en beschrijft tevens de recente ontdekkingen op het gebied van non-CpG 
methylatie, hydroxymethylatie en processen van DNA demethylatie. Gemethyleerde 
CpG dinucleotiden worden specifiek herkend/gebonden door Methyl-CpG Bindende 
Eiwitten (MBPs). Er zijn drie verschillende types MBPs in zoogdieren: de MBD 
familie eiwitten, de KAISO familie eiwitten en UHRF1 en UHRF2. Ze voeren 
gespecialiseerde functies uit en associëren met een variatie aan andere eiwitten. In het 
onderzoek beschreven in dit proefschrift hebben we 1) een assay opgezet voor het 
identificeren van potentieel nieuwe eiwitten die specifiek binden aan gemethyleerd 
DNA, 2) potentieel nieuwe methyl-DNA bindende eiwitten onderworpen aan verdere 
in vitro en in vivo analyses, 3) een methode ontwikkeld voor het direct meten van DNA 
methylatie niveaus binnen regio’s van het genoom gebonden door een transcriptiefactor 
of histon modificatie van interesse.   
Hoofdstuk 2 beschrijft een methyl-CpG pull-down experiment gecombineerd 
met SILAC labeling en massaspectrometrie, met als doel het identificeren van nieuwe 
methyl-DNA bindende eiwitten. In deze proef wordt synthetisch DNA gekoppeld aan 
beads en gebruikt om hieraan bindende eiwitten uit een nucleair extract te vissen. 
Gebonden eiwitten worden vervolgens geëlueerd en kwantitatief gemeten in SILAC 
gebaseerde massaspectrometrie. Gemethyleerd DNA wordt gebruikt in combinatie met 
een zwaar-gelabeld nucleair extract en ongemethyleerd DNA met een licht (ofwel 
ongelabeld) extract, of vice versa in een omgekeerd (reverse) experiment. De 
verhouding van zwaar-licht eiwit, welke wordt gemeten met massaspectrometrie, geeft 
informatie over de DNA binding: een hoge verhouding betekent methylatie-
afhankelijke binding, terwijl een lage verhouding juist repulsie door DNA methylatie 
aanduidt. Het omgekeerde geldt in een reverse experiment. De geschiktheid van de 
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methode bleek uit de detectie van meerdere bekende MBPs en vrijwel alle subunits van 
het MBD2/NuRD complex als methyl-DNA bindende eiwitten. RBPJ, bekend als de 
transcriptiefactor downstream in de Notch signalering, werd ook geïdentificeerd als 
methyl-DNA bindend eiwit. Vervolgexperimenten toonden aan dat RBPJ methylatie-
afhankelijke DNA binding vertoont in een sequentie-specifieke manier. Het is bekend 
dat RBPJ bindt aan de consensus sequentie 5’-GTGGGAA-3’. Wij ontdekten dat RBPJ 
ook bindt aan de gemuteerde sequentie 5’-GCGGGAA-3’, maar alleen wanneer deze 
gemethyleerd is. We concludeerden dat binnen de RBPJ consensus sequentie, thymine 
vervangbaar is door methylcytosine.    
In hoofdstuk 3 presenteren we analyses van MBD/NuRD complexen. Het is 
bekend dat MBD2 en MBD3 subunits zijn van het NuRD complex, maar in aparte 
complexen: namelijk MBD2/NuRD en MBD3/NuRD. DOC-1 peptides zijn voorheen 
geïdentificeerd in MBD2/NuRD en MBD3/NuRD complex zuiveringen, hetgeen 
aanduidt dat dit eiwit mogelijk een geassocieerd eiwit of nieuwe subunit is van NuRD 
complexen. In hoofdstuk 3 laten we zien dat DOC-1 een bona-fide subunit is van het 
NuRD complex, aan de hand van de zuivering van GFP gelabeld DOC-1 bevattend 
complex en SILAC-gebaseerde massaspectrometrie. Vrijwel alle NuRD subunits, 
waaronder MBD2 en MBD3, werden opgezuiverd samen met DOC-1. Door gebruik te 
maken van de hiervoor beschreven methyl-CpG pull-down methode in combinatie met 
SILAC-gebaseerde massaspectrometrie, toonden we aan dat het MBD2/NuRD complex 
en DOC-1 specifiek verrijkt waren op gemethyleerd DNA. Daarnaast zorgde DOC-1  
voor transcriptie repressie in luciferase reporter analyses en co-lokaliseerde het met 
MBD2 in de celkernen van muis NIH-3T3 cellen in immunofluorescentie 
experimenten. Kortom, met een variatie aan methodes toonden we aan dat DOC-1 een 
bona-fide subunit is van de MBD2/NuRD en MBD3/NuRD complexen.  
Hoofdstuk 4 beschrijft analyses van de in vitro en in vivo methyl-DNA 
bindende eigenschappen van de transcriptiefactor ZHX1. ZHX1 is een eiwit met twee 
tandem C2H2 zinc-finger domeinen en vijf tandem homeobox domeinen. Zowel wij als 
een ander laboratorium identificeerden ZHX1 als methyl-DNA bindend eiwit in 
methyl-CpG pull-down experimenten. Het bindt zowel kaal DNA als DNA in 
nucleosomen in een methylatie-afhankelijke manier in pull-down experimenten. In 
hoofdstuk 4 laten we zien dat in vitro methylatie-afhankelijke binding door ZHX1 
sequentie-specifiek is en plaats vindt via de homeoboxes. Onze in vivo bevindingen 
tonen echter aan dat hier methylatie-afhankelijke binding door ZHX1 niet plaatsvindt. 
We genereerden genomische bindingsprofielen van ZHX1 en genomische DNA 
methylatie profielen, aan de hand van ChIP-seq en MethylCap-seq, respectievelijk. 
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Deze toonden aan dat ZHX1 bindt aan CpG-rijke regio’s die ongemethyleerd zijn. Aan 
de hand van andere methodes, namelijk het bisulfiet-sequencen van ZHX1 ChIP DNA 
(ChIP-BS-seq) en de analyse van genomische ZHX1 bindingsprofielen in 
DNMT1,DNMT3b knockout HCT116 cellen, bevestigden we dat methylatie-
afhankelijke binding van ZHX1 in vivo geen rol speelt. Tenslotte toonden we aan dat 
ZHX1 in vivo geassocieerd is met actief chromatine.  
In hoofdstuk 5 beschrijven we een nieuwe methode voor het direct meten van 
DNA methylatie niveaus binnen genomische regio’s gebonden door een 
transcriptiefactor of epigenetische modificatie van interesse. In deze methode, genaamd 
ChIP-BS-seq, wordt DNA afkomstig van een ChIP experiment direct bisulfiet-
geconverteerd en gesequenced. Via het ChIP experiment wordt een gereduceerde 
representatie van het genoom verkregen, waarvan vervolgens de DNA methylatie 
patronen worden bepaald op het niveau van de enkele base. Deze nieuwe methode 
maakt directe meting van cross-talk tussen DNA methylatie en andere epigenetische 
modificaties mogelijk, hetgeen prefereerbaar is boven correlatie analyses. Bovendien 
zorgt de gereduceerde genoom representatie ervoor dat voldoende sequencing diepte 
wordt bereikt met relatief lage aantallen reads, vergeleken met sequencing 
experimenten van het hele genoom. We lieten aan de hand van MethylCap-BS-seq 
experimenten zien dat de methode –het integreren van capturing experimenten met 
bisulfiet-sequencen- werkt. Vervolgens gebruikten we ChIP-BS-seq voor het 
analyseren van cross-talk tussen DNA methylatie en H3K27me3. We zagen dat DNA 
methylatie en H3K27me3 over het algemeen samen voorkomen in het genoom, behalve 
in CpG-eilanden. In deze regio’s sluiten de twee modificaties elkaar uit: CpG-eilanden 
met H3K27me3 bevatten geen DNA methylatie en vice versa. Deze observaties werden 
gedaan in de humane kanker cellijn HCT116 en in muis embryonale stamcellen (mES 
cellen). Daarnaast analyseerden we Dnmt triple-knockout mES cellen, waar we zagen 
dat totaal verlies van DNA methylatie leidt tot globale veranderingen in het H3K27me3 
patroon: H3K27me3 pieken nemen af, terwijl brede regio’s met H3K27me3 toenemen 
in H3K27me3 verrijking. De nieuwe ChIP-BS-seq methode biedt een nieuwe manier 
voor het onderzoeken van dergelijke cross-talk. 
Tenslotte continueerden we onderzoek aan de transcriptiefactor RBPJ, zoals 
beschreven staat in hoofdstuk 6. Deze factor hadden we aanvankelijk geïdentificeerd in 
onze methyl-CpG pull-down experimenten als een factor die sequentie-specifiek 
gemethyleerd DNA bindt. Het is bekend dat RBPJ downstream van Notch signalering 
functioneert en hier transcriptie van Notch afhankelijk genen reguleert. Volgens het 
huidige model is RBPJ constant aanwezig op Notch target genen, en zorgt het voor 
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transcriptie repressie van deze genen in afwezigheid van Notch signalering en voor 
transcriptie activatie bij Notch signalering. Deze switch van repressie naar activatie zou 
plaatsvinden door een verandering in interactie partners van RBPJ; associatie met 
repressieve complexen wordt vervangen door associatie met het Notch activatie 
complex na Notch activatie. Wij onderzochten genomische RBPJ bindingspatronen bij 
Notch ‘aan’ en Notch ‘uit’ condities, aan de hand van ChIP-seq. We zagen dat RBPJ op 
een groot deel van de bindingsplaatsen dynamisch bindt, met lage binding bij Notch uit 
condities en hoge binding bij Notch aan condities. Deze bindingsplaatsen noemden we 
‘induceerbaar’. De overige bindingsplaatsen vertoonden wel constante binding van 
RBPJ, ongeacht Notch signaleringsstatus, en deze noemden we ‘constante’ 
bindingsplaatsen. Induceerbare bindingsplaatsen vertoonden ook dynamische binding 
van p300, vergelijkbaar met RBPJ, en waren gelinkt aan gen-activatie. Dit was niet het 
geval voor constante bindingsplaatsen. Tenslotte voerden we ChIP-seq experimenten 
uit met GFP gelabeld NICD. We zagen dat RBPJ induceerbare bindingsplaatsen 
overlapten met NICD binding, terwijl dit niet het geval was voor constante 
bindingsplaatsen. Samengevat toonden onze resultaten aan dat RBPJ dynamisch bindt 
aan Notch targets. Op constante bindingsplaatsen vindt regulatie door RBPJ plaats 
onafhankelijk van Notch signalering. Op induceerbare bindingsplaatsen vindt Notch 
afhankelijke regulatie plaats door RBPJ en is RBPJ binding afhankelijk van de Notch 
signaleringsstatus. In tegenstelling met huidige modellen is RBPJ dus niet een 
constante bindingsfactor waar een transcriptie ‘switch’ plaatsvindt, maar wordt het 
dynamisch gerecruteerd bij Notch activatie. Hoofdstuk 7 geeft tenslotte een algemene 
discussie van alle bevindingen beschreven in dit proefschrift.  
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